var title_f33_49_34576="Posterior vaginal wall prolapse 2";
var content_f33_49_34576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior vaginal mucosa is undermined and a midline incision is made.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34576=[""].join("\n");
var outline_f33_49_34576=null;
var title_f33_49_34577="Patient information: Cardiac tamponade (The Basics)";
var content_f33_49_34577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/14/38113\">",
"         Patient information: Pericarditis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/62/31717\">",
"         Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/53/12115\">",
"         Patient information: Pericarditis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cardiac tamponade (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cardiac-tamponade-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14362092\">",
"      <span class=\"h1\">",
"       What is cardiac tamponade?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cardiac tamponade is a condition in which extra fluid builds up around the heart and presses on it. The pressure can be mild or severe. Cardiac tamponade can happen after a heart attack or heart or lung surgery. It can also be related to an infection or cancer that has spread.",
"     </p>",
"     <p>",
"      Cardiac tamponade keeps the heart from getting enough blood back from the rest of the body. If the heart does not get enough blood back, it cannot pump as much out to the body again. If the heart is not pumping right, this can cause serious health problems. Cardiac tamponade that happens suddenly, such as from an accident, can be very serious. It can even cause death. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14362107\">",
"      <span class=\"h1\">",
"       What are the symptoms of cardiac tamponade?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on whether cardiac tamponade happens suddenly or slowly.",
"     </p>",
"     <p>",
"      If cardiac tamponade happens suddenly, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Shortness of breath, fast breathing, or both",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If cardiac tamponade happens slowly, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tiredness",
"       </li>",
"       <li>",
"        Shortness of breath",
"       </li>",
"       <li>",
"        Chest pain or discomfort, such as feeling like the chest is heavy or full",
"       </li>",
"       <li>",
"        Fainting, or feeling faint",
"       </li>",
"       <li>",
"        Swelling in the lower legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14362121\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor can often tell if you have cardiac tamponade based on the symptoms. But if he or she thinks you have it, you will probably have the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram (ECG or EKG)&nbsp;&mdash; This test measures the electrical activity in your heart. It can show an abnormal heartbeat. Most people with cardiac tamponade have a fast heartbeat.",
"       </li>",
"       <li>",
"        A chest X-ray &mdash; A chest X-ray can show if the heart is larger than it should be. This can happen if cardiac tamponade happens slowly. &nbsp;",
"       </li>",
"       <li>",
"        An echocardiogram &ndash; This test uses sound waves to create a picture of your heart as it beats. It shows the different parts of the heart and how well it is working. If you have fluid around your heart, this test can show the doctor if the fluid could cause cardiac tamponade.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14362136\">",
"      <span class=\"h1\">",
"       How is cardiac tamponade treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cardiac tamponade is usually treated by draining the extra fluid from around the heart. This relieves the pressure on the heart and lets it do a better job pumping.",
"     </p>",
"     <p>",
"      To drain the fluid, doctors can use a needle and thin tube, or do surgery. If cardiac tamponade happens suddenly, the doctor might do surgery right away.",
"     </p>",
"     <p>",
"      After the doctor drains the fluid, he or she will order another echocardiogram. This test shows if enough fluid was drained. It can also show if the fluid comes back.",
"     </p>",
"     <p>",
"      A few people with cardiac tamponade do not have fluid drained right away. In these people, the fluid is not causing heart or blood flow problems. Or the extra fluid only causes mild changes in how the heart works. In these cases, doctors do regular exams and tests to check how well the heart is working. If another condition is making extra fluid build up, the doctor or nurse will treat that condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14362151\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=see_link\">",
"       Patient information: Pericarditis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       Patient information: Pericarditis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?33/49/34577?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82942 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34577=[""].join("\n");
var outline_f33_49_34577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14362092\">",
"      What is cardiac tamponade?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14362107\">",
"      What are the symptoms of cardiac tamponade?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14362121\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14362136\">",
"      How is cardiac tamponade treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14362151\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38113?source=related_link\">",
"      Patient information: Pericarditis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34578="Patient information: Peripheral artery disease and claudication (The Basics)";
var content_f33_49_34578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15738\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\">",
"         Peripheral artery disease",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30242\">",
"         Patient information: Doppler ultrasound (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/35/14900\">",
"         Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Peripheral artery disease and claudication (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/peripheral-artery-disease-and-claudication-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1481812159\">",
"      <span class=\"h1\">",
"       What is peripheral artery disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Peripheral artery disease (PAD) is a condition that can cause leg pain that is worse with activity. Muscle pain that is worse with activity and better with rest is called &ldquo;claudication.&rdquo; PAD involves blood vessels called &ldquo;arteries&rdquo; that bring blood to the legs.",
"     </p>",
"     <p>",
"      Normally, blood flows easily through arteries to all parts of the body. But sometimes, fatty clumps called &ldquo;plaques&rdquo; build up inside the walls of arteries (",
"      <a class=\"graphic graphic_figure graphicRef60105 \" href=\"UTD.htm?6/23/6514\">",
"       figure 1",
"      </a>",
"      ). Plaques can cause arteries to become narrow or blocked. This prevents blood from flowing normally. When muscles do not get enough blood, symptoms can occur.",
"     </p>",
"     <p>",
"      Some people have a greater chance of getting PAD, such as those who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Smoke",
"       </li>",
"       <li>",
"        Have diabetes",
"       </li>",
"       <li>",
"        Have high cholesterol",
"       </li>",
"       <li>",
"        Have high blood pressure",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481812166\">",
"      <span class=\"h1\">",
"       What are the symptoms of PAD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PAD often causes pain in the back of the lower leg. The pain is usually worse with walking and exercise, and gets better with rest. PAD can also cause pain in the feet, thighs, or buttocks. People who have leg pain can have other symptoms, too, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble walking up stairs",
"       </li>",
"       <li>",
"        Trouble getting an erection (in men) or trouble with sexual arousal (in women)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms of PAD can be mild or severe, depending on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Which arteries are affected",
"       </li>",
"       <li>",
"        How narrow the arteries are",
"       </li>",
"       <li>",
"        How much activity a person does",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481812173\">",
"      <span class=\"h1\">",
"       Is there a test for PAD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can do different tests to make sure that you have PAD, and to check if your PAD is mild or severe. He or she might:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take the blood pressures in your arm and ankle at rest and with exercise, and compare them",
"       </li>",
"       <li>",
"        Take the blood pressures in your thigh or lower leg",
"       </li>",
"       <li>",
"        Order an ultrasound, CT scan, or other imaging test &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481812180\">",
"      <span class=\"h1\">",
"       How can I help treat my PAD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help treat your PAD and prevent it from getting worse, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stop smoking",
"       </li>",
"       <li>",
"        Get your diabetes, high blood pressure, and high cholesterol under control (if you have these conditions)",
"       </li>",
"       <li>",
"        Exercise &ndash; Doctors recommend that most people with PAD exercise each day. Ask your doctor or nurse which type of exercise is right for you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481812187\">",
"      <span class=\"h1\">",
"       What other treatments might I have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Along with exercise and getting medical conditions under control, most people are treated with medicines. Doctors can try different types of medicines to reduce symptoms and increase blood flow to the legs. Medicines can also help people walk farther without having pain. Most doctors prescribe a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?34/8/34948?source=see_link\">",
"       cilostazol",
"      </a>",
"      (sold as Pletal&reg;) at first. But people who have certain heart problems cannot take cilostazol. They will need to take a different medicine.",
"     </p>",
"     <p>",
"      If you have severe PAD or if you still have symptoms after taking medicines, your doctor will talk with you about the possibility of having a procedure. Different types of procedures can be done to increase blood flow to the legs and feet. Procedures can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Angioplasty and stenting &ndash; A doctor will use a small needle to put a wire into a blood vessel in the groin area. For angioplasty, a doctor threads a deflated balloon over the wire to the narrowed or blocked area. Once there, he or she inflates the balloon. This opens the blood vessel. The balloon is then deflated and removed. A stent is a wire mesh tube that stays in the body. It is used to keep the opened vessel from closing again.",
"       </li>",
"       <li>",
"        Surgery &ndash; A doctor can do surgery, called &ldquo;bypass,&rdquo; that creates a way for blood to flow around the blocked artery. During bypass, a doctor sews a tube called a &ldquo;graft&rdquo; around the blocked artery. A graft can be a vein from another part of the body, or it can be manmade.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481812194\">",
"      <span class=\"h1\">",
"       What should I know about the different procedures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Angioplasty and stenting are used to treat 1 or 2 blocked areas. Surgery works best to treat more than 2 blocked areas. People who have the fewest long-term problems after bypass surgery include those who are younger than 70, do not have diabetes, and do not have PAD below the knee.",
"     </p>",
"     <p>",
"      Your doctor might recommend a procedure for you, depending on your symptoms, age, and medical problems. But many people can choose which procedure to have. If your doctor offers you a choice, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of each procedure for me?",
"       </li>",
"       <li>",
"        What are the downsides of each procedure for me?",
"       </li>",
"       <li>",
"        What happens if I do not have any procedure?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481812201\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"       Patient information: Doppler ultrasound (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"       Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?33/49/34578?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15738 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-201.248.109.99-7E3FD85ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34578=[""].join("\n");
var outline_f33_49_34578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812159\">",
"      What is peripheral artery disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812166\">",
"      What are the symptoms of PAD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812173\">",
"      Is there a test for PAD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812180\">",
"      How can I help treat my PAD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812187\">",
"      What other treatments might I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812194\">",
"      What should I know about the different procedures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481812201\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\">",
"      Peripheral artery disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34579="Selenium sulfide: Drug information";
var content_f33_49_34579=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Selenium sulfide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30356?source=see_link\">",
"    see \"Selenium sulfide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6259?source=see_link\">",
"    see \"Selenium sulfide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dandrex;",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Clinical Strength [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Medicated [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Moisturizing [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Normal to Oily [OTC];",
"     </li>",
"     <li>",
"      Tersi",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Versel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dandruff, seborrhea:",
"     </b>",
"     Topical: Massage 5-10 mL of shampoo into wet scalp, leave on scalp 2-3 minutes, rinse thoroughly. Usually 2 applications each week for 2 weeks will provide control. After this, may repeat at less frequent intervals (eg, once weekly, every 2-4 weeks). Rub foam into affected skin twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea versicolor:",
"     </b>",
"     Topical: Apply the 2.5% lotion to affected area and lather with small amounts of water; leave on skin for 10 minutes, then rinse thoroughly; apply every day for 7 days; rub foam into affected skin twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tersi: 2.25% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 2.5% (118 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 1% (210 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dandrex: 1% (236 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Clinical Strength: 1% (420 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Medicated: 1% (120 mL, 207 mL, 325 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Moisturizing: 1% (207 mL, 325 mL) [contains aloe, moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Normal to Oily: 1% (207 mL, 325 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical [with conditioner]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; 2-in-1: 1% (207 mL, 325 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes foam",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well before using. May damage jewelry; remove before treatment. For external use only; do not apply to broken or inflamed skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Foam: Invert canister to administer.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of itching and flaking of the scalp associated with dandruff, to control scalp seborrheic dermatitis; treatment of tinea versicolor",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia or hair discoloration, unusual dryness or oiliness of scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Vomiting following long-term use on damaged skin, abdominal pain, garlic breath",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, itching, irritation, stinging (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to selenium or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue use if irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Avoid topical use in very young children; safety of topical in infants has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eyes and genital areas.  Due to the risk of  systemic toxicity, do not use on damaged skin or mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. Avoid use in pregnant women unless the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6474346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F220415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Tersi External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25% (70 g): $230.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Selenium Sulfide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (118 mL): $19.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Selsun Blue Daily External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (207 mL): $5.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Selsun Blue External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (207 mL): $5.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Selsun Blue Medicated External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (207 mL): $5.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Selsun Blue Moisturizing External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (207 mL): $5.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Selsun External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (120 mL): $12.44",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abbottselsun (ES);",
"     </li>",
"     <li>",
"      Bioselenium (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Sebo-Lenium (CH);",
"     </li>",
"     <li>",
"      Sebosel (IL, TH);",
"     </li>",
"     <li>",
"      Seldron (SG);",
"     </li>",
"     <li>",
"      Selenix (PT);",
"     </li>",
"     <li>",
"      Selfide (TH);",
"     </li>",
"     <li>",
"      Sellon (HK, MY, TH);",
"     </li>",
"     <li>",
"      Selson (KP);",
"     </li>",
"     <li>",
"      Selsun (AE, AR, AT, BB, BE, BH, BM, BR, BS, BZ, CH, CO, CY, DK, EG, FI, FR, GB, GR, GY, ID, IE, IN, IQ, IR, JM, JO, KW, LB, LU, LY, NL, NO, NZ, OM, PK, PL, QA, SA, SE, SG, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Selsun Amarillo (PE);",
"     </li>",
"     <li>",
"      Selsun Azul (PE);",
"     </li>",
"     <li>",
"      Selsun Blu (IT);",
"     </li>",
"     <li>",
"      Selsun Blue (AE, AU, BH, CN, CY, EG, FI, ID, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Selsun R (NL);",
"     </li>",
"     <li>",
"      Selukos (AT, DE, FI, NO, SE);",
"     </li>",
"     <li>",
"      Xi Er Sheng (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May block the enzymes involved in growth of epithelial tissue",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption: Topical: None through intact skin, but can be absorbed through damaged skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lester RS, &ldquo;Topical Formulary for the Pediatrician,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(4):749-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34579/abstract-text/6225068/pubmed\" id=\"6225068\" target=\"_blank\">",
"        6225068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9885 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34579=[""].join("\n");
var outline_f33_49_34579=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220446\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220422\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220423\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220408\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220397\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220410\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220409\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220444\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220413\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220401\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300034\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222893\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220405\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6474346\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220415\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038826\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220400\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220412\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30356?source=related_link\">",
"      Selenium sulfide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6259?source=related_link\">",
"      Selenium sulfide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34580="Uterine size by age and parity";
var content_f33_49_34580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    The comparative size of prepubertal, adult nonparous, and multiparous uteri (frontal and sagittal sections)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 303px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEvAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiuC8SeMb+W8vLLwdbR6jJY26XV1PGyShVbzNqKhddzHYT94fjQB3tFeeaX4WvvElpb6zrPizVxdTosiQ6Ndm2tYMqPlVRnzMHklywJ7AcVH4M8UbPEcWiy+L9J8UQ3qPJbXEMsIuImjVd8bpF8rLzuBGCMkEEcgA9HooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoPAoooA831DxF4i1Wxtp9JTSzpusRrFZpDNKLpdxAeTzApQbVLHGBjbkMak+H9/FrHjrxU9qZbe00RYNDhtPtDsGCBpDMUPy87wqnk4Q5POKi8RQahF9j0vXW017Z54xpwsLaa2LSDIEZfe3l5GckEcAjvXOfDDwM3h/xxHqq6lPavfx3FxPZpmOO6TeEgDR5IyiktkZJ3cnrkA29ZttM8J69HBfzahpOh3kv+iLpLPHDuESho5VjXcGypcMpyecnANU9F8RaHqMWi6Lo1rNpxttUEdgcTbmgjX5pN7IArMrMpRyTtf1IFaHjfV7LxLpes6DaXsFxrNtqCRWsdp80sciBJNzLk/dy2c4BAIrmdXN3PYw2Nva6sl3Z3LXy3Lv+6b93iIRt94YKrxt4weSCCQD3Oisjwxrtr4h0z7VaNh0byp4j1hlABKH6bh+BFa9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAetFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVbU72DTdPub27YrBbxtI5AycAZ4FACf2jZfbzY/bLb7aF3m381fMC+u3OcciuUf4p+C0nuIX16ASQglh5cnzY67Pl+fr/AA5zWFpvh+z1K9Ol63odrdTTzXF7e3YtXga3V1VlieZcCSX98BwQNqnjI56rwNc21vaDw/ZXd3qi6REkEuoSIAjHAKx7hgM4QrnaCBxkgnFAHSwTR3EEc0EiyRSKGR0OQwPQg0+uU8HG10O6n8KRx3EQtAZrNplY/aICELvvxglZJCpHUDbxzk9XQAUUUUAZfiLTptStbeO3kVHiuoZ/mLAEK4JGVOc4zjtkAHjNcPDqjal4c8Dam9ldLNb3whuUCbpU2wyo5UAEuu9VPyg5HPYY9Mrwa7u7rQ5rzVtNYXWqWFwuqX9pcqyiNS0iXEaLx5YEcscgbkN5ZOKAK2q65qvhq91DX4kFz4buLl7iXUbG0mhaJ2hWRTLDy3lsCAZBnLKM4yK9h8OX2n+LPDVrfwss0dzGpZ0OCTt7kYzw2fTmuR01rXQNX864eG30mS6nj85SnlCEsQI5TuA2hniKHB2hinHU5PiLwrd+FIJNb8CxreaBLOt2+kWEI3RI0eDJbFWww3YkEYHO5sHkCgDZv49S8F6jcajaiS5tXid3tt0knn4K5I5IVwo4Y5z0PqO70HW9P1+w+2aTcefBvMbEo0bKw6qysAyn2IFcb4V+JNlrDXXnlTBbMInmSJ1KyZUEMjDK/eU88jcBjNad74XtNQ1ODxL4Zu10rWJIFVriO3Vo7uIgFUnjOCwAAxgqw6AgcUAdhRXNaB4na5vl0jXbSTTNdzLthKsYblUI/eQy4CuCrK23O9cnI4JrpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqK5giureSC5jSWGRSrxyKGVgeoIPBFS0UAeMxeBri5m1XRNV8S3Utleyx2BsLW3EMIRLWMs+N5YZTIJ3EFivGPlq14I0G58nUovAmrx6PYQTi2LXdu15PMyqp3kGYIg5KgbASBnI4qp8VI7nSPEV7cwaebwapasZLmO4ZJbG1SMLcsq9NxXbtIycn05GlH4v0Pw5pmv3enQS2tu080FviNAm+3iVWYHAwpOCCxOeTwCaAO78UeGdK8TWX2fVbVJHQN5FwFAlt2OPmjfqpyFPHdR6VlWOq6toN9b6f4oIvLa4kWG11aCIIGduFSZBwjE8Bh8pyBwa5nwD4z02Ty/7P1CC6srhpHAjZfmfAYkE87v9k889K9BjfTvEukSJPbx3NlN8skE6BgcHuOR1ANAGpRXJaXLL4W1K20W+maXSLk+XptzK2Wjf/n3dj1OMlCeSAQckc9bQAVlar4d0XWJ1m1bSbC+kVdgNzbrJx6fMD6n8z6mtWigDyvQ/DF/Y6tcaVplskOl2+pS3G+WBDbxbl8xDFGGHH7woygDpuGCK6T4d6hbXEWo20UC21xFIkksUcRjiy0agtGMn5Syscds881Do9zLD4vv0S6+a41KSO6tWCnGLaNonXByvyIo9Du6Zqjr/h+28K+I4PFumJdEyTrBfwoVMYt2VhkLjOQ+w9enHTAoAueNvh1YeIXe906SLSNaZXVr2K2R/ODKAfOTjzMbVIyQQVHPFcdDqXiPwZOI/ENnBC/ltEmqwjdbzquw4JLZRyAcK45KttJ6V7TUN7aW99aTWt9bxXNrMhjlhmQOjqeCrKeCD6GgDml1DRvE+l21tqsKSPKV+VkzslwCChGSp5yDnIFRTXur+E/KOpM2q6Cu4PeKmLi1BkG1pcv+8RVbllGcLkjrXLeJPhze6C0WqfDtmVredpW0JvLWCVXfc4iY4MRySwBbZ2AXNbPhjx9bapcy2d8HiuI55ba5t50USQOrBQrBSRtPJB5BB4zQB30ciSxpJE6vG4DKynIYHoQadXF2cT+Ddc+yxQ3LeGdQkRYAmwx2FzJI2V2gBljcsmPvANx8oIrtKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzHxi9hFb+Nby5mWO9Sa3tFlJUukRiiYRrzlVZmf0yT3qjrPhddGggfRNVg/4Ri91WFpLGGFZJpWlKQuFndm47kKobG8bsV0HxK8OHUbnTNRt9Fl1toZGjurBblYlnh8mYLkOyqdsjrjPTcSBkCszwxqcvibxlpUENvapoejWH2ny7SVZFgvGVYhDL6Mg8/AHHIJ5AoAueIvBuiaTBqV8NLtpdEmila/sljiQRKUG6WJiAVwFJK7gCWLD5uuFe6FqXg5bLWvDF5eeINCJ8+SOSRJZIUJBWSN1AMke0kH7zbeQSa9grj/BLLo19feF2iES20kt1ZBfum2eQsAOeNrOVx2AFAE2l6jpPxA8Lkwzh7e4/eRvBJh1CyHy5VPYhkB54ypBzg1c8J6s16l7p19Or6vpkvkXS4CswOTFLtHQSJhuOAdw/hNcV4hSTwR8QNL1GG9uE0TWZZIJYZNhhgunkV87j8wEg8zjJ+YDHXB6LxYlxofiGy8TwXMgsW8rT9TtmI2GEuwjmH90o8pJPdSc9BQB2NFNikSaJJInV43AZXU5DA9CD3FOoAqf2ZYf2odT+w2v9omPyftXkr5uzOdu/Gce2cVX8URCfw3qkZjWXNrJhD3IUkfTnHNadYvjbUJdK8H63fWzRrcW9nLJEZPu+YEO3PtuxQBxXhD4h2Fra2tjrXn27zJG9s2BKMGFHZG2ElSGZwMgAgDBOK7FPGHh1twfWbCF1IDJPMsTKT0BDYNJ4H8OL4Y8PwWDXc97dcPcXUxy0sm0AnHZcAAAdAB1OSdyeGK4gkhuI0lhkUo8bqGVlIwQQeoIoAcCGAKkEHkEd64L4k+BYtblt9c0eIQ+JLJlKvHsT7ZFuUvBKSp3KVU7c42tggjnNm58IHQRJfeC5buydCJDpMUqizuBv3MixuCsRYZG5NvJ5rqNG1KDV9Lt7+0LeTMu4BhhlOcFWHZgQQR2INAHD+F9V0rxj4UuNI1W3ltxcSXFvLDMyhoplndWjBydrq6FlHYBSOldB4J1O7mtG0jWo5I9c0yOOO5L423CnIW4Qjqj7GPYghgQMVyPxAsT4W8QW/iW0tmbSLu5txqkcTogilEqiO4IYgEEsFfHPCnB+Y1vXNpd6npOl6xpdwJPEthDF5hRljW6UiN5YHyCNrjocfKxBGOQQDtaKwNE8X6Lq8ptob2ODUUO2WwuWEVzE3cNGTn8RkHsSK36ACiiigAooooAKKKKACiiigAooooAKKKztS1zSdLbbqeqWFm2M4uLhIzj/gRFAGjRXPnxt4VGQfE2h8f9P8X/AMVTZvHPhKCMvN4o0KNB1Z9QhAH47qAOiorG03xV4e1Rd2ma9pN4udube8jkGfTgnmtkHIyOlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDb20Fs0zW8EUTTOZZSiBd7kAbmx1OABk+gqaigArkPHlnNBe6J4ht9Rks/7LuBHcJtDRzW80kayBhjPGAwIxjBrr643x7ZXGv6lo3h2K/nsLa48y/uZbaQxzlLdotqow+7mSSMk9cL70Aa3iLSrHxf4YlsvtRNrc+XLHcW7A4ZHWRHU8g4ZFP4VxvhHxJe6Xqk+g+NZoU1MADBlURTRl2VJI1JztIHI7EMDnFTwJrfw4sJDcTRaz4Vhl3vKwMd3YxO5LOwUFZUTduY/IQoJwcV1Or6ZofjfQFjmeK+sJSJIbm1m5VlPDxyKeCCOx7EHIyKAM3TBL4SvrLTHnkuPD1yqW9hJIwZrWTnEROMsjDaFJyRjB6iuwry3wTeX1z9t8F+N4hJf2+xftCzti5QKrJKh4wSRnAwQyt6V2HgrUbifT303VTjWNL2W11mTeZPlG2YHAJDjnoOcjsaAOirnviDH5ngnWV8wRf6Mzbz0XHOf0roapa5ZvqOi6hZRuI3ubeSFXIyFLKQD+tAF2isjwtqT6no8b3CeXewsbe6i3ZMcycMPx6j1BB71r0AFcbqmkaj4fvbjWPDHnXUMsjTXujtJlZieWeAn7kmckjO1vY8nsqKAOd0bxF4f8YadNDa3VvciRDHc2UpCzRZJVkliPzKcgjBFcNdwaj4D1BWlN1Ppjp5MOpoquLYMwG2ZSM8nZhuRkdVziu78TeDPD3iaWKbW9Kt7m6iULHcjMc8YByAsqEOBnnAPWqh8D2UEESaXqniCxlhKmJxq9zOF24wCkrujLxgggigDGTxH4c8ZWRiuodK1VUUlliuFkaNucKccqeD37Zpmh22lwSRjTNf1rTLcArHaCeKSIKBwcSIxGMYxn0FQXPhLQdW1+PTvGGiWi6rNbq0OoWM0tuLzYxZh8hUq64V9uT1yDwa2pfhj4YkuDOYNSE27duGr3Y5+nm4oAq3Lyqg8vx5q+WBKj7NZlj8uf+eAHcD68VdignjidZfHN/KVU5cQ2gPGDniHHQj/ACKp3Hwr0CVQi3WvxwglhEus3LIGII3YZzzgmsub4P28Uhl0zxR4jglAO37RdC6APGD+8BPbseRxQBvNaeIZk8/QfFa3LqAfs2o2cRBPoWiVGX64NTWnjKO11yDRPFNvFo2qXIJtC1wHt7wBlTEUhC5fLoNhAb5hgEc1w8/hnx5oaXNxAdO1eELkpayvbzuFIIXaQVI4YfeB6YyaTSPE+mePNDbRtYyty7MpjuHZJoZllAKsBgoQQdrcEbcjGKAPZqK8r8PeLbjwo1rYeJ7mO40WeSQQas88jvBuf5EuN4J28sBKW7AEZDEemWl7a3lml5Z3ME9o67lmikDow9Qw4IoAsUV5j4l+L2mW9ybHwfbxeKNQVUeQ2t2i20IYkDfMNw3HBwoBP06149r9z4t8YXTSeI9cMMEqIj2WnXMsNnEhydrBWy7d9zn8OMUAe5+Kvi14N8N/u59Yhv7zcU+x6awuZ8gZwUU/L+OK4bU/i/4ku9Ikn0vQdP0pycIb68aeUAgYbykQAHJ+6X7GuN0rTLWytETTrOGOyt+VSJhvd8DBYkdccAnPJJ6jFbK6feDTftU4QROQTuJDSOVH3QewAxx2waAMjX9Z8W6zdtZ3fjDUDbQpJJM9jJFZqRtXIGxdxAJKgFjknqADWUfC+lh5dumWjXsqud9w32gphQdzSNksegx0LE44rpZreFLuUo0UUUac4JxIwGBj8BgcdWJ7mtC5SO3ct5cYupAdzRSEiJABhR9OfxLH6gHOXfhjQJrdpJdI09o1ypHlIDtznC/Lxyevf6Cks/CPh2HdqP8AYtmqRtlIxEnTcAo6YPbqOp7456Dy0uSC52ornI3EnAIx06VLPNGTGkMYCIcjD7cfMPzPUdB3PrQBw974K0W4uXup7ZPNkYLDEERUUBmG5lC543Huckf7uNPSPB4sZVm07U9S09mRQptbuSMJgY5GSDz6jtx6V03lKzSyEory4wMHCICcZ7++PervyofLUq2/DMd+3aoPXj8h+P4gFBdS8Z29tbx6Z40vVMY+Y38Ntcbx3JzGjev8Q6Vp6X8U/GlpYRpqnhvSNVvWYBPsl+9ozLjqVeNl3euHx+War3SERQwpKmZAGYluijdwOfQZ+uPwsY+zld8kW0Yw5l5UbRxj8s/h9QAdJ4e+NnhHUXW21m5k8O6jxuttWAhHTOVk+4V7ZyM+lej2d3bX1us9lcQ3EDfdkicOp+hHFeAalaRXNo0lxEieaP8AVsxwTs6kexwTkdcCsT/hHG0DR5JvCV1qWjapPIXhjs71oYi20AF4iTG+fTaM4HPOQAfUNFeFQfFbxb4e04nxFomm635bFpLjTro28gjwOfKdSrNnP3X59PX0bwF8Q9D8brMulfbILuHcJrW8t2ikj2kA56qcEjoT1oA6+iiigAooooAKKK81+IXxb0fwtMljppttY1cyFZbdLoRx2wUHcZpAGCEcfKRuORxjmgD0quf1fxr4X0a4e31bxHo9lcJ96Ge9jSQf8BJz+lfL/jPx5rV/eTSeItflV5oSV0nR7uaGGOJlXhygyS2erk5zxgYFcvbaDPdzXKWVnY6dZLCt3LcoxuHUMOfMaXHCdWzn7yYGGoA+jdZ/aG+HmmFlj1S4v3ViCLO1dh1xncwCkfQmqVr+0d4NnuViez12BGYL5slopUc4yQrlh68r0r5619redzY3Hiy6SK2uGiErzfJNGGJjdYgI9h+Vcgb+gIbnm9dWN1dWCz/2vLqG5Sq3cd5K3lpwflSVnEmcY29BzyOtAH1boXxQ8Ea5IkWn+J9LNw7iNIJpxDKzk4ChHwxOewFdlX5+a34dtVt2aXWxDejZJHaTsmF3NnCxL8y9vlQHoeucV7L8FPidqWiv/ZviKd7rSPOht3ku7r59LZiQPmcfvYTujIO8lF68c0AfT1FIrBlDKQVIyCOQRS0AFFFFABRRRQAUUUUAFFFFABXN3auPiRpbbGaNtJuxuJ4Qia24A9Wzz/uCukrmPGqmxbTvEEbOp0yXE4UM262kKrLlV64wr9P4KAOnrhdQt5fBOsTazaStJ4evpUS/tZrmQ/ZZpJ/+PmLcSoUmY70G0YUMOhB7iN1kjV0IZGAII6EVBqdjbapp9zY38Kz2lzG0UsbdGUjBHFAHAfFPS5bPWNA8W6c6RXVncxWNyZJGCmCaQIrEdDskcE9MqzjPIFbVze+TrWg67G7RWOqRrY3Ecm75WbLwNwCAQxZOwPmjngZoaA8t9Z3PgjxpZxm4is0RJklZo9RgA2mRSQGVwQNy8kEggkGub8BXMk9pdeBPF8JW8toY4pCJH2uQGImjdsNtwibcdCD6cgHsNFcn8P8AxA+pWtxpGqBovEGkFba9jkYky4GFnUlV3JIBkHAGcjtXWUAc5rdlc6Zey65o0JnkEbm8s/McfagEXayAZHmjywo45BxkcVt6fe2+o2cV1ZyCWCUZVgCPYgg8gg5BB5BGDViuZ1Brrw5qM1/DA9zoty3mXcUEZeW3kwB5qqMl1OBuUDIPzDPNAHTUVX06+tdSsobywnjuLWZd0csbZVh9asUAFFFFAGX4i0n+1rFUjmktryCQT2s8bEGKUAgE46qQSCp4KsR3pPDerHV9OEk0ElrexERXVtIpBhl2glfcYIII4IINatcP4n/siDxnZr9u1Wz1y8tW2DTxJJuSM5DyIAyEDJALL/FjPSgDuKK4K+8Va1pemSzrZW+ohFJVrmO400tgZIbdE6AnnBLKv07aOn+PtGubKC5uVv7BJmZV+02rlAV6/vUDRkc8EOQfzoA6yuL+Ifw907xhCLlJJNM1+BNtpqtsSJITuVsMAQJFyg+Vs8E4wTmuutLu3vIRLZzxTxHo8ThlP4ipqAPn7QvE2taNcr4X8aWMseq2MRitrplYwX0QI3OjbcMCPL4PKlgMcEVz9zpcWt6lrEitLp3hrzpoIrCy1CXydRKyyK0rIrBdpK/KoGOCSete7/EHwhb+K9NiK7IdXsmM1hdksPJfjKnaQSjgbWHcH1ANeAaBpMMumaloU6S2t1Z3dzp81pA74iBlcgI5AJUIysG4yCPc0AdBpeny6RYiCwXyIhhkjiU7V69B0OMjPbHA9rmp2VzbraLPPLLdPEGdV3ny8nhQBxnBCj6k9c1n2ulXlhAILOVLu0iCY3SywSxlTn5XXcmRnvGabFda3FfwPqMUEtuo4dw8yhdrYJeKPd3bgwgcnmgBWH2KGOyiVPO5c5JJQD+In1HOPqemKmLs0KFmYsqfuY2JyoKnk8dwT9KdFa6ndq97a6a+pWzy+TJJp8hlaPjlXRlR1IyOozj61l66y6Y6yanb39jG4wj3FrNGgAXn5mUKD2/w5oAurMEZmiUDaxSPzCcAjHzdO3OMd8n0offmRWD9WVAVbGQByePccfQHrxHaXMeonZYzRXMew4EUhdVGByMDBx0/rgUk9vM0rRxxyRquSzfMNo2gsT37D9BQANOYzHIBuJmMcEY3schsb+hwFw/JznB9QTrWghEUDyRbfLZneRmJLfMck8Hpz0/+tWVp8DNcyz+WY4d2IomL7YolYYHPJPT9O9brusVoioj+YWEjEjDH5gQBj8/woAjilM0sp8tkHmAbecqm48Y5wcnOT3+pqZRFbo1zL5hW3VFfY7tubPyoOOSPT8vUV4TcFHMQ2ySP8m4FtzA4J4HRc5PU5IAqYYRotxK+UiDbk/NLnOT9OePz9gB9hbybA14FJAUyckhWIbC8Dkew68DrVxArIkz5iAbKJhtzDGdxyOgJ7dW56Uy58uOC2gKMDjJduTnB49PT/PXA8T+ILayYRNf2dvLIBGglm2MqgcEDrwMY9zQBLdlJ3MjIyxI20fMfncIcc9gTzWp+8igmurp5A7ocsd33cDOM+uTk56E96xfD00V5uk+y6hcW9uoKw29pcStKCAPlIXaeeSc9vTNO8ST3TiR9XS30S0lJWKPUrlonkXAyqRIju3XuOeeuMUAZ1xdNql7b3CBzFtzDHk4IKrhzlVOQBgEADBOOGFd98MtMD6xFObaTy4FeQSiV1G4nGWA4bqwAPHLHqK4mCyupZbz7SkzG23BV3zWEHmYUgFtnnOoyWziPpgE9a9L8B3Nrods63dw7Ncnzmb94+WYjaqrycDIAJ5PHLZyQD0SiiigAqtqd/aaVp9xfajcRW1nboZJZpW2qijqSakubiG1t5bi5lSGCJS8kkjBVRQMkknoBXzP8QvG7+OtWgjhtJ5fDsR8yxsMsrajIuT58i44jAAKqxA/iPYAAt+NvibqHi6X7NpMt/ouho4eNrZpI76/BBCHC4MUbNnC/efb26V5VosMUN6C2m3ljFAYntoEnnFr53l7QjusZYyfM2cYIG4Z4JrrvDVlci+tV1Bbm7vPPjv7omQxpG3kSYTAIBAKoOT8q7j1bie114jRrZmsRH50ktkyx3EkSW8kWMyq7xhZiBk7EJ46ggEUAZtnY20EUsG4X15aKXu5PnZFuo8F5MsSob95krgkHkdQBz+qNqN94Znt76xeO5EommnubkSNIF27EkABJ+63AGBhs8AkdY9jeyW11d2+l3sTXlpdGY29z5Qubp0IaR9mVZXPlgKMbWkQYPeax8HSSyfYpPEN4+qmNszafDNcA3JQnOWTGC2VOOMDsMGgDlpdLe+0yOHT7UyX0s7fafPmklmALqiiN4Qq4GV4dzncORmn6VBDa+HLZ7xZRfXCtBHCGnWPd54RljXn5x8pGB8uSDg4Nely+HLaz1Ex3dtYPJNayxXNlM9yscci4KhJNuJeQQV+UbSNxJUE0LnSk1LTGtorO81Cymu5GVJZpDE7Rsu3ysAbQwJcMFBTcByoJYA801q1sfsWmTTXBvZ4QtzM9xLcNgxy4kGdhII9jyqjB6AS2Avre/wDNt7WWd3t7eSWKSaSRpsSgHZI4U7dolwHBALnJOEx1muWtmsUMkOj3N95kRt74lnX7JAo+dGkU5JwIwA24FsEZHBwr2G9037JfWmntZ2kL2q/aZmM0jhoyZZN+d6IfLT5Pm+SRgMghSAe/fATxK2oaEmjSv5kVpaxTWMzE7nt2yBGwI+9FhVJyeCucHIr1Wvk34Ua8+h+J/Do1S/8AtNxFdpZXdwpZBsuI3CK+QMgN5HIyDgHtmvrKgAooooAKKKKACikBBzgg44paACiiigAqO4hjuLeWCZd0UilHXOMgjBFSUUAYngxJYfDltbz7y9s8ttlySSI5GQHJ9lFbdclLdp4Y8TrFcM66TrEhZGELskF2zRoELKCqiUuSN2MtnnnFdbQBkeJdFGsWsPkzfZb+1lWe1ugu4xODzxkZVhlSO4J9q4jVLS58X6RZ69oYij8T6diK8sZt8ayMFO+A5I2MC25H57dQcj06uR8SW8+ha0viXTIHmikEdvqttDFueWEEhZlAGS8Zbkc5TIHIAoA4uzK+NLb7dbXDaF4y0qb7Ml7JEQ/ygZhl3feUs3KnrgY9a6zw74uvbb7Jpnj21h0rXJp1toZIBI1nduYy48uQjCthWGxjnK8ZyKZ4m8F6d4oNprug3Fvp2rSBZl1KK38wXMTIABIoZfMG3aVJOVKggivMLaNLfzfDPjez26jcrKlypjYRXR8s7Xgk2gNjKlSOY2HPKjAB9EUV5j4f8Uy+Fb1dI8UXTPozgjTtXmVsbQQFjmbkAkEFZGIBAIPzA16dQBzl74TtnuWudLvdQ0m4Z2kf7JOwidm5LNEcxkk8k7cn1pLPTfE1pEyHxBZ3vzHa13p2GC56ExyKCfwrpK5zxB458L+HeNZ17T7V8keW0wL5HbaMnP4UAS7vE8Jx5Oi3o/vebLa/ptk/nRb+IJI2aLWNKv7K4VQ2YoXuomGSPlkjU+nRgp56Vy8/xj8Kiz+02C61qMZyENrpFzh2HYM6Kv4kge9c5P8AFXxRqK/8SbwxaWI3bQdSuvMcjIy2yLgDH+1/LkA9HvfEc0irHoek399cyAFDNA9tCuR1Z3UfkAT2qTw7oJsby71TUZI7nWrwATTopCog+7FGCThBz7knJrzm18ceMmtIJbqfw5FLIis0S2FwShIJxnzhnsKbF488UG4USXelYYH5I9NkOMLng+f7jOemaAPZSAwIYAg8EHvWC/g/QxNJNa2X2KZ0aNnspGt9wbrkIQG9eQa84/4TzxfLEj28+h4fJXfpk33cZBOLj0yfpUUHxG8c2czNe6Jouq2wVmxZPLaS4BGPlk39ckDnk/Q0AdnL4He1y+k3iF1GEFz5iseQSDJE6Ht3B/GqF14Vu7qaTzJvGNoByBY64GjYg5BUyPu9sHg55HoaV8WtNmhnbWNG17Smgz5hewknQYGT80Qbpz+VdL4W8beG/Fe4eH9ZtLyVRueFW2yoOnzRthl/EUAYMMWt6VbNbWzeL7lQARLcGxnZefUtubqTzXnXjCLUdCvbzxMz6rJC5gi1f7dpflqI1Yr58bRHGVDfNkNlemMV9C02SNJY3jlRXjcFWVhkMD1BFAHi3nma3jdJoXhkjRuFZlRdxOAc4K8AnuenTOTzJZEEkiEvnbEpB3SNg4/D+Ln+lZt3oq+D/Fknhk3Uo0u7g+1aU8kTEqoZ99sHJw3l/Iwzg7WxyBU9qyiZnd1VI1VAQvzYAyB6knIzj265BoAmk0e2YyX0JmtNRYr/AKXZyywyN8nCfKQMDnkg5GOcVseD/HtzptzbaL40eNoZUSO01UqVEhIA2Tgk7WJzh+Fbpwax3fy1M9xg7drJCiHJyPu49OQT64rF1OFZ4JYbqAXBuEYyxspAK7cEH0AGenQe+TQB7Rqngjwvqru9/wCH9MmlfOZfsyiTnqdwGc++c1l2vwu8J2csslnY3kDSLtYR6lcqpHpt8zH6Vi/BnW5oheeFNWvZbq9sMyWkk2Wke1GwFXbu0bMFOecMnfNeoUAcBN8KtEd2aG/1y3yc4jv2IHOcDdnj2qJvhVYkYPiDxFjJI/fxdScnnyvevRKKAPP4Phbp0LbjrXiCRjhWJuwmVBJAwiqBye3t6VatvhrosE6yi61h2U5+fUJOT+feu2ooA5WX4f8AhyaXzJrO4kb/AG764YH6gvipLi38KeBtJN49pp+l2qFU3xwDfI5+VVAUFnc9ABlj7101fPXirXJPGfihLtnuv7HtmaPTrZEMZkJRszMSRy2CAeCqZ4BJoA0dV8ba94rsXXTWm0SweXeiwArdGLbwruDhGJySFGV4Gc5qvZWNvDJLLES12wJa8uS8kwOAOCxJ5wOAQOpNMggWO3SSSZF3lduUZTgR8KFzwO5wOoz7C26wsSJFRNrDH7nHb37+3PQ59aANGOEJcSpEx8t14UK43EqDxlufx49gKveCdKXWPFAup0lls9KDbGkMg/0hn3BeThgg5xg/MQc5FYWqa1Fo2gXt3BB5wtY3f5o2PmtjCrn3PfHPyg5z8vrXhHSG0PQYLOaVZros81xMq7RJLI5d2x/vMfwxQBsUUV5Z8cfESDTf+EVtLiWG6v4xNfTx7gLWxBO9iw6F9jRge7HjFAHnHxU8aT+PJ54NOnvIvA9n5JcJaur6xKWPyKSQfKzsXoMkk5xyOa0O7mC/a724S3m8lYpYtrbEkUMxDNuPlqE3Ng9dik5yore15f7Oj0uwntY7OxaJZDPKu1FgEamPYxA+8xCNjkbCGA3gnPtJ4YL7UbmxgjlsbmWRlcQApKPLdo3IcYPyoyEkHgH2oAsQ6XfWPg2BbXUZpNUv2hCSJGWlkPlMC7k5ION2Rg5Dc986vhW4W4ttI0xNJuZEt4YDPO8MtvDaskKwPEpIAkLqXzg4ZUGR1BbaalcSX8GjpI1xqAja7ubiG0lX7PI/lZQOPuIyzSLu5yoIBBatHw/aiaC/uWiaG+it/s6l7IxgoF8ssSpbJaRRydrAZHVeQDM8FpcR6u51ybU7u6ispTqNncQSx21o2YWh8tWUKjFkX7rEsASRk10Wi6dqdtqutzXHiK7nsVM9pHYTZQPDuBil8zhmb5GAIwCOBgA7um1HXrN9SWKOXfbXsM72qxwOEUrsC9AQDudODhtzDjOK5uHVjJHPp8FxFe+JFUS3EBQKQB5WNjtwp+V8ZyrZcg46gHA+Fra8ubzSSk+oXxunm895klt97RXKLHsmMfJWMucqWYhWzjto2OnPpuo2Om2l14gWX7df2krC2unitVdpgkrSEFJC6+QQ+T90e+d7w+2nw39j4bT7bbNE8iSaffWhnmIaZZGkkAUq+7zd2QxUAdCcgv8AE00UVwt/dzCe182eSMPCI44di52jC4bJGOScbx16AA43w7qGo2utW11u1O9HlzSPJLZzRtp5FwzbpFLCJdy5wEYKVQDaDg1FqMMGpaJZTXN21smo2Svcw3EUjpA24KSoJztAXYOCVGPTI77w3rsU/ha2OtXfn2Yt0jDSWvLxtMytJxuG0HPGD6DODXnN1aWXiXV447e4V7eBLe3tbs2LxKD5qtM6t/31GWJ+YKcZLE0AVNd05LJNfVpEl1KFNMvYZ0csSpEkg6nKsOM4yTnOa+xLKVp7OCVwFeSNWIHQEjNfIhhj1exjviblYtR1iCK2jmX5kRrhYMe6jymx689MV9gIoRFVeijAoAWiiigAriPiT4iuNNtTa6ZqFvY3KoJ7m6lVWFrFkhZGDMoKlwAQMtt3YGcV29eNfEjw04199SmHlslymoWN0FRleeNflt2UsDk7OMcHPJytAEvwttZrTxhdF7q2soTF5EFtBarHFfRoMCRWDZZxgsdwJAfg7W49gr5/0XS9a36nBL4TsfEBNwJZra+ht0uLUvveNWDS7SArj51OSdwwMVpR6d4r8K/YL6SFNG0fcBOtnfy3SWOQFUPBIdrpnAbYVK9RkCgD26iud+H3iIeKvCOn6sRGssylZhH90SKSrbeTxkHHJ4710VABRRRQBV1TT7TVbCay1K3iubSYYeKRcg4OR+IIBB6ggEVgWeqXWgXVtpfiGR5oJ5BBZakEOJCeFjm5O2Q9A3CufQnaepqvqNjaalZS2eo2sF3aSjEkM8YdHGc8qeDyAaALFFcTp3gmbwzLK3grUPsNo686Zdh57XcM4KfMGi6/w8cDIOKS3m+Id4Sr23hrSgrbfMkM12WH94Ipj/ItQA/wJqMOn3N74Tu7nbeabO0VmkxIee12K6MpPDhQ+w7c42jPvseMvDNh4s0G50zUUX94jeTOFy9vJj5ZEPZlPIrmF+Grag8s/ijxFf6rcPK0wRIYoreIkY+SMq5Bx8uSxOOPXNaD4cavpAhXw34vvrS2hz5dtMhkQcYxjdtxntt+mKAObW7m0rUtW8O+N4rSQwW73S6mtrtS6tdse5wpY7SNpDqen8Jw1YWnaNres2k1/oFxqvg3TJ0X7BYxOyPJG0aEy+WspSIkk4UISBz1xWp8Y9F8RXPg26u/ENvY3dzpdtdGHUrW3I2RyQMr713k7SOpC4yAcYBNUtf03+1rV45R58PlrKTJGJEZAqrmRQ3PBwApBB5VlIoAo3ngzTpblJ9Ze6166BKedqty9w+MjopbaDjHTgYFXLLwdpeneXfnT9OhZVzFHBbRh5CW4ckc59zx3HQZZY/2/Hbl9ZtluIECFpoLfDyxbhgyZfOeny7Tnu1dM19pzael1LbXcNsxKC7kjUww4IXadhYhuehxQBnqYrpppdilxIY41kVNsYB5wDkHjjGcCnafb2kV4NyyykbMxso5O4ffO44UDPHBPoKuT2rm1gW1FuYvLZhKmGGN5B+YH1HXrnOKrxpMpLpGGY8qoUDcfUUAVJZvJucCESEAAZIUDr2PfOTmpEjtIGK3MUofaOEjVggxnuRnv/KpdMtnnkM7xrIQec9jgnOO/T8hU+nx+XqCzXMaNs/eso+XnHGSfXAyfrQAmqQrZwK2yUySBs+ag2hcZJAye2M46dPWs5PtBUOUKyfM4En3o8gfMc5wcdugycVPGTfTtdOsqMyAYkIDqoXOOvvnHY1LFaNdySSomUgQmQnsOhI9+e3PzUAQxQ/aN6Rg+VCGLFF656jqMd/1+tc34j0vS9VdIr3S7N445XYyzwKzqoYFvnJ3AZwPQD3roLgL50iKXgQ/OzKPl6ghRk+w7dqo3dlJG+EVZHPyqGXk4OcHn/69AFHwxqvinwurR+HdW87TsMI7DVImuY4yW+XY4ZXUdsFmHPtmu38P/F2/itHHizw1dJLFII3udKKTREZILeWziRQMc8N3xXE3QiV7X7SfL2sViAX5mbOCVA5Y4B4AJ604ajYW9qYIrd5Lhjgr8rNjdnOxWLk9vu9M5oA9P+KMFv4n+HKaxosEWpTWM1vqtkwHJ8qVWfbkjkxiRcZHXFcPDLBd6dZ6hGhNnPHFJbgDa0mV+XkH3HbJ/OvXfBFnFB4UsVRZvLuIhMUnAyN4BxgEgDnpXiGkT3toT4c1VAL3w+RpyP5eC8QX9y4HIJaNh9Me9AGwk7wKLqRIi+dqRN/Dx069gOvT60yKxl+yGdolMhJJGAf4G/2uAM8e4HTGDJY2lxLcrK6sCDsjVEBOCMjv37dOOTTLjzNoCqh83ATbjIwvPflRgj3oAy5GfT9Rs9asIHjl0iRrkZ+Vp4fk81c7hwUzgY6hR6Y9f+Ieo3lpFpNnZ6nFpCajdG3l1GRA3kL5bsAu47QzMqqCf73HOK8c8QEtpN+Y0WTKSKJVwCz7Bwq5B4OfqT1617poEtr4k8IabPdwRXNvd2scjxTxhlJwCcq2e/rQBiyeMTa3nh+xiMWqJdxL5+oKwhR282ODMa5OSXcttHAA6nIqYeMLxrXW7geH7xbfTPtI8+SeJI5mhfbtX5iw3L8wJUDggnpnpJdK0+aS0eawtHe0/wCPdmhUmHp9w4+X7o6eg9Kx/ED+HrO2OiXl3ZaXLrbyJHGpSN55XIDMo/iYs65ODksM9aAKVj46t7rQ49TNlLDG15b2pV542AExTa29WKnCyKSAfXk8EuuvGEiHRZ7awWTTb+GG4lujOMRLKyqoAXJP3s5OAexPONqx8O6TZ6FDo8enWZ06MD9wYE8tmB3biuMbt3zZx15qVtD0l7i3uG0yxae3VUhkNuhaJVOVCnGQAeQB0oA5D4z391F4bttLsGjEurXH2WUMTuMAjd5AuCCCwUJntv8AXFedWVpb2io9lbxOzEJ5ohASIlBtCYOQcDgE44Oema6z4nzRt4zt1uEJjtNO8xT/ALUsjDjnr+6/z0rkzcB441tbdfMGNwZOFGzo2GB98AjqScYxQBNLMzSCPyWkmcbi7KHfaNwySDgDgfXcOGzmpp+ZkAiSVhubylix/CMfLn+Z57jqKoRIkEC+SWCqTG9wOpJU++SxwRzzx2xU8BebZsi2KSTHEB83TJPXPr1zwT0oAd4V0mTxL8QNNs9ZRFtbCN9TktinmBnQosasW7ZcvyOdg4HOffq83+ClpG+naxq62yxfbL0xQOE27oIlCLgHsXEh7Z3ZxXpFADZHWONnchUUEknoBXy6t+PHPii6mcW99Nr9z+6iuVdYodMhlZYcqG53kDPIyZiOhr1n9oDVY7XwKdH82SO6164i06Py13EIzAytj0EYfn3FeKwXCSaneLZWkMNtbqbTz8JlUgmy4Yb8rGGCMrEBcgEZwcAGhqtpA1zpUdhfW9xNDaQpLYPZRnd57FyrwgqQdp5QKCSd5K7qcdXZYxZ/Z5oLe8jRFWC1SVo8wSKQPnK4WZ2XkkEEYzkA3LvRYdeNteWPlC2uTC00otYUil2fImQxU78lSzEcBVAIzkGj2MuvypDb21vGHLDyZYVRCu/dGxBBy+PMOQFIJXnHUA0tMtbh/FGn2j29j5ck908MckalSdpJWNV+ZQVjhzyCCMkHkiv4i06+068b7Ei2cV5b7DCIykcebUlgPLyzLv8An2EYJUHPIFb0llq2kf2Ube0tLWaziit7VZ4t0lyDb4MM7nqWYLySPmK5HPFG90fUrmXRZ/sMM4yzLDI2EiJi3hmIbDFckr12443c0AXdGsG1TVhH5cllDFaM90sMRiiiG1cEAvlg5OVXAAAJ4JAHNa9Y3vjTXr3S/CjGw0uO3ilvdS+yRiWaUCNkVASpDBW3552h+MHr2XjDWBoyweD/AAzarLrd4hO6RwCqAqxllJ6pl+nU/dAOc1W1zSj4T8Mah4e8KbILy4iku727uwssqoyRq7u24gFtpJ6jgADpQA/xnbJqmppNpbyLBFAsTCALFbzSq5biQsAWBKDcTjIGDuAxy97psMVjdpf20Mk6iSSExXAEsaDgGM5BQkkk/KxGcn7oA19M0HUl0GwMN1a3lvDK0rJ9kWEeWHHyMy3AClSW4IkGSB2zUWpaVY3Eht3067tI5AWZ2VGSM7w6pG+SVLBeueOCM9SAef8Aj3UobDQRc3mkaTFqN3FFIqyhPPRg7BtvIOSyj5yAxUsMcjEfh+2R4L291u1sbRGhs5oUt9oKx5YHYivuVFBzsZtxKFs8gCveR6Dda3f6ppc1obYbZVf7OhCZchyZDk54OW3HOct6FNBv7bUPEMUFikCR3ahR5FosUbLGOu3cSEC5QnJBLt8uWzQB2Pw4sPtev+BNO1OyTzAzXcqxqpCPGkkwJOT8okdcYz1HavpuvJPgnpsc2q6zrq2yLD5UWnWspUZ2xs5kA79WTJ77R6cet0AFFFFABVXULGG/ijjuAxWOVJlKnBDIwYfywfYmrVFAHm/wr1ltY1TVb7V7i3j12+hgk+xQbfKjt03hDGwJMhDM4dmwQ2FKqAue08VadLq/hnVtOt3RLi6tZYYncZVXZSFY8HocH8K5rxnoctvfQ6xprXcSJI01x9jVGkhcRMonRX4Y4Ox1wdwIOMqK2PCHiOLWrKGO4eKPU1iR5YldP3mY0bzIwGYmM7xg/nQB514S1CfwLcw6fdreWtpPdI0+n3UMOYjMG3SwSo+HjEoAK4yN3TkV7NXGfEbwjJ4ljsriza3+12gljMVyD5U8MigOhI5U5VGDDkFffI53wV47i0y9u9I8UztYwQsyxXV9cIVidFG+CSQng870JJ3KTzlcUAeq0UA5GR0ooAKKKKACiiigAooooAjuoIbq2lt7mNJYJUMckbjKupGCCO4IrwfRrMaTLrmg31y5XSZDAPnjDtCQGgZj3Plso6cnPHce+V5h8VbKLT9asNemWVdPliNneskoRA+9TbvJnsN0q7s8bx26AGTpdzGtwWlVnkkUsgCrywPG48k/KOMDrjrya1b620oXEd7FKINQXdvnt1WN5MkZRyVIZcL8wIPHHWqnh2a4ikllsZ5EufuPhAR94AAbiRg8Zb8+nOTqH2gXFxvDKGbc7NJ8uzcNx3N1HT6kCgCC01bw8hkt/FvhmB4YZtsWrWUUUJ8tpCA0qoyupUY3FAy9fcV3dr8P9InSK80rWtUFpKivEYrmOeNlI4ZWkRyQRznPOa86IW5klMcjLCpQyEhQJGDYyCTwu0+h7+ua6f4Wzalo91PZQ2V5c6XJ5UvkQiLbbNKx/e4aRSqHazFVVvUDOdwBu3Pw+uCcWviC5WLIYxTW0TAnHPKhTzwfTjjFZo8G+LIoJoUvtEnDtkSyxSK33SozjPY16ENY003c1r/aFp9pgUvLF5y7kUdSRngDFVm8TaEsKTNrWmiKR9iP9qTazbQ+Ac8naQ30OelAHnH/AAgvi84Vrjw/s+4GPnMVTHYYGfXqKtSeAvFM2FbXNJt42cM4hsWz29Xx29K9KOo2QiaU3lt5aZ3P5q4GF38nP935vpz0rjPFnjRmSCy8Jz2lxNcKWk1ISK8FpGCVLDGQ8mQcL0yCWwBggHL6tokHhtCdc8US3V1tLrY6fZQm6nOeNobd6jkgDnJIrnZ/C19rt3dMgmtIEkdt11dpNM5Eg2kogWEBsHhvM4PTNdHeSWunyzLaTSXN9IC91eXTB3csqru6dQq4Cjj0AzzBeajDp81jAjNJPK2zyFw2/L8jA5Ixkk4wMdgKAOdGi6dBqO5LOEybtrhYY4kRNwIwigICATzj8TiqWpyW1nDcwwRqsOAZWAVQ3JONxxgY/QZ6V2OoySLYt9llVIJGKFiY8KN4O1Twe2CT3x/dOOV8JaT/AMJx4zaxiVX06weKbUZhJG21NzEQbQclpCh3HA+TIz8wFAHrPwoiv7jQ4dVuy0Fpd28Rs7UShx5e0HzWI43PnIA4VQowDmsD4m6LcR+NtN1G2TdbapB9hlREXLTxiSSPJPOGQyZPYRgZGRXrIGBgdK57x7oD+I/Dc9pbTG31CJlubKcAHyrhDuQkHggkbSO6sR3oA8uJjt0W3CDe54BZRtG307Zz/T2qGeWK2YxnEiLzPKWAAXbkKD68DgdBj2zn6TfxahpsGowKqwXMYb/WLuDbDlM9cq33u4OR1FR3F28Ks0TswwQFUqPMYqQ3OM4+nT8qAKmr6iTcziOFZ5tmxIECjJK4wCpwOBncD69eM+yfBqVZvhd4bKnlLRY3Ho65Vh1PcHvXkYutsk8pB3Fc/JjAXCjI5xk7R0OSFHpmvSfgTcs/hK/sm+7YapcQoQFAKuROOn/XbH4UAejV4z8cZdRs9Y0XUJzYwabFcJDBJJdqis5kibM4aM4jDJk43AKpY4IWvZq53xb4RsPFMlkdRnvUjtiQ0ME2yO4jZkZopVwQyExrkcHjryaAN63Mht4jOEExUFxGSV3Y5wT1FSUAYGB0ooA8W+J9+ieOLrypESaCyt0ZiVBQ5nbuD13rz9a5W3ngtYIhZ7ZPMkDKUdV3npgN06nPatLxrMbnx/4mMLKHWaO18wbQQv2aMlc56ZZ8/l0zWbaiG2eEiR4bYBXLM43rjOGHTnAOOn4dwCxbRmWFpIgUcx42nYojBTO5v7oyenXGao+L7m2tfD+qvZzFIVtZf3q7QSQhIOMcj+uOa0LVJtTmkto5W8jGTHgDzX24wWxnHTn/AGRjPBFieKXWvE+l6KJRJPf3SNdbERQLaJlkcYGMA7dowP4sYGSaAPcfD+lwaLodjptqm2G1hWJR64HJPuTkn61oUUE4GT0oA+dvjhrE+reO2s9LktY20Kz8oTz7SqXdy8ZVfpsVQemN5rG8M3EFhomr7ILO2u7021pC3G2aRpFMr/d4UsQctg4wDjHBfSR6tdXr2ESypq+pXN6Z5WjYSRpdRhTgkcGMoq9RxnrWLYW0N5qV7pAa/hnkukUspRRJBHM7vCGPCSFvLfceqp32kUAdi9jat4etZbNYbyZLe1mjjllheJN7LuDbMqWXd8u7P8XUYw+31ifWrWyzb28mkXSKqmeaJCGKMd2GI2jdn5Sf4QM8qayX17Uf7Rt9L0WTYbJ7fS7eWV4gbiERsDlAckKzEDjq6ZbB+boBefaNCsbq1mK39na2sd1C6LLuYRsGLDDYUjABIxgEnkDABKfsYtDGdMKS3sewxO0SWsgaEbxgnqSmWJAYFgQSAcM8JXlhpXha78Qare3DaXpBMbwSpG3zrbK6ySchGmIdEzgsWYDJOcXdEazlv9N0XSbJ8NC6fbURHWPdCSiBtylowzSv8uQcKoOMUzUdKh8S61ZeHLeCS/0Dw9eR3l7c+cCZ544CwgCkNvO5oy+CFUFQBmgBl/Be6DY3HiKeygXV9ZuVcyzMs09rbqirGTuHzhSELn7q7ifSqF7dSNbz3j3dzqOpHLPLbIksmwlQUzhcKBzznjOBXT+PdQj1LUbyBImtXtiUZ3ZXjnYAbD0IABYZ5B5weQQOE1rVUsWnnudivcSeX5qSiRHYJGrSLwRnbGuQxOdo6dwDrJ9TtrXS7eW2xp/22UmGF5I0eZ1bByxVSHOCBx1HfGR5b4v1ezlnlhvb3VJo22xSrB5UWAV3mMbRuLBQSTgZwRlsg11l/q99a3lzG17J5szraiRrm2LSJ5h3KAF3FwuRkZB7jkrXMaFALuG4eIXVlI14Z/N0141kvPMkBK4baAscWUHDYPzED7tAHMRSG/MVrLpYjtVINv54MY8vzHVndcYAzGykY3ZUnjIrp/ClpPa6Za3qGBtY1URWdgZYo0IV2ARV7hcncQDjaOmBzNr8b6xqdykCMuhlszGSUKscBdjKikYyGVFQcMAN7Z9fSvgboVzq18fGGqac1lYi2SDQ7eQqCsLcvMUXhdw2Be+Ax/i5APVvDWkw6FoGn6ZbhQlrCsZKgDcwHLcdycn8a06KKACiiigAooooAK828R+EtSsbpbjQBJPp8UhuYbe3nWC5spDnf9nZlZTG4JzE2Bnoe1ek0UAeb6J44uIoEWUnXE3neIAseoQDaDtltQBkqdwJQnoOK15ofDPjhGuNNvbaTUI4mj86Egyxq3BWSM9V4IKuPXoea6LWNIstYgSHUITIqNvQrI0bIfUMpBH4GsCbwFp8uotdyalr+7ynhjUapMpiV9pYK4bzOSoPLHBHGKAMHQNZm8IX1/pOsEmyth9oIDFhawbRmRMgFoQc5GMocjlelp/iXFqN99l8IaY+tKrMHvHnFtagAgFllYHeOvKgjjjNcp8T/BFzpngHXmm1bVda02GznkT7Xclru03KAxWbq8W0EsjZyM9eMVLHSb+yS3vRc/2rpE7Mwla9aWLyCwMPCqWjVVbb8m4EDJC4yQDsbjU/F941041PQtPtEfMZtI3uHdc8Lvk2qGP+6w/SsnS7zxY9+JLjxPPJYZCnbBbdc5YBvJ6qMdAR1/BLbV4ntCrxo87yZ+0W0guYokJHzHy84XHHzquO3pUF3e6Q1tJFLqltKI12x77hGETF2VjjOAMEDnIXnjvQBt6lb6xcBZLTxFrsVywBjWRrcLs3cFlWEAd/vdv0vCa9meC2tvGUiXaqjSlobeZGZgfkCiNTjODndnGPrXP22ppPqei/bx5el3sEix6j9oURxeUMhW7EHDH09euBtxahY6ZqJjs7nTcSFGcx3SAIASABjkk9W5HAxwKAKU3jLxPpmo3FlJaaHrKKdsM6XMlk7eu5Nko7ZyG5yOOa07L4labD5MPiu1uvDd5IEwt6uYWLLn5Zl+TsfvbTx0rhm1/GsHWIEa4hV8FrYvLgBSCzyEKi888sM9c4INNbWtX8R6iYIhHOiH7RIv2kmC2GBgySIGUnBOArMc9RknIB7Tp+radqTSLp1/aXbR43iCZZCuRkZweM03xBpcOt6HqGl3RKw3kDwOwAJUMpGQCCMjOeRWd4U1D7es32GGz/ALKhIiiuYJjILghE+ZflxsBLLncc7a6CgDxPRL28h0sWLzQz6rZ3c1nKoxGpmWTaJGwOhAD84HzYHFNvkYoto0ySgTHzJFlEvzAgZ5HTK5wc9OR66HxS0qCz8X2d5BLJbPrUDwXDKcB5IjHs5P8AEULj6L9ax5FAghtlz9m8z95KWyXYEZOe/b2AoAltYPtjkkyLYRSBRL5oV5G3cvnBITPTA5JPbgsutXvNPv5bnTL+a0nnSNLkjyhDJtZiD/q8g/MwJBHUdcU1ruF7K4jhePysBAjOfm+c/N06AAHJyccfTOMayeVbb0kTALJ5pBlbnKg/hgjH5ZxQB3Pwsu7fxQ11qP2i6hlsbmZRZSBMxPJndIGChmV8kjOcY6nFbV/ocd5d6Fp2l6gqjRiYbwxPG0yI1uUUMpBwWG3sOORXC/Cm7XSfHv2HaQmqWbLkkLiSA7gMDP8ADK2ORwtdV4c1sR/E7W9Na3hS7vds0hEj8LFGq/LmIbuq8kgfeAJ2mgCbxRoq6Rokwjvrya0eFbWHT8QqrMYDDksYyfufNg8ZXpjiuflSTTNOitLaZriZvnlkmRQ0jFVH8IHTbnpyc59K3fiBeSXOuWthCVCWtu9xKxbIDv8AIgx/e278HtnPFZZv12mNogZIo92/eS5zwTu656DrxQBg3klwJre2gaNLhFJEjyKFAzxz2Gc9Oep6UR2cZWM20jveuxSQRS8sC3y8EAqSO2SPp20ri6Bt7p4Qrq6k/PM0pGQuSW6k9OT6du2SrytfQwvG8KSHYChMhlO4cALzk9gM5554oAPFWpXka6T4f0nym1i/lNqkZYOqHdyemNkYO5yo54HpXq/gXwxb+EPDcGlW00lwweSea4lCh5pZHLux2gDq2B6AAc4ri/hBpt3eaxrHiDUGdIreSbR7C2EhKRpFJtmk2j5cvJH1GeEAzXqlABRRRQB886rBb6V4x8U6TbLKZIb5byNWkGPJuIw5C8ZA83zSevWsX7Zvd5kmi+zQ4UsG5kIXOFAGNoyOe+OAcE13fxx0DPiXwzrsEiIZzLpdyjPjzgYpJouOhw0bdf7wrzmaOaWRoxOIoYATNKegIACxrxy5Hp0zzkngA0PtLXCyPeyoiRjLJuAZgduAeCRkDOM9O5yc9t8FdRmtfF3iHRX+a0uY01C3IYfIyrHFIpAHX/Vn/EkmuQlgNkZUVobcZZ0QXOdmVUlVYnrgZZu2cADgVi2+rXvh7WbXxFZx4+wGRzAshEcsGB5qAntwGDEcnB+gB9XUUyGWOaFJYXWSKRQyOhyGB5BB7in0AFFFc98QNXfQ/CGp38AH2hYxFEd23DuwRTn2LZ/CgDwC1vGvLq+1J/8AWX97PdFcDkElVOMf3VXn36Vej2hrW4uJHneNysUSONi/KBkjucA5JxjP4Vn2SOs9tHbSMirapG7TSM5dwTyST8g6fKMYAHI61es3ttMhti7y3Usac7QGfOMgbeB3zjI/I5oA6Kwna20e4uVdA2DFw6hY1ZDg5x17ls5yMHvV74O289/441zV3JaK2g+ymRzlppJfLkLfdGAAij3yD71xd3fyPC0t0YlWJd/khwViXByWOACf044r134LWU8HgiG/vAy3WrStqMisSdu8AKOemEVaAO7rlfilq1zongDWb2wYLeCEQwMccSSMI1PPHVxXVV5b8fNSeDRNK02Ibmurr7RIu7BMcA8xhj6hPxwO9AHkmnLbmxiiCNeGwvEtrZAFXdHbyIzKMjOWHmZbkYCntTVjgaW9uYNXjh1BLm7cxT+XsUtdzK0iKyYbcjqd2GAOCBgEVm6LqeqeVayaNY3Fo9iZL1ne7LJM9wBOCy8bXUgR/wC8QOhNdrLbLFqlr5S2V3OqyGJ0LI9ixMkgRpCGb5lbA6ZCnAPIABQu9Km1owXgmW2h0w2U0JjaExo8TAeb5ajKl2AAbCgjeD14saFeX73P2vWRbwX4gRPtJA8m4Vs/MAFykg2ow25BO4j7wFaej65b36yeTNqMlxHLbxEiZpdgy0iSI2QTFlW45CnHY8aXhp7e88QWOjwTWF59llD/ADTMdiqS4GwdNoyu1sdevFAEmoXsnw88HRLYSQ3mtaxOlraW4O6JJJIzgZJGEBQgnd91V4PQ39GiPw68CadodiEn1ydDJIsTysZJCp3zHKknMhHXHUDtiuZh1228S/GW8mudSt/7H8NRZAjuco1w6bZJCASGKqdmAOrEdc1p3l/b6/INStXaxcsGka4v5oZ1QR4XykjAynPQjDHcOcYoAy7jT9fbWRL9pN5MVzNIwUPgIuFCuQQexJHPr1zo6u9namZVktpZAWiMls2WikCrkHACY2jk9i3GCeYrXX7TSdHQosrGASukAkZnlfj92zMAckAcYGRnggCuW8VXkj3KQ3M63K27SThpL4hpXlCsiK+AeMAfIBnbwWB4ALll4ggm1a+fSraxhuLAPPFeS3PyTBpEJwTERHIRztwwOFX0IoOHE10+qahp4Z7cf6KsuGWHfuVmVUXnD4BCgccE8qK2utfvqNlLo8lqsria8mvdQmw0GJgwO3dliucrv3EdDgoxEemeGbjV9GvvEc0kUuhQzeV9ovrlz/bE4lEZd/LBIhB3D5ey4AwS1AHV+C/D118R3ZriQx+C4yFkCnnUGVs7VIHCAjDYPOSuTkkfQUUaQxJHEipGgCqijAUDoAOwrzQ/FPRrLw2k2laXeT+TYpcR28MBjiC7CwQNjCnaj4BH8B6V6PZT/arSCfY0fmor7G6rkA4PvzQBNRRRQAUUUUAFFFFABRRRQAUUUUAFedJjQPEDaRLAyRySSXtm8SEJMjTBjESBhSrOc/7BHvj0WuR+I9ij6bb6mJXgmsZV3Spuz5LuglU452kAE45+WgDjfFttHfarb3QST+0Jp1WCWGR1liXdnhuqg+g7KOMHBuaXfeIvDgnJivNe0liZZbe6kbz7IbzkJI4JlG3OEcjBAG4cgaaW9qXndHgluYMMJFJwnIBYbRwvBI55OB0qG61FtPtb67t7m5lkMhVYbu1dreGLzmUPHGqgv8rAttJJA7c0Acz45vhPr+keI9AvZLzSYVtrq5t0mdWhieVo/kiJHzyFSgQDJIcHsD3l3repa1NNb+GRHbafBtM2qXCMqsP3gZYAy7WxsX5ySoz0NcrKWt9K/tyHw7pMn2WCO5dds/nrNnGEUKScFQwA5BPrknT0fX4wlnYnSVkE0UUAmPm7HRVfBdjH8g+SPAbBPmHg45AMXUtJ05pbGW4udR1ZQXZDeXEsyE4K7sO2zg5+6oB57YFWWzqslvpcKyoNQmni2LNtCR+WTudQBwBkADue3ONDQ9Sl8T6Nbf2lEdHv2kEUcZgkhIQoCCFYZzgsACR0yKufDvS3XWtc1C4maYROllbqZGZYlWNWbbkDruUZ5+7xxxQB3UEUcEMcMKLHFGoREUYCgcAAelPoooA4z4vRxf8ACEzXk0MkgsLm2vMx7tyKkyeY3HJxGXyPTNebytI9yIWVvKU7QWcnBzjLccnOD6d69i8ZwRXXhHW4Lh9kMllMrtkjAKH05/KvDFuLyLwtplrGm2+kgR2YyMzAsBlyCo9Tjvzk0Aat1b/ZLdrWS0klkYg+a77SMOSRk9M468f0qeDSpLaG3m8uWLzyJJbkhj5adgv+8RgeuDnHWq6eQll5M2+WaEiM+c+TI28kgjJ9ep4HbmoL2+dY2Q5EZAMkwLMFycAYAx3/AJ+vABZ0zU7a18V6Bd3NsFEeoJErtkMpkikizuPXmQZx/QY9O0bwbb6V4kv9Zg1XWJZb2Z55bea5DQksAAMbckKAAoJO0cDivDij6oJWvIttrtjSOMSMWXqwJ9DkfhivedE8QQ3Hgm21y4lDKLQSzkAjDqvzrj2YEUAcHqGqxT6/rLw2suLi9aJJAzfvvLiETcAZ2hkPIPb/AGqpmCR4LyC2fyPKXa8ckjoD0O48cnpgds+prnNIuGj0fToUMiXCgSTPKzMyyMAznJP94t09+D0roBqEU73MsUJaHccEknbJwepHzHk/T9aAIp4WUyLcQuWkyzZOwKBjqAeR229c8cnonibxBJoWhXms3MTrNbxyMvlPteRjnbtGCAN3OQOvPQNUfmyad9ta6KxXSjd9llVmPzDClhj5SAcgZGOD3GcHxx5F5oU093kCaa2hAZixQNdwqWAGDkglh6cfiAe3fDbQH8MeBNF0ichrq3twblgxbfO2XlbJ5OXZjn3rpaxPGOvL4b0GXUTFHMyyRxrHJL5SsXcLy2DjAJPTtUV94x0Gxs2ubrUI1RbQXpVVZ38k4w21QSeo4AzQB0FFY914n0S0imkutUtIUgjSaUySBfLRyArMD90EkDmmR+KdIYWxN5GFupVityGDebuUMGG0navOMtjnjuMgGF8adEl1v4castom7ULJBqFpjORLCd4Ax1JAK/8AAq8j0i+txothfQh4UnjWaF1y20vFvCqOfnKnr1HJ45r6C0jWtL12Kc6VewXscZCSGJtwG5QwGfoR+o6g18teApRqXhrSrq/XyY4LZbRItzHDIhi3AYwATGfXOSBgZNAGu5urzXUZo5hZqjbxlthUAMY1yAdx6k/3QB3BXYt4wba5uLgL5RDBFYlFwMbT6444UAZ+9nk4rul1f3TxxqI7JwwkQO4YgbSSTjlfr1OTgcVLeXLpbsNkclwoYo0e6TadvBHrgf5HBoA7n4Q+JIILqXwXNE0U1lHJc2Tb3dZLcyZMeW6NH5iLt/ulSOOnqVfJ2qzXdpqljf6HG0E9jc/aN6vJ+8lDj5WbI+Q7iH65BxXv/wAPPHdp4utjBPA2m69ChkudMlLFo13sgdWKrvQ7c7gO4zg0AdlXjXxE19Nb8Svp9vMp0rSAPtDHcqy3LkgqOMN5ar15G5yCQVxXSfE7xu2ig6HoglfxBcxK4cQsyWsTFh5rNgru+Rtq9SQM8V5NoUEFtbQ2kOZpIwqwo0rZG0Eu5PQ5JyenLHgnNADp7lr2Yra2lxFBJg4bfhuuCM5Jx2JPUY5pltALe0URQvKRlcIThtwGAc4AGMHkqD68jEF3NlWVZIjDKiO7732rwRyCo3Nnj+7weueKNzePbQMbdWgYyKRM5bduwVxggYPHB68fjQA7V5Z59Mk04SL/AGjeTmxjt0aTKzSqItpJCjAL5JxuOOgB5+rIkWKNI4wFRQFUDsBXyz8OYbe7+KfhqKaKZlF1JKhclc7LZ2U4643AMM8ZJI719UUAFeL/ALQT7dU8PHlo1tb1p4wzDfEGtyy/KCecY49eOa9or5++OxvrnxvFHaOqrDaW8QLsFAWS4/eZJK8bQpPPQUActLeJaSxXF9Z3phs49rTefP8AZriZZGO2Ngg/1W0jcOWSQnjAIseFSgtb6W21G4Hm3SQI0k8kqq24HJZVDPlY0O4Zxk91zWfZ6Dd6d4hktbG4uF0d1MECTmcNGGmVcr8uxkySC+c8EHBYbtzSdKhg0V4JLWO21OzS1uVWzkk8olZplLFQCY3DFVP3vuqcscrQBYkhutK1ZLzTreS6t9WMLrNb7iJGUPu3IwwSrh2kAAbLA9S5rS0/xDb+G9K8SeJ7m3ZrjSNPSKCJzLjdI2I4yzLk5ZVH8Q9wMVlJcwW5trbFxbtex2l3bymd90UhEm8xlBtym5jtbAIA5PzY0f7GWey8JacYpYrfV9bhuLtZJnVLyC3tXYSMGwefJRyuACRyOMkAl8IaH/wjfgHw5oenaTc3F/Igv9QCpKQsuwDYzclSS27AxgJ93JzWdptmlssgSxjEqKJUnPno75+VQFUKV2/KFJJ5z06Vu6pFpNx42u74QCT7Mq2CzLK0bmJYwGXPCgbgy89TxkVz3iQXEllf31vJcwkRiVEJbfNIYt42Z5yvGOADjAO3JYAx2uBcyTSXNtqFlDPYM8JkMixsQUO1P3e4sQHc46KdwOMgQHRp4fEt9plmtumnWO6YWOLiN13QgPMd5yCWACnJCgPjbwagvdSsru8tTJKCZI3M5uriSY+Q8ULPGZXBIkcsiHdjCqyrgZ3dBf8A2/R5dRjEEy63eSrY2kEYc+cxRXVsYxtDFlxwP3bH1JAINF8PwxWEcl9otzceHrS4WG4DSNCL26muFjEeXAxCj53ZP91SDhhXo0/j+x1mW2trLwvNfLaGC4tlaRYxHOWiVADjZwbiPBDEEbiBgAkvoXs9J0zRLSym1HRLa6js5muZzG19eeersx3o2Yw6Pu5CneQudoFVZ/FxvNWEmjaNYWEkV5Na3E8yK0ksNusrLgEKQR5IbHOMpgnBAAH3viTSLKPVLLVNAjk06aR1keB9plJku0uWYE8bRHLhQSzkkKOQBP4b8fabBc232fwprNjPq32ebDlXH2QARC5chyERAACODj5sHrUmn+PtMvrV3u9Dib7PdWMJnlVEjeaXMjSAsPlCEswJOWLcYJqC78R2I0rQdQ1nw1YXE80NhJBbxxqywSP5zYicpkuApCx4HznaD8xNAG38PvibY+N9fvtP06wu7ZLS1juHa62q4Z2YbdqlhjaEYMGOd3bFd/XBfCqfS7uzmns/DFh4evPJgdoLZVyYJE8yIsQic8sCuDgg8mu9oAKKKKACiiigAooooAKKKKACq+o2lvf6fdWl6oe1niaKVSSMowweR04PWrFMnhiuIJIbiNJYZFKPG6hlZSMEEHqCKAPIPC8hh8Jx2y3Nu0qXEthJcRqcGKCZow+7POdoIx3708OtvbyBSGmlOM7DuRd5xzzjO3PHr7ZrufA1pDb6bdwx28UVvBqFzHbxpGqLFGshVVUDgAbcceldGsUaMWRFVjwSBgmgDx+1h369Lp2pmZraaztRJFucIwa6jXAOevzAcdeK2pj9gizHbWollc5lIJYsAfLCqPujlgTyOvNavj6y068vNJttTt1liupUiUbSNzi4gcfMOQQEZvwPpVqTwjJbyLJo2ualYsBt2SFbiMjnqHBbv2YUAcPPPezafp0v2y6n2SK5VEdtp7BeQGYgHHP4467nwSvv7Q0vxLIxfzY9euo3WTO5CAmFOf8AZ2//AFulbMOjeJYLLyxqXh2acEEM2iugbAA5AuOvuPyribGz1nwzEdfihS2k1BraW6S1ujJbXcrmNMLCU/dswwu8HoBn1oA9jorz+98V69YWsl7dWFp5aWjyfZk37hITb7SzngIgmfd/u5HQ0ah4y8R20MVxD4Wjnt5Aq5F6d0bfZhO2QIyCo+ZQQeWXHcUAaHxQvY18PJo6Xv2XUNcnj061wrM5LsBIwC84WPexPAGOTzWXZfDiOOOJm1RpCmAGEGCcHg/erlLK7trH4gzaja+G1t3lvp2k1IxySExKspdAzgqhchWwpUdvc7uq/EC6sr2U21natai42MWilRokDja5Y4D+YgLIF9R1oAkvvClraa9YWjz731ATASMPmXZhsY53Zz3Ix754p654d01NbtdLk1K8s3bywrSWr/Z2kOdo37gu49lyR2GCTXSX3iGyn1O1Fr4S1rUbuBy0M/8AZvkiJmHJWSbYBkdSD7H0qvPpuvatfLfnwz4Y067JUm4vv9MnAHqEVeQMAYc4oAwn8MWlh4h07TLiS5b7bBLKt0wVI49hAKld2STvXnPf3qP+zITdaj4HSa8hgn1BJXuFikZZd1uZXQkDaudg+XOT8x712kmga1KtsBqmlW3kRlE8jSslc/eCl5GwCQvGOw61xOiWzabLd+OrnVdQ1K1huRa7rlgImthsjkuVjRR8wfeQxyfLUjuKAIF0vw/LrZ0j7drhuxcNG8i2jrFvUKCS3TA3Kv8AwPvyRs6jpvh7TZ4I7jU3tJXjTyRLEcNukCZXOPmLEDHbI9a9COk6cZN5sLQuWL7jCudxIJOcdcqpz7D0p93p1leTQy3lnbXEsOfKeWJWZM4ztJHHQdPQUAebaloWkReIINIvr6/mvLkblk2N5ZkIO1WkJPzHYTjOcCqXjf4ZtN4V1AaTczXGoopuLdJFPzyRsJFjxnjcyjnBzx+PqZ0nTTcC4On2fngECTyV3AHOecZ7n8zVLxVM9jpAltI7cXD3NvAjSoCqmWdELYyMkbycZ5NAHOf8JR4c1bwtoHijWpLmC3d2jWBo5SBcfMrxvCoOWVkcDIOCDikltPBMFvIs12o8lQrTG4feBNuCDcDzwSAOwqfxhonhu3Nu9zphhN1eCWVrCyZnnkAY/P5Q3bjuY5OScHrXOTanpFjezHwro6sZZZGne7tZUhX7L8wMbhf7wJHOMr05oA2DYeC7e61C6vLpgs8ME04uZW8secdqMr/3mMOCFb+DJAzksvr/AMB3txcak+qGQfaljna3uJjGzlcAELxs+TJI+XKcng1nHVvBureGroNb6rJFZRW0EqWsM/mEh2RYoyACxzK64Xkq/GRg0XB8Laq0EOoaJcqlrvgtbZoXM8rW0zR/LtO3YTL0JGd3PA4AOx0rVdC042mmaWy+V5slruT7sTpGZSGY/wCz35rhPgnpttP8K9HuptIijklEkm+S3GdjyO4YA84IYEN6EVe8P6B4H8QRS6Ra215PbiRb6WG5EgSbdEnyEnqFV48r6+vNdJ8O7e1uvA2nwGFPKhMlttXAH7qR4scdhsxj04oAy/iHpFhp/g3WbxY7W3kRUzLFCuVBdM8EEDvxz1+lc58Xb/S/CR024h0nS2SdblQ1xE7MzL5ZVVw6gA/N3J4BAPNespplmkBhS3RYiu0qO4/yBUcejWMZlKQ4MihT8xOMZxjJ4xk9KAPOta0qBLTTZbSzgj3arb2zGazLMYpHGcgMNpyeTjgj8snVb/VtM1m31zSvD9rpsSQXrXP2uZvNngSS3P8ABnaTlioLYxzjjFexGygyMJhAANg+7wcjiuT8X2Edz4g8L6ZawyL5l497OUyFWGFWJ74GZJYx7gkHI4oA4a6nu7zxXr97pmnWsyq1ravLqMc7GRPMWMKpDgAL5sjZ5zyO2avXd1Z2fh3Qb/WNLtoIZ5Io7yQQyKsCneuTjkKSAvPPzAHPFHgfwjrnh3xB4m0q11mC+XzYdTSXVbQzPI0oYbtyOpBDQsO/GOnOejh1fV9Ee3i1zwxdSRRqqrd6OWuIxyc/uv8AWKOenzcfSgDjPF3iGDTrHwtf22ircx6nEpniisjK6MY1YKiyOmGOWxlicrwpI46y30nSTaRzvpSyggSOstuVZDgcHdyrDA+UHjpgVsaNr/hi91hbO3vCmrRgAW92klvMRz0SQKT909AelbR0WyLW58t/3BJUGRjkkAZbJyeFHX0oA8s1S20/R/iN4C1S2NslnLe3VnLcBsBZJLZ9iEdiWjIHXuK9lrzvxJouheLraHRDbvqFnHftpuoCWF2MJWB5d24j5W5jxIOPnAB5FdF4J8NHwtYT2S6xqeqW5k3Rf2hKJXgXAGwNgEjjPPrQB0VeKavLBqnx9nspWMa2MNs8m4ZWUFWYJjpznvXtdeCeIE1HSvjX4o1eCwe5RrfTxbPNbnyd2QjYfHONwOAckkDrigDs/F+k6Hp2g32q2ehR6hJYQtcpB5zIG8vaw2nO1cBc9Oce5qPXx4ZTw/aXHiGFLa1vnhlELxPOskxO/nYCWwQTg/KcdK4nxF4y1/VrCys7axtI9H1KSfT7iW2jbzYmMhjYKCTtOHQEFSR82MVW8RahP/ZdjoWtzSWtujpGl1FL89yyM8boVKkS9zjacZyuGHAB6Atn4Vh1a20CHTXe6urUNDttJjH5aspO6Q529ABuPAUDpgHH0S/0fxl4v8LzaHdrHa+HYbqWbT5I5BINyNAigHhlHzD5c9h3rI8N6jenW7KLw1odvLe6Pp1taLMyTQRxiVgp8yI5c5VI8OARhWbcVPFL4L6zfXg8T32o2UIvfCVm2n2kkUUqJNgyPKWVjydyDoAQCc9aAO/0vXfBes31vYabMJbxpHngKWEyIHMfmdSoVmMZLDksRkjiqss/hN9LjkuIftumxvEYI5LSedw7QmaNtpUvuK5JYg8HBORWBo+rXMNxoiafBZQqrpIss0M0rb0tmgUqit8y+WRxnIJxycE8VqVlcz/D82i6XeK090srPcK8rjba7YtofgYR0TgjBGV5XJAPdv7N0+2a7Mtpaq0vyzT+SQZMjKs2B19c9u9eP6JrF9N8UNX0V51XUbKykPn3DNuswxCtOWzgbIgMdOZfrW5pHja7kNpG72VpHErRQKllKjFV2ptYGQ9gSQOxXngkeb+IPDun3kMmva/FJY3wtXbyZ4pD9pkwGRd2e7KuAwwrEk84FAHsMvj+CCyitfBFun9k2wMk2oXtvK8ZG8Fii5VmzuJ8xiq5xgtnjf8ABvieHVtQS0ksEkeUPMbq2s2WLdnBLHLYLA9c9jyc18+aTa6lrlrbRaxZPptmbsQSW9hZzGZYvNCM7hu4LoM7QSBwpJwev0nV7Tw+3h/Tjo1rDf2V5NELZ7cmNE3xth5WcgyhwNrAnlSSFFAH0N/Z1llz9jtsvsLHyl+bYcpnjnaRx6dqmaGJlVWiQqpBAKjAIOQfwPNVtFvv7R0u2u/3O6RfnEMokVWHDKGHBwQR9RV2gAxznvRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGB4LRl0+/ZnLB9TvSuew+0OMfoawNX8ctpWta0t3NYra6cmE04DF7cHy/M3qWcKE6jlf4Tz2rpfCRU6VPsGB9vvfz+1S5/Wr0mmWEl615JZWr3jReS07RKZDH/cLYzt5PHTmgDg7zWrjXl0i5m8P3guNPSLVZVhuIJFjyZU2g7vmz5bEEeozg8VPqHxGttPNncS2lzJb3/kJbxAwps8zzykjOzgbXES+mMr6nHP+OtSg0r4haRBDqc+naXYRWomt7ZljgVWlcbHQEZBXA+YBVXJG4nC+oPo+lTxRq+nWMkSxCFAYEIEYBwo4+6ATgdOaAJ9Tma3027mT70cTuPqFJrL8CKV8D+HVc7mXTrYEnufKWpvGMgh8I65I2AEsZ2OfaNqf4Vx/wAIxo+37v2OHH02CgDUIyMHpRRRQAydBLBJGwDB1KkHvkVznw0uftPgPRDjBhtxbEZzzETGee/3OtdNXEfBXn4ZaM/H7zzpOP8Aamdv60AdvRRRQBkeLtaTw74a1HVZEL/ZoS6oOS7dFUfUkCoNN0JYvA1toN7HFKq6etnMqoFR/wB3tbjoAeaq+OdPl1N/D1qiq0B1aKWdWIwUjSSTBHf5kXiuooAxfBM8l14M0G4mcPLLp9vI7DoxMakmtquR+Fivb+EItOkDB9Nnmsjkg58uRgOnHTA/CuuoAK4/4j3bRJ4ctFHF5rVojHHQJIJf5xiuwrgviArXXjXwDZIVBN/NdEnniKEn/wBmFAHcTW8M5iM8UchicSJvUHYw4DDPQ8nn3qqmjaYm/bp9oC7vI37lfmZwQ5PHUgkH1yav0UAZ/wDYmlbJk/syx2TKiyr9nTEgTlA3HIXtnp2pr6Do727W76VYNAxYmM2yFTuYM3GMcsqk+pUHtWlRQBTtNL0+ydHs7G1t3RPLVooVQquFG0YHAwiDH+yvoK5n4UqIfDN1ahSrW+qX6MSANxa6kfOPo4rsq4n4UbZNH1e5B+e51e6kkGMAMH24HthRQB21FFFABXHeCY21fV9W8UXLxSedLJp1iqDPlW8EzoTn1kcFjjsE9K0/HdxdW3hS/On4+2ShLaEns8rrGD+BfNaGhaXb6Lo1lptmqrBaxLEuBjOByT7k8n3NAGF4nSTSvEmj69bRmRZZE0q8RRkmOWQCNxz/AASEevyu9dXXPfEGymv/AAbqkVpn7XHGLiDBx+9iYSJzx/EgrT0HUBq2h6dqKqFW7to7gAHIG9Q39aADV9H0zWoEh1jTrPUIUbesd1Asqq3qAwOD71zb/D3S7W5S48Nz3vh2UXAuJE0yXy4JjgAh4DmMggAfdB967KigDz3xh4cudVW6sZ7uK2bUtSklttjv8wGntGm7HdZED4PHyjqa5bx1oM+h+IYdTuNUistNu9SnmZIZ5ImkMkVurblXczsVilXAGApzkHkeh+JvM/4S7wcFTMf2q4LHI4/0aTH9at+KPDFn4jFobqa5t5bYvslt2CsUddrocg/Kw4PfpgigDzbSPDV7rNqknh7xjeXs9hbizuXfU7kxi9Qwq5wMEpsWYDtukJGDgrhahdyWdhc+HNe1K41XWdOXFwI1lmb99PbTRoGJBYfumXqDyvuR7F4T8I6X4WfUZNLSTzb+YzTPIQSTkkAYA4BZvfk5Jrxf4iq9n8VvEYt1Zbm7t9Onj52htjPkBgQQ2E4PGOvagBtrFFPKllbNJLYQXn2V40URBrg3EQCyOH3mVshi2fvbctg1Y1FbeKGaFba2tUnwpW1s9ksoMjZG4Or7sZKj5vu43ZVice2jtNSeddNheSBr3M9rPaRSTSNNMkgkLbhvKlDgD5iQVBBGa2rrR5bhofKikubq2vIrzbcwGEFjKUwxd96hlxlccGQnOOoBmfDBdf0nxxaNp90l9pyQpBeGC3VYpVclgRl8rJnpnI2kDjhFofBrQ5RonxJ0rTYxFJZ6o8cUNzEryhS6FUkO4hwwjK9SAcnnNdRpD2nhrWtIme11GLT43MvlOAZVZlYCPduAkAZuMctjPO01R8C213B46+K6x3tnqs8i290ZXtzDGLlUldY/LWTcwHy5IIzjqOhAJNPafRm/sq1nS51OcbLcPbrtWM/KMv5mX/eZAU4yN2M9ayb2XXYY7i/mgiOmkx2st0kSqZI9rqWkAcouXZRlCAynllXitTStGluNO0u4u9Oe6vryeKWULpscxGIeEO9ym3JIIA3KoPIxxiXs8Ng8fh+K3gimClijW6LMyi2YELFI24IxwCVAwOTjbigDpfAGizfbEmltdOEdtayXELQJyyypCTltq/LgHoAScHtzmeMHj1zUJAsZgtYA7hre2XzmJXJCru9FJU8H5c4JrS8O3rXej201rpxSG8DMuFKNjeQQ+SDnCL0GTjqeK0bewSGIaZbW+n6p9ot5BcWMkQNyQxINwJN+Cx3L8pA4XhgCMgHn/jKaO3S8021Fhd2U1699BN5Jb7OZW3AxyEln3h4yybcLsHLc4zNI1C509Y/tWn3E6u5tlmKxuFkZgQC7svlqG2oeMdgxya1/FdnfzyrHpdpBPrs1yAizRIDIzNjcCMKMkP8AeI4AA6gV6z4W+GaweH7JNRkEepROdzSQRy5TzGfawJYHLMzjk7cgD7uSAb/wj0+z07wJZR6c8j20ss86l0CH55nbG0cAc9BXY1HbwRW0KQ20UcMScKkahVH0AqSgAooooAKKKKACiiigAooooAKKKKACiiigDkfhXcSXfhDz5WDO+o6iSR3/ANNnrrq4r4OuZPAyMSW/4mOpDJOScX045rtaAPL/AIs6RJqOp2D2ltbLdwSW0scs8sCxTf6Qissgdg+1QVxtB3NIq89D6gBgYHSvOPiLIya47EHMWmrLEx5UMt5ASCPchMfQ16PQBneJLVb7w7qlo5KrcWssRI6gMhH9ap+ArlbzwN4cuk+7NpttIPo0Sn+tbNyyrbys4BUISQfTFc78LyG+GnhIgBQdItDgdv3KUAdNRRRQAjHapJ6AZrjfgz83wr8LvggSWMcvP+0N39a6vUSV0+6I6iJiPyNcz8IQq/CvwiqMGC6VbKSDnkRqCPwORQB11c/4+tri78K3cFra3V4WeHzLe1dUkli81DKqlmUcpvGCRkcd66CigDyXX28Q6ZBodj4S0y60jTPs7i2haGCeaO4O7CkM7bQqZPB6MQSuDXU2uneI7+81Y3OvX+noHRLVYre2KqDbJuPzIxOJSx5P8OORWj4naCPVvC8tw2wLqTKrHAG5radQDn1JAHuQO9cj4G8VvN8QvEWkXelXtpe3lyt0yy3MDrAFtYUK/K5yflUkJnG8E45NAEKXGtyeGptVW0MWrW/2vfHbW1vJNayi0BJIAPzPKm7A5PmoCMdOr+HV9rWo6HPc+Jre5tNSa6k32k0aKLccYjjZM70HZyckk9sCneAT59jqt92vNUupB7qkhiU/lEK6egArjPENs0/xU8GuCNtvZalKRj/r3T/2euzrnL4Z+IuiN3GlX4/Oaz/woA6OiiigAooooAK4L4Mc+FtQyhjcazqCshOdpFy4x+ld7XCfCZg0Xi0K2Y18R3u0f3cspP5kk/jQB3dFFFAHnfxO1Q2+s6PYXHiAaBZSQyXnnskUgmmhnttkZVwSR87H5SD78GkHxIuH1bU7S20CeaO0n8iOQymPzmW6S3fBZdvDPkYY8DDbDiuk8aRJ9i0+5NtYzTQalZhGuolfyw9xGjFCfuvhjgjnOKyfiDbad4b8LeJNf0tNI0nW5bYldQmt490ko5jBJxvYtjaDn5scHpQBl6n48lEd3peuaFdWOow232+5gjvEKpbAZ3eYOoLqYyMdm5x1k+GHjG1v9Qm8JR28du+i2scSObuOX7QqsyAx7PvAKqluhVm2kA9er0u90jUNKbxBCbWZJ7UJPdLtO6OMuSjMOCFZpOM4BJo8ImHUPDehanJZW0FzLYxygRxBfK8xFZ1X0BPUD0FAG5RRRQByvigsfGXgxUYgfablmAxyotpB/Miuqrjtejab4oeEVV/lgs9QndAf+uCAkf8AAzXY0AFeIfGbT5YvH1jqUMEsjyaQ4jCEBTJDOhGfwm78V7fXmfxps7mBNC1+z+0ObK4NnPFCVy0VwyBTz3E8dv8AgWoA860aWxaa00uK7t7eV52ucRje9vM9yTkluqgs4XaDyBk4ziC01W5P9ra0msWFtY3Np9phCtjYiyuAJQrEvuULvKjhiVCscAxaNb293HbiJ5Le4SeeNY7hUCJFLcQhoCx++hAYllBGST15qhdR6bpXiWaaPdZ3csbi4ecxvDJDJKxdSMtH05AICPjIIJbaAb9j4o0t1OowpMNNgtreWYQLaXTP5kjRxl1jZvmWQj512yD5QV7Cn4e1PTfDvxK1LxiqXkejX2kJO1lPCIrm4nEhhOUfCeZuPQMPlkB6NVbRI7qVo30DVri8tHksTcjUrhbh0EEqOFWVCNijavA3buTlulbfim4t3+I3gabxHdLbeERFFcxXUjQiH7bEZpEWSQsdm4Pkjdgsi4z2AI7m8ttAgOmnTIbdraZrCNovLEzyGJXVA5O4O4YquzgsW5HFedazqV3qduU/sqWC5WZBA8CojeX5aL5hL/vRtwBtVNnGd2RmvUvF+n6db+MLyTUry3W3v7p7xIW2ySM0lr5QZe+FXJBUqAzD5mrI8VanquoWklrazsmn26x2sN3NKsk15IsQLKHYqoJ2l2ZS2V9QwoAvadc2Vx4a0ybTg0tjNGHZIwqNvIG47UOM7mbgeh9DWSySzXlzcB4zqUTtLJDcpC0ccIWNRLC3GyUlFXC7ty9BkHNXwnfWFnp1sI9SV7mO4x5ETxvIJfJSRUYqNh5aVRxj5RnmuxvLm2nuUn1BXuLa3UyxSwbDvDRqVOcDafmbBPI3c9DQBzml3qnxLp8l9DcQwRXcUMKxxxGGSMlGddwYNvymRhcYQL1YV9M181andNLIo0ub7KoK7IS4JMW9ZDuIBKglFA5DHa3zAYB9f+DmB4Ds0a6S4mWSUyhGUhCzlgMD7uQQ23tu44wKAO2ooooAKKKKACiiigAooooAKKKKACiiigAooooA4L4Q3cC6fr+iJtSfR9avYnj3ZbZJO8yOR2yJOPoa72vN/FTReCPH9v4umZo9E1aNNN1eRnVY7aUMotrhyRwvLxsSwA3oT0r0WCaK4gjmt5ElhkUMjowZWB6EEdRQBwHxNt421jQFmcJHqEyaczeZtPM0cuFBHJIiP0616FXl3xO1q1n1zRoYJ7QxeH9StNR1Sd5OLZHdoUTgHDEuzHOMKme4r06CaK4gjmt5ElhkUOkiMGVlIyCCOoIoAzfFt6um+FtXvXKhbe0lk5bbnCEgZ9+lVvAEBtvAfhuA5zFptshz14iUVzvxOnt9cuNL8EwXafatVuFa9ijYGSKzQNIzsOdoZkVATgEsR2Nd9GixxqiAKigAAdAKAHUUUUAMnjE0MkbdHUqfxrjfg0rxfDnS7eQjNs9xbDHpHcSIP0UV2tcV8P72WHWPFWgXpQXFjqUl1CA2S9vcsZlbHoGd1+qmgDtaKKKAMnxVp8mp6FcwWzBLtds1u5GdkqEMh/76ArmrCztdLivPHEuoXMbX1sl1cW7rbmM/ulCxiTyhJtBAwN/U9Oa7uvLNJAvdQ0zwdMQy6Pfyz3AD8mCIA24YYOdxljPUf6s0Adz4JtGsPCGjW0iusqWkfmK/UOVBbP4k1tUUUAFcjNetJ8WrKyUKUh0SeZj3BeeEAf8Ajhrrq878ISf2v8WfGmpLKHg05LfSIwOxCCWTt2Z8dT0oA9EooooAKKKKACuR8C2sNjrPjO3hk3M2sfaGTGNvmW0Dce2c/jmuurh9Lkk0n4r61aXIUQa3axXtrJnG54VEUiYxyQNjdehFAHcUUUUAY3jHSZdb8NXtjbSiG6cLJBIf4JUYOh/BlWsjUPtHjP4dssFjam7ulEclteNsRJEkCyYYxyYZSrFWKNyqnHp2FclpHmaF4xudJklV7HVRNqNpvcbklDqZowO4JkDD/gVAGDF4cvPD3whTw159tb3Eswsoys+9UjmusAbyil28t+TtGWz9a9JjRYo0jjUKiAKqgYAA6CuQ1EnX/HsOmrNF9g0OOK/uERgXa4cv5SsMfKFCFuvO5eOhrsaACiiigDhdK36j8YtcujjydI02GxX3eZvOft6JH+Yruq4r4XX/APbVpr2tqI/s+o6tM9u6Y+eGNEgRsjrkRZ/Gu1oAKxfGWhjxH4ZvtL897eSZVaKZDgxyIwdG6HoyqfwraooA+ZtEcSy2l7qUlvYXNpI8MkjhV8qYuIWIOOhIK4JGRjBBFa15LPb3V5czXa3KylfOYkshJlYlCNm0jcDhW+7uyeeln4g6a/hXxtLLbvHLbaus1/BbvJtd5kdDNEOMHcJMqPXP1rlp722vY1OhgmykA/0PJijZROSRHhfL4Lk4+badynHKgAo+Nb2XT10q3ml3RuilAt3lmC5IO5SN4P8AeYAkg5FbL6PF8Q/A8XhXUpGgvYY4b63voiBFvKHCnIycAMTz39gDkRahYy6rZvbXv9kyhQJIPtAKTnDZcZChuOfmQkHOcc41vC+m2/h0iax+xW0u5fNmWZpHH38bP4ceu0YB9jigDe8KXd/4g8MXOlajqVvYfEfRt9nNF9pjV7iJUQ79oJZ0ZCDvG07s4YCuf1bSGFzaRrLOdTFyyW32aZIxabldWjYkE7SGb7vzHaPuAYqTx/Bq18dO8X+EROPGmgoDJuUEXlqVIIChRvbJOVHOD1yRVxdTg8feHbLxRKJrWM3hg1G1d/mgmjCkjgjYmVU8jPzoO5oA43UdRttA1W5vNStroS3aOG+wlVYQuxXkY25QnIx22nqcDt9Cum1nVp9NsWt7/wDdvdNLC3EatGMbjjB5JA75BB6E1keJLVItEkvbmRW1SG1mS0R5Am+WSNFxGD/F8p4ySCDxzWf4fu1TVdTg0pLm0bVNPktY5lWMXNlIWHTAJKKQueeOxHWgDpPEJvrGRYIxb+VKh86J4VBRmA2yMwxvIG7gnjco6bse8eHYvJ0KwQxqjCCMEK4fooA+YAA8AcjivG/hP4y1Sd9E0jxpFpxa5NzDaXr3UapdTQXAVxHGFUh9xQhSCCBkFSNp91oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGyIsiMkihkYEMrDIIPY1wN18K9Ijt7mHw/qGt6BFOzO0GnahKkAZmLErFu2pyeibR2r0CigDzXw14H1/wAI2TWHh3UNEFixLMJdPKPIfV2VvmPqTkmseXwANEhgfUfGt14bst/liLTr+aKNxg/IPPkdV9flUEY4xXsVcl4/0S+1aXQp9Pt4rr7BeNPJBJP5IdTDJHjdtbjL8jHSgDV8N+HtN0CCcaaszyXTLJPc3Fw9xNOwQIGeRyWb5VAHOB2xWxXnP/CJ+ILq8kN7ePFY/wBp219bwQarMDbxov7yLiNdyli5C52kbRgbaqaZ4Z8cS6YBqGuy29/HfS3DGO6LJMpgwijKnCGXBK4GADgc4oA9PlkSGJ5JXVI0BZnY4CgdST2FKCGAKkEHkEd68p1nwr42li+xW+qfarFhmX7Tc7jOjRxLLE6lMEErJtwQPmOcVuajpHiCTwZoFnp6tb3FtbIl1bx3xgYMItoAlVTkK3JAIBx3HBAO7rifG0g8P+IdK8WusIsYIm03UXZirJDNLFslz0KxuvOeiuxzwcx+GNP8Yaamtm6ltbqWa4Mlobu8kdQPMORgKdq7CCAMYIxjvWhdReKL6ymtNQ0zw7Pbzo0csTXcxV0IwQcxc5FAHVA5GR0oryaLXdf+HNkNO1fRreXQYtzWmox3l1cR20e7IinbyZJF2g4VyNu0KCRiuz0nXNV1awhvdOtdCu7WUbklttWeRSDyCD5FAHTV534KnW4+LnxHUoA9q2nxg5zkNbBj9O35Ua58Q7nSL6GzkstIubyViqWtpqMtxOxAJIEUVuzdB1IA964nwvF440TxTqXjTWPDVw8N+we7tLK48+ZoJETywkJCnfAYwrAjLeY+BwKAPeqK5XT/AIh+E76SaEa5aWl1C2yW1vybOeM4B+aKYK44I5xg1D4i+Jvgvw8ypqviOwjlbpFE5mc/8BjDH9KAOj1vUrfRtGv9TvCwtbKCS5l2jJ2IpY4Hc4HSue+FVle2ngy3n1ezSy1PUbi41O5t1JJia4meUI2QDuVXVTx1Wufuobz4nauLa8sL6w8D2TsZVufNtpdXk2oUUxMqsIFyxJJ+cgcYBr06gAooooAKKKKACuO+JEraXBo3iFbU3EejXwnuiiM0iWzxvFKyhQSdokDkAchD7V2NVtTsbbU9OurC+iE1pdRPBNGSQHRgVYZHPIJoAs0VxnhfVjourf8ACJa7dStejfJpdxckk31sMcbz9+WPdtYdSNrc5JHZ0AFcR8XBDa+G7PWmSQ3GkalZ3cTxyFGCm4RJVyOoaJ5FKng5+hHb15b8f/FOkaP4atNF1G6Md7rF3bpDGkTyExpcRNK5CAnAXPHU9ADQB03w3itm0rU7+3SQS32rX0kryklnKXMkS9ewSNQB2AFdZXmnwV8Y6Nr8Gu6TpZeOfTtRupvLlSRGkhnnklSQB1UgHcQRjKkehGfS6ACuf8e+JE8KeFr3VDE1xcqBFaWqglrm4c7YogACcs5A4HHXtXQV5jb3c/xC8e2s9ktq3hLwxfOxuC5c316Ido2DbgJEZXy2TlgMdM0Adj4D0iTw/wCCdA0icRiexsILeXy/umRUAYj2LAmt2iigAooooA5b4keHZfEnhl7eyWI6lbyx3No0rFQHVhkZH95dy85HzcivnzUdPU2k2q2DX9m8s/nXVk0k8a/aklBYvGikh90SgkA8x5OPmNfVleIfFnwxNo2tz69YhbfQb8It+8Urq1rc+YcXOCSqocqGIHX5mBySADyPxDqouLjTBd+ZApKW8hme4liliDbWbGGIAU4BRAemQy4Y9TaWcFrp0kmiW1xbXfyMirLIUnTPBCAkYPcsEztYdiK5zVJJNItLm1nsNR0KVoooxqwkllhlmU/IoVcmIMNoAbqe68k9Z4c0/wAQSx6ZcXWh3k9ldWiCKeNzMq4bcAXiB+Qlt2clTuZgOSSAW9J1XXdM08QxYiuY5ceeyyNC25QArwAkIfnBC4xz2rN8WX1z4f0688dJY6mLlnSw8QaY9y0EN4phEYkjwpCsjbBnGRlgeuTpWUNvqUcs0mlG/wDNIAeG6utyuNoUSMNxPAA4z+Jqj8U9RSy8Hr4X1GGOG/1xYmWwN47+RCm1mlcMCVY+WMZJJPuGyARDxt4F8R+G3UrqWmOUeOK0e1ludjqihQhVWHBGCCwzk5xmqF3rN8uu3OieDfDWqHxHe2T2j3E5niMJZY1LbWGQqlgSXCKOMHGK5z4ZeFru/wBUlPhPSzqMhuZAHuJ5DZWSgqVLShceZgr8o398jtX1B4A8CQeGZbjVL+6l1TxLeoEu9RndmJUYxHHuJKxjA4zk4yT0AANHwL4UtPCXhHTNChZrlLMF2mm+ZpJWYu8hz3LMx9s10VFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVjeK9QutM062uLIwb2vrS3cTIWBjluI4mxhhhsOSDyMjoaw9R8bC70Frjw5FKL1rq3tl+32c0aJ5sojLkHaWUYfJU4+U846gHagg9OaK4y1+ImhGJVnN5FLs81gLKUrswSZcqCAmAzZJ6D6Z0fBXiGTxHaajNLZTWZtNQuLNRIpXzFjbCuM+oxn0IIoA6KiiigAooooAKKKKACvP7/4O+ArzUxqH/CPQWt2MEPZSyWy5BJyUjZVJ5PUV6Ac44615/wCH/HU0j3H/AAkCC1NkkFjdxRWMzP8A2iQ7SrHgtuj2CN1wD8r5LdQACKy+Euj6ZcPNo2reINMkddrG2vuo567lOevepZPhzdyOC/j7xmB6JeQr/KKt3/hNtAMlskd7JLJcuY4UhtpZGcgyg4CqT1gl56fL7jL7Dxfo2oX9taWk88j3O0QyfZpRG7NCJwu8rtDeUQ2Cc496AOZuvg/4d1JNniC98Qa4u0jbqGqzMvIxnClR+lafhT4X+C/Ckxn0Lw9ZwXBz++k3TyDp0eQsR0HQ1rav4itLX+0rSG4EWpWsHmBZ7eUoCY5HRuB864ifOwn7pHXiq1/440Wye+jdr+Sazm+zSRw6fcOWm2hhGhCYdiCCApPUetAHTUVyVh480ae+W2ku0JuZ1jtGhhldGVliK+Y+zbGxaZQAxH3gOuQOtoAKKKKACiiigAooooAxvFfhfRvFmmiw8QWEd5bq4kTcSrRuOjI6kMp9wRXI2/hLxp4emvT4Y8YR39jJl4LLxDbyXbRMccfaBIJCvHAOcZ716PRQB4trb/GC8hjt7m3toIC+24k0HylldN3PlNPL8hI7kHGc1b8Mz6b4UumvH8CeM21qeMRz31yv9pXDKOxm818A9dq4HtXr1FAHk/iN9I8U3C6gfDHjSw1i2Qww6lZ2slrcRKTnAO4b1zn5SGXnpzWda6r8WBbxW2hW9pqBjVd9xr+mGzYg8f8ALO4IY45PA+le00UAebTeFvHfiOO1j8T+K7LTLIOHuLXw/aywSTDB+T7Q0pZRnGdo5HpXd6FpFhoOj2mlaRbJa2FpGIoYVJIVR7nknuScknk81ermvHGqalpFtpk+kRrcObzE1t5Zd7iFYpHdI8HiTCbl9SuO9AHS0V5p4R8Y3dlpl9J4rklkui1zesog8r7JGkMExgIJzuUTbRk84NRr4+1ZdSvYLi2toLS3jvD9q8lpPnhvUgQBBICwKNk8jBx9KAPT6K8z1n4v6XpCaqbzR9YD6fdtasEiVhNtDl3jO7kKsZY5xwR74nvfipZ21vqFyuh61La2TpE8ywDbI7mLy0TnLFllDYxxjHUigD0WmTxRzwyQzxpJFIpR0dQVZSMEEHqDWR4N8RWnizw1Za1p6TR210Gwk67XRlcoysOxDKRW1QB8/wDxG8Aat4etbj+wUvNW8MTJHG1iJJZJ7MIwKhcHe8YIUjB3JjrjNeeeCtQv9M+z/wDCLXssUUcweaG2d/OiO1vl+zSP5U6gDOVCSepbgt9h1534n+E2g6xqkOo2YbTbrzlkuDb5CzKOo2ggK3ow6ehoAq6bY+KvEugtdaX4zsraeXMJuG8PyRXEBA2sjxtOAHBz95Tg9ulZOg/s/eG41luPF19qnijVZ9vn3d3dyx7wqhQu1XzgADhmb06cV6D4a8HaX4duZrjTjeCacl5g13K0cjlVBcxFtgb5ByB610dAFXTNOstKsYrLTLSC0tIlCpDBGERR7AV5B4113XNS8Q6rFoaagZdKbEf2NnYkKV3YjUgOTuYfMCMqo4ySPaazLTQdMs9Vk1K1s0ivZFdXlUkbg7h2yM4JLAHPWgDyyDx/Dp2uQ65drfvHqkbxf2dFJJMYzHs+ZI+55PRR1PpXVfDX4gv41uLyNtEutOFtGrM0pY4c9UbKLgjj1zz6V11npGnWV3c3VrZW8VzcyGWaVUG92Ixknr0GKugAZwAM80ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBeWdtexxpeW8U6RypMiyIGCujBkYZ6EMAQexFUb/wAOaNfxW8V5pdnLFbyRzRIYhhHjJKED/ZLMR9T61q0UAYtn4U0CytXtrXR7GKB4jA6CEYeMgja3qME9fWr+nabZ6d9p+wwLD9pna5m25+eRsbmPucCrdFABRRRQAUUUUAFFFFABXN33gnQb86h9ts2n+33Ud7OJJXb96ihAV5+X5RtIGMgkHrXSUUAYOmeEdD0zV5tSsbCOG7lYNleiEBh8o6L99un941iaR4Bj0zxgmsW8lkttDgQRC0PmxoIFhVBIW4AVB2yfXk13NFAGfe6Lpt9qEF9eWNvNeQxPDHM6AsqOMOufQjtWP4x8KjXNMltbNrS28+5W6ufNtzIs7qoCk4YcjahzznYAeDXUUUAZFh4d020s4IfslszxmN2dYVTfIgTD4HAP7tDx/dHpWvRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHLDFK8Tyxo7wtvjZlBKNtK5HocMwyOxI71JRQBmX/AIf0bUVkW/0nT7pZJDLIJrZHDuVCFjkcnaAuT2AHapJ9F0u4Rkn02ylVt5IeBGB3urtnI7sqsfUqD1Aq/RQBz9h4P0S0fUZG0+1uJdQumu7iSeBHZ3JJXJxyFzhc5xWk+j6ZJZzWj6dZtazMrywmBSjsu3aWXGCRsXBPTaPQVeooAitbaC0gWC0highXO2OJAqjJycAcdSaloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy; 1980 McGraw Hill. p.22.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34580=[""].join("\n");
var outline_f33_49_34580=null;
var title_f33_49_34581="Flunisolide (oral inhalation): Patient drug information";
var content_f33_49_34581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flunisolide (oral inhalation): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/34/9766?source=see_link\">",
"     see \"Flunisolide (oral inhalation): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aerospan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When changing from an oral steroid to a breathed in one, there may be very bad and sometimes deadly side effects. Signs like weakness, feeling tired, dizziness, upset stomach, throwing up, not thinking clearly, or low blood sugar may happen. Call your doctor right away if you have any of these signs. If you have a bad injury, have surgery, or any type of infection, you may need extra doses of oral steroids. These extra steroids will help your body deal with these stresses. Carry a warning card saying that there may be times when you may need extra steroids.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702136",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flunisolide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sinus irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More asthma attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4013443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime puffer (inhaler) before first use or if not used for more than 2 weeks by spraying it 2 times.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11681 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34581=[""].join("\n");
var outline_f33_49_34581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026123\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026125\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026124\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026129\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026130\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026132\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026127\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026128\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026133\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026134\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30691?source=related_link\">",
"      Flunisolide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=related_link\">",
"      Flunisolide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/24/22915?source=related_link\">",
"      Flunisolide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/34/9766?source=related_link\">",
"      Flunisolide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34582="Intermediate case 19";
var content_f33_49_34582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Intermediate case 19",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 112px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAClAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P0tpjZX+Yfm+0SYXd15q/OZPPtMRg/Mc/N0+U1R0gH7Lfjzwc3EnzYHy1fmBEtoBL/Ec8fe+U0zrq29o/n37CW7P9tugY8L8uDnrxWXqTP8A8I4SIwW85OM/9NhWpCT9su/nGPl49OKyNQDf8I0AbgZ85PnwOf3wpPYqj/Ej6xNadpPt9oNny4bJz04p0Ly+Zd5iHD/J833vlFNnP+n2n7zAw3y+vHWktxiW8zcZy/t8vyigx+z8v1Gq8otLQrEu4uAwLdKp7pv+Eux5Y8v7GPmz/tmps4s7LF1t+dctkfNzVVsHxacXZXNoPlyP7xoZvTS970fcsM9x/Yt2WiXcPMwN3UZNTyvP9rscxpglt3PT5aoKpOj3m6/Y5MmDleOtW5wv2uw/0s8Fu6/N8tApRV38+/YsSNIWuwyKAIxt568Gs7TDOPD+nkInmbkyM8Y3Va3KJ77NzuHlrgFh8vDVR0rB8OWCi6KtuT5gwz96lccY2h849+zNMmT+2CFVdnkDJJ5+8aooZ/7P1f5I93my4GTyNoq1hf7YLfaWz5I+XcMH5jVBVVtP1YfbWXMsnO5ePlHtQEF+nfuN1Uz/AG3QMrHzMc9ePkrUtvtH2673rGE+XaRnnisfVEX7boJF82BLyCy/N8v0rTt9gv7o/bmbhflLrgcfShFVV+7j6Po/5iq7XC+H7M7I/M3R/KScdatzNc/21aqFi2+RKd3P95P/AK1ZnyN4esx/aDZzH829c9fpV2RY/wC2LY/b3/1EnG9fVPakOUbN/wDb3R9ihpIu/setjbDuNxLgZPpWmPtYFgNsPTnk8fLWTpCxm01kG+kANxJzvX0+laTJHmwH9oSDHT5154+lNbF1177/AMn2LFv5/wDad3kRfcj55/2qzNWNz/wik2Vi3ZHGT/fFXIFT+1Lv/TpM7I8jev8Ate1ZmqiM+FJv9NfqP41/vjjpQ9iaMf3sfWPRnQSm4FzDgRbcNk80im58y4ysOAfl688d6jlRPtcGbyQEbvl3rz+lIFjDXJN9JyefnX5ePpVHKlp8uz7j5ftJW1IEW/eM9cY2mq0f2n+35eIdnkDnnPWnFY/KtQL98bx829cn5T7VBGqHxBJi9kz5A+Xcvr9KTNYrR+j6PuTL9q/s254izvlx1/vmppjc+ZY4EWNx3df7jVXUJ/Ztzm8cjfJzvXj5z7U+dUMlj/psgy/GHXn5G9qAa1fz6PsTg3Hnzhli27BgjPPWs3RvtY8O22xYdwJ4Of75q4qL9puf9OkJKDguvHXnpVDRlT/hG7fdeyAZPzb15+c98U1uVFWh849H2Zpn7T/aa8RY8k5PPrUB+1fY9R3LD1fA55+WpTGn9ooftkgPlHC7l55+lVnVWtdTxeSfx8Bl4+X6UiY9Pl08yLU/tn2fSsCAf6RFnrxV1Bdf2vIcQ48hM9f7zVnakiG30n/Tpf8AXxYw68/pV1YgdYlxey/6hONy/wB5vajqaSXuff0fcb/p39mXu7yPMzJ646VamN359thYeSdx544qkY4jpt6DfylMvlt6+n0q1Msfn2ub2TOTtG9fm4+lNIzlv9/R9ippf2r+2dYyIvvR46/3Kuf6SbGDiHfvTPXGM1Q0tY/7a1kC6fdujz8y/wB36Va2xrp8GLtym9Pn3j19cUiqq99f9u9P7pcYXH2tDiPbsbPX1FVz9o+zX+RF959vXpjvUzKv2yPNy4bY3G4c8j2qqyIbPUP9KkA3Pkhhxx9KZlBbfL8xbIz/ANl6bxFnbHnr021dUXPnsT5WzaMdc5rOs0Q6XpYN1J0jx8w5+Xp0q6iD7Y4F1KW2jKZGB74xSWwVVq/n08yNjcnTyWEW/wBBnGM1FdfaP7csMCLb5UueueqU5kj/ALKbF1IU7uWGRz0zimXaKdd0/M7hvKlwMjn7ntQyofE/+3unkW4fO8+5z5ecjb19KkXz/s8ePL38Z64xUUSL513iZ8kjdyPl4/SkURiygBncJ8uG3DJ9KZi1f8PyJ/3/AJx/1fl4985rNsTcf2dc8RBvPlx1/vmtH5PtTfvm37RlMjGPXFZeniIaZebZ3K+fLubPIO80uppD4X6rp6mlMZvNtsbMFju/75PSljEv2iYnbt42/lTZQpltj5rZ3HbyOflNLEym5nUSEsu3I9OKZl0+X6mfrAuP7LQfu9/nJu9Mb60G+0fao/8AV+XtOfXNZmsLCNGj/fv5fnJh88n560W8n7XFulbzdh2jPUetI2l8C06y6eg0C58i53GMHLbMA/rSuJilpkpuDDd6dDUatAIbzErnlt+WPHHamOYDDYjzX2hhtO45PB6mgmzvt+HkeW6b8SrlLG/2fD7xQ6NO7OBbjA56E5q/L8T70yWZ/wCFe+K+vy/6MP7p6c11+lNqpstROLUsJ5No55NX5Dq3mWeRZ5JO4fNx8ppanTVgud3a69fI4/wp8RINX8aS6Je+HdZ0nUJ7f7Qn22EKHVRg9K6S/aL/AIRnmF9nnJ8pTn/XCuS1ddTT406BJi1/eWNzGG5xwobp1rpdQOq/8I7nFmT5qcfN/wA9RSu7MqFNKcLNbx6m3cOn9o2eYn3YfB2dBim28kHmX4W3lxv+ceWfm+UdKrTHVv7QswRZhcPkjd1xSwnWPMvTiy3B/lGG5+UUzH2a5d1t38xpmtxYWANpMV8xdi+UTg5qBpLceMMm2lMhsxz5R/vGnIdY+xWRxZFi65BDcfrUf/E1/wCEqxmy/wCPQc4b+8fekzeMUubVbS6kqSwHR71RZzgAyZBhPXmrlxJF9qss2svVsfuuny1QA1ddIuyWsush6N0596szjV/tVlk2Octn5W/u/WmRKKu9V16+RIZIftF7i1lyY1z+668NVLTJIf8AhHrH/RZiu5flEWT96rDDV/OvMtZbfLGPlb/a96z9JTWG8O2IjazByuMhs/e+tF9SoxXJ8S3j18mbHnxf2r/x7TFjCOfK6cms8TQ/YNWBs5yDJIceV/sirONW/tU82OPJGflb+8feqgXVRp+q4ay+/Ln5W/uj3pMmEUuq6dfMh1eWL7b4f/0Sbibj910+WtO3ng+33eLKcN8uT5PXisfVRq/2zQNz2Q/fdlb+735rVtxrH9oXWXsduF42t6fWhM0qRXs46rZ9X/N6FJJIToFmPsM/VOPJ96vSyw/21an7HNnyJefJ90rP26uugWgL2ecx4O1s9eO9XpV1b+2LU77LAhk42t6p7/ShMU0rvVfa6vsVNMkh+y6x/oku0TScGHGeKuNPDmwP2G4OOmIOny1m6b/azWms7WtA3nSDlW64+taKrqxFhmSzyBz8jf3frQnoOrFKb1X3vsT20sTancj7JKuUj5MXH8VZertCPCdwPssnBHAi77xzV+Aap/a13+8tNuyPA2t/te9ZWsJqn/CJzZktuozhTnG8e9DYqMV7WOq3j1ZvvNG15ADazZIb5jFwKXzIg1xm1lPPP7rrxUEqap9sg/fWmz5sjYf8aAmq5ux59qSfufIeOPrVXObljZarbu+/oK80LRWZ+xTYMg+XyeR8p5xUUckQ8QyD7NKD5A58rjrSGLVhDZAzWu8ON3yHptOe9RImpf8ACRy/vrfZ9nH8B/vfWk2axjG0veWz6vv6FhZYv7OuR9llI8yXjyuvzmpppIhJY/6LIfn4/d/d+RqqxxamNOuR51vkySlfkPHzn3qSSLU/MsMz2/Dnd8h5+Rvenclxjd+8uvV9vQmDx/abnFrL9wc+X168VQ0R4v8AhG7bNpIwBPyeXk/fNXgmo+fcbprcqUG0bD1596y9Fi1M+HLdUmt9+TyUP98+9F9Sopezeq3j1fZmz5kZv0H2eTPlnDeXwOelVi0Zs9TxbuD8/VOvy04x6j/aSET2+wRHcNh5OfrVd49R+yalmeDB34Gw8fL9aLkRitNV06vv6DdRMRt9J/0aT/XxY/d9PrV5Cg1iX9y3+oTnZ/tNWXqUWo/ZdJxcQ7hPFk7D/jV2OLUP7XlJuIMeQv8AyzP95velcuUVyfEuvfv6CM0f9mXv+iSdZPlMfXirUpjNxa4tn4J58v7vFUHg1UadeA3dvv8An58s+n1qaeHVfPtcXUGATu/de31p3JcY3+Jder7egzTDH/bWs/uGHMfOzr8tWd6DT4D9lkA3qPL2cjnrWbp0WonWtXxcwjmP/ln/ALP1q0ltqv2KISXcXmB1PEXbP1oTKqxjzK8l9nv29DRYqb2P9033G+bb05FVWK/YtSxCThn+UDluKJYNRN5GUuogmxs5j9x71TNvqZtdRAvIuXfb+66cfWhsyhCOnvLp37+hZsmU6VpR8huRHxj7vy9a0Vx9pceUQQo+fHB9qxbC31D+zNNzex4Cxk/uu2361fEGo/aGJvIzFt4Hlc5oWwVox5n7y69+/oOkI/s1j9mZf+meOTz1qK7bGv6ePKLfupvmHQcpUc9vqf8AZ7L9rjMvr5fvUNzBfnW7DF3Hjypc/uvdKTHTjG795fa79vQ1Im/f3X7o8Ef8C4pqSH7FAwt2JO0bOPl96rpBf+bc4vE5I25iHHFNW21MWsSi+jDDbuPk9qZHJH+ZdO/b0NDeftRXyTjbnzOMfSs/Tm3afdfuCuJ5Rt4+b5zzU32a+80n7au3A/5YiqFhbagLC6H21d5mk25iGPvml1HGMeV+8t138/I15mImth5ecsef7vymkiZvtNx+6wPl+bI+biqcttf+dbH7euAxz+5H9006K2vhcTk3ykHGP3I9KZPJG3xLbz7+hBq0rrpKk2xJMyjZuHHz1os8n2hP9Hz8p+fcOPasbU7TUf7NUG/Ut5q5/cj+/WgbXUPPQjUB5YU5HkjOaDSUYci95bvv5eRKJJDDc/6KVA3fxD5qY8k3lWh+ynO4fLvHy8Goja3/AJM+dQHO7b+5HFRyWeo7LUDUfmDDd+5HoaCVGHdf+TdippawfY9RzeyhftEnzeb0q/LHCZLMC9lxkkHzevymqOlSr9k1EGxnI8+Tjy15/Wr7yr5loBZTjkgZRePlPvQjarfnfz7djjNfjhPxV8Ln7VJkpdLxJ0Hkg10F+kQ8OH/TJMeanzebz/rRXPeKZlT4l+EWa1mUebcgHYvzEwdOtdFfyg+HSPsU2PNT5di/89R2zStuaQvzQ9Y9vM0JkhN/aYvJCcNgeb14pIY7fzrz/Tpfv8/vunyinTzAX9oBZTdG52Lxx9aIZV867/0Cbl+fkXn5R71Rz68vy8u5WSO3FhaD7fLjeuGM3J5qEJB/wlGPt02fsg/5bcfeNWElT7DaZ0+c4cYHlrxz9ah85P8AhKgPsUufsgP3F/vn3pM2jf3vR9iXy7cabdYvpSCJM5mzjrUtwkIurL/TJuS2D5vX5aY0q/2Zd4sZhgP1ReevvU9w6i5sv9DlPLY+QfL8v1pmbbv9/bsMdYPOu/8ATJOIhn970+9WbpYth4dsgb+ZQWXkTYP3q03lUz3i/Ypv9UvOxefve9ZelTIvhqwzYyt8yj7in+L60uppC/J849uzNPZB/amDey7vKHHm9eTVKOGA2GrD7bNjzJMnzv8AZFaQK/2r/wAej8w/e2jjk+9Uo3X7Bq3+iSf6yTjaOflHvQRCT/Lt3KWrRQC50IfbJiTPwfO5+7V+1jtv7Tu9uoTlgEyPO4FV9VdftWhYs3/13XaPl+X61ftX/wCJneA2MijC4baMEfnQtzScn7Nej7fzGakMB0C0Y3s+3Kc+b71flii/tm2H2ybcYZeBL7pVRJS3hy0P2OXO5Pl2jn5uvWtGVh/bFri3b/Uy/NgccpSRM2+Z/wDb3bsZGkRQNa6z/pkxX7RJn977VoNHCV07ddzD0Pm9flqrpD4h1oi0cYuJMDaPm4q+zhRp/wDorEHtx8vy0LYdaT9o/wDgfyhBFF/al2RcybvLjBHmf71ZOrJD/wAIfPm4kZcjrJzneK1oJX/te9AtXwEi+bjn71Z2qsw8Hzt9nIfj5eP74olswo3VSPrDsa1wkf2+2Bmk3YbAD0kCQ+belZ5TyN/z5x8vb0p11MYrqF5Igsaq7NIzABAB3NJZ3K3CXEsCJJGcFGRgyyDHUEVRy3fL8v1GusDW9lmaTy967G38k4OMmoUEf/CUSDzG8z7MPl3dt3pVovIILQi2BJcApn7vB5qshceJnHkjBth8+f8Aa6UmXC/vej6ruKEiTS7s+bJs8yXcd3Q7zUsqxCTTcyP9/wCT5uv7tv6UZkOm3P7kZ3yALnr8x5p1wziXTgIlPzn+L7v7tvagV3d/P8gXyxd3eJH3BBuG7pwazdF8g+FrYvK4iycNuwT+8NagaQ3FwPIX7g53/e6+1ZmiSTf8I1bkWwJyfk3dPnPtR1Ljf2fzj1XZmiyxDV4iZG8wwkKM8EZqNljNpqgVmOS+/J6fLU7tJ/aKAQgjyiS27pz06VCzym01DMSjBfA3fe+X6UGcb6fLr5lLVUh+y6NudwouItvzdfrWggX+3JTk7/s6cdsbmqlqbTfZtLPkKT9oi439P0q+hf8AtWXMY/1C87v9puOlIud/Z/f180VZRbjR78bm8r95k5Oc4qxcfZxLZ7iQ275OTzx3qKSSb+zL4+Qm4eZ8u/rx9KsTSTiS3H2dGyeT5n3ePpVEu/59V2M3SvIXXtb253Zi3df7tWT9k/s2HBbyQ64POc5qDTWmGt6wRCvWL+Pr8v0q0Zbj7HETaoG3r8vm+/0pI0q351/271X8pM/2f7ZGxH7zY2OD0yKpt9lNpqQb7u99/X0qa81AWl7bJcG3i87KRmScLvbj5QCOTUZkuBa3+LaMgM//AC168fSgzgnp8uq7kNp9kOlaUSOAI9vB67avqLT7UxA/e7Rnr0qpYzXK6VppW3jOUjBHm9Bt+lXhLc+aV+zJtx97zf06UJaBVvzP59V3KUqWP9mt8p8vv1znNR3gtP7d08uvzeVLjg/7FWpprtrNm+yxhv7vne/0qG5e6/texIt4z+7lz+96fc9qTLpt33/m6rsSwi08+6AUdRu4PpQFsfscOV/djbt4NPgkuvPuSbeMHIx+968fSnRyXQtoiLaMtgZXzen6UzN3vv26rsGLNbk8fvdvoelZlktiNPvPl+Xz5N3B/vmtfzLnzSPs8e3H3vN/pis+xkuvsNzm1jz50mB53X5z7UdSoN8r17dUWJ1sxNa5UZ3Hbwf7pojSy+0zkIN+Bk4PpUkkl15kOLaPG45Pm9OD7UqSXP2iYfZ02jGD5vXj6UyLu2/Tuu5kasLAaSpCfJ5y4GD/AH60HTT/ALTEDGN5U7eD0qtqsl2dMBa1jV/NX5RLn+P6VoNJd+emLaLbg5bzeR+lFjWTfIter+0vIqrBp5hudsfdt2Qaa8WnhLUCP5d4xwfQ1deS6CSYt4+Acfvev6VznjXxanhSw0y71K1ylzeRWoCS/dZ+B26UnoRGUm9//Jl2LulC9FpqJMkJP2iTHymtKUXRltCHhHPPynn5TWDpWn2Is9S/0q78sTvu/wBKk/xq/Lp1iZLLN1edfk/0uT+6fehXOisoc7/+R8vU5bxtHcf8J74OkMkIUX0gAwc5MNdLfi6Hh0/PDv8ANTnBx/rhXG+PLCyj8X+E5PtF0ZP7UWM5uX4DR8c54ro9Q0+xHhok3FyU85ety5/5ajtmp1sy6aheGvWPT18zoLhbr7daHfFtw2flPXFOhF15t388Odw2/KePlFUJ9NsxqFmPtF1uw23/AEp+mPrSQ6bYNLe/6Td/ew/+lSf3R71Wpz2hyrXp/L5+pMgvPsFn+8h3eYuTtPPNeZ2Oo3j/ALT+oWTXA8pNET93zt6hunrzXcf2bpn9nWG6e52+YoX/AEl/X614zpkFi/7VN+vmzGEweQp85slhChI3ZzjPapbehs6cXzNX6/Z/4J73suxpV3mSIsfMIO08DmrMwn+1WWWj6tu4PPy1hx6dpg0m9KyXBUGTOZn68+9WpbDThcWADzFWLbczOf4frTuyJQjd79fs+XqXytx9qvfnjwYl2jB4+9WVpsV23hWyRZYlfcvJXtuqRtM037Tfj97xEu796/8Ate9Z2m6XpjeFbJpBJ5ZZed7dd1J3uawUFHd7x+z5PzOnAm/tPJZNvkjIx7mqaCb7Bq2HTd5kuDjp8oqAaPpi6rjyn3mLP329T71WTStOGn6sdkhVZJM5duDtHvT1Moxp930+yu/qW9UEn2jQvnXiYbuOvymr1qbj+0rsM6FAEwAvTg1iajpunLPof7twWmG0bjz8tXYdF0ptRutsTGXC7xvbH86NRzVP2au3s+i/m9RqrP8A8I3ZgSoJNyfNt4xmr8wm/tm1+dAvky5G3rylc82j6T/wj1s3lyeXuTJ3N1zzVqbRtK/tm1Tyn5glON74PKe/1palyjTu9X9r7K7eo7SBdG11vEybxcSbTt6cVoLDcsmnEzLlcFvl6/LXP6Vpukraa0VtztWZxyWPatJ9N0t4dOZ4SAQMfe5+WhXsVWUOd2v/AOAr+X1NO3SX+17wmQbTHHgbf96srV0mPhC4BmG7I5C9vMFPttL0kavdgW2W8uM4IY/3qzdVstKPhCdhbKFBGDtOc7xQ9hUYx9rG194fZX+ZF8YpLi38Ca1LDPs/0KVMAddwC/1rK/Z5eeb4SaK8k2f9HVFGPu4GKX4x6bpP/CJyRtbhHleOJSoI+9Kg/wAay/gBp+mj4dvDNbiRoLmaFiyEnCsRxR1M1CPsd39y7+p6pIkohtB5/wA4cZbH3uDVdUf/AISRz5vH2YfLj/aqi+naI1pak2SbC6gfuznODUK6ZpP/AAkjqbKIj7MODHkdabFGELS1ez+yu/qa4jl/sy5HnfMXkwdvT5zUlwj+bp3708SHPHX921ZC6bo4066/0KIjfJnMX+2elPl07RhJp/8AoMQ+c7f3XX5G60C5I3er6/ZXb1NYJJ9quT5pwUGAB061l6EkzeF7cCch8t823/poaP7O0YX1yDYw52An91x36Vm6NpujHwxCz2MTAlufK+b/AFh70dTSMIez3e8fsrs/M6rY/wBsU+aeIyCMdeetVikgs9QzKTkvg46fLVM6do/9owr9ggz5R2/ueOv0qL+zdH+z6gRYQ9Xz+6/2e1PUxjCK6vp0Xf1LGpRy/Z9LxMeJ4snb1q6qv/a8n7w48hOMf7TVg6hp+jiDS9thAA08YH7nqPfiryaZpP8AbEiiwt8+Qp/1Ix95valqXKMeTd9ei7+pcaN/7OvVMxJPmfNjpxUtxFKZbbFwQFbkbR83FZLaXpDaXesNPg2DzP8Allz07VJcaboqyWwOnwctwBD7d+KepPLG+76/ZXb1JNMgmGt6wzTHaxj2/L/s1aEcps4R9pJO9fm2j16Vh6fZaQ2sarE1jAY4zGVUwjC5XnHHfFSDTtBFhEf7OgCeYv8Ayw5+9QrmtSEXJXv9n7K7ep5l+0xLcQX/AIEaCYgrqyNwBx0Gf1r2DyZfsmoA3J5Zudo4+UV4f+0Rp+mHUPDqW1jEnls077IQMgOg549zXrNtpmhSabeMumW4GCf9QP7o6cVOuooxjyLV/wDgK7+pqWkUh0rSv9JIwsZztHPy9K0PLl88/wCkHG37u0fnXO2mlaIdM0xjplsSRHz5Aznb34rQXTNFNyyjTbbdtyT5A/wqlexFWMLvV9fsrv6lp4pfsDD7Ux/2to9aZdJL/a9iv2gjMcv8I5+5VFtM0IWLFdMt9menkDPX6VHdaXow1mwX+zrbmOUgCAY/h9vrQ7hCML7v7X2V29TZiik+0XJ+0NyRxtHHFNWKQWkIF0R93DbRzVGLS9HNxdf8S224xn9wOePpSLpWjfYoGbTbbbhcfuBkfpT1ItC+76fZXb1NYRS+dn7ScY+5tH51m2Ucg067H2kk+fJ82Bx85p39n6R9r2f2db79u7d5A/wrP07T9JaxvD/Z8OBPIDmHn71LW5UIx5Xq+n2V5+ZuyxuJLbM5yGPYfN8ppIkf7XPm4Jxt+XA44qnNpuk+dbA6fbksx2/uRx8p9qItN0r7VcAWFvuAGT5I54+lPUztG2727Lv6jdWUnSh/pmB5q/Pgc/PV90YSxE3eOD8uB83vWHqOn6QNJVxp8IQyrgCEA/frTfTtL8+INYQFsHafJGAPypalyUVFavd9F5eZMqsY7g/bNwy2eB8teI/tS3jW/h3wwiXW8/2lHLjjnZzmvZV07S/JuCthAPvbv3I5/SvDv2lrCye00OK0s44ykU87BY8HaqUpXsVSjGU7K/3Lse1aS7C11E/ZGJ+0SfLlef1rQld/MsyLVsk88r8nyn3qnpUcq2upASgM08hU4+7V6VZPOsv3o4J3cfe+U1RnVa9o/n37HE/EdnGpeG3W2ZlTXLX5ht7gjFdDqTsPDZItmJ81Pkyv/PYe9c58WpXsdKh1SS4WO1sNTs7qUkcIit8zH86121G11DwiLiw1S2uYmlUrPEwZSPOFS3ua0rXh6x7m7cO39oWf+jtjD5OV44+tOtndpLzNqykPxkr83yj3rzbxj8R54vFMWj+CtPfxHqltGzXEcDgRwk8AO/TPtXMeHvjXfnXGi8U6JLoWlz3DWbX05+WG5VBlD7e9HMZqk3BPTbz7nsnmSfYLIiy5Mi5Usvy814JoVxL/AMNC/aTbjM2o3kIwR/AAvX/gNe6L5sulaZKl4pR5EbcAMMCeMV4A1r4gjvdP8V+GrL+17tNQvb0W6sF3RPPJzn6DNKT2OujFWnttLufQxkmOj3n+jKMeZxuGD19qnuHm+12H+jr1b+P7vy/SuW8C68fFPw/OrrJJA1wJd0T43RMCQVP4iuqnRvtVgPtB6tnp83y07nLJJSe3Xv2E3zm8vgYI8eUmDv6/e9qz9He4XwzZEW6Egj5d/wDtdelXwjfbL3/ST/ql44+X71cZq3jHQ/C/g+2k1bWo45htKwRsrSyHd91UHJpN2ZcUnG2m8e/ZncF5xqu0QoU8kZbf05PtVdGmFjqZMaE75MAP1+Ue1eV3njzx9f3bX3hrwVcNp6RBhHfSrFNMuT8yr/SruhfF7wtd6DfPq2rLo+ol5BJY3nyzRNgDbjHrRzEqnZLbp3PQNWeQXGiDykJM4yd3T5T7VpQPMb25UxIAAuG39f0rjLjxl4Zvv7BntvEmnSJ5oO4Tpz8p6+lacHirw+t/csfEunkEL8puEwOvvTTQppezXo+/8xf8y5Og2rCCPflMLv8Af6VdmM39q2uI4yfJlz859U9q5MeKdAGg2o/4SawyGT5vPTPX61cm8WeHRq1sT4m07Hkyf8vMeOqe9K6HJK7/AO3u/Yv6Z9oWDWMQxbjPIceYeePpVwPd+Xp5FvCTxn96fl+X/drl9F8TaJcDVYovEdi8slw4jCzpk8cYGeateKfEem+GNBtNS1PVGWCPaAsZDPKxHCqO5NNNWLqJOb2/HsdFC91/aVyPJh27EwfNP+1/s1kas91/wiM+YIu3AlJ/jH+zXleq/EH4iRTPqWmeDJ3sLgxxwwSuBOAc7WZR90Gt/wAIeN7Txb4DvImuja65aYS9sZCBJC3mDt3X3pNl0qaVSG28e5r/ABde8a00KBIYiZtUgXHmE5w4bH3faoPgp9rh0PX4PJiDQ6zdpgyEYO/p92rnxEjebxJ4LtVuG+fUTIcY4Cxsc/rXHWmseIPAHjLVbXWbAf8ACLarqzvDqUcqlonm5XevYE0dbmS5XSUVa9vPuexb7zybYmCAybhkeafQ/wCzUCNc/wBvv+6hx9nH/LQ/3v8Adp4hc2toPtj53D5xjng1Esbf8JC/+kt/x7j5eP71UyIqPvbbPv3JQ93/AGfOfJh3b5MDzDz8x/2adM935lhmGH/WHP70/wBxv9mq91NDa6Rdy3GoLFEpkJkdlAX5j3rzjxJ8TUu9VsdF+H4fxFrQJZjEwFvENhGXk6Z5zik2gjFSb0XXv2PTxJe/bLgLBAQEXH74+/8As1Q0KW7/AOEahZYYTJluPNIH+sP+zXlN5qHxb0G5Gq6hHYataAj7Vp2nqDMiHOCuepFS+GfjL4Rfw0kGo6vc6XfxOyzW1xCQ6HeT6YPWknrqbezjyWVt49+zPZGe6+3RjyYdpjOT5p4Of92ome6Ntf7ooRjdjEh5+X/drz5vjF4F+3xN/wAJQu0RkH92cfjxWpa/EPwfdWV28Xi7TWWQMVDXCKR8voeaq6MFC1tO3fudLqLXJt9N/dQ58+Mn96f/AImrqNN/akmY4wPJXkOf7ze1cVqXjvwm1vpoXxbpZKzxk4uUPHqeaux+PvCJ1Z2HivSSDCox9qjwfmb3pXQ5L3Nu/fujo5HujY3mIot3z4HmH0/3alnkvBJBiCDBb5v3x44/3a5NvHXhP+z7xV8W6WWbfg/akz0+tY3iv4jQy3umaV4EuLfX9cuWJWOCZTFEoHLyMOgp3QlG7tZde/Y7fTmuhrmrHyYcHyv+Wp/un/ZqZXvvsMP7i33714844xu/3a8O/wCEn+LGgXmv3GpaJp98lmkc9zJbyYBj5+VB3IGa9S8HeJNP8U+DrHVNO1LdFI67/mG6Jt3KN6EUJ9zapBcyen2e/Y4v4vzXNx4jmhEEDfZNGecjzCcZnTn7v+zXpemz3c2iyyeTCGZMgeaf7g/2a831XTpvE3xK8Y2Vpe4ZNGjskY42+YxL4P5rT/hn4o1GO+1vwb4xuLa116xiV4PKcbbiIp95c9SMDIqbi5VypadO/c9Ks5LsaVpeIockRg/vT02/7taINz53McPl44IkOc/981nWS50jSf37EERYbjn5a0lXFyT57E7fucfnVLYwrW5np379yFmuzbHMUPmZ/wCehxjP0qC6M/8AbVjtSPHlS5y5/wBj2oup4LbTXe4v1jQEgyO4GOema4PxL8WPBula7Zh9cW6liSRGisl84liVwDt4zwaG0OnH3tF/N37HosTTma4zHGCCNvznnj6URtci2i+SLfhc/Of8K888P/GLwRqt5cxf24LGdmwI79TAQQMcbuK7y2uLefTbdob5HQhCsiuDuzjH50XRDjbddu/YtFrj7QQI4vK29d5zn8qo6e901pdZSLcJ5AvznpuPtWgADctiU7tv3M/rWVpgjWwvR9pZh9okyc/d+Y0dRwtyvTt3NGZpvOtvkjwWO75z/dPtSxGb7TOGRNvGCGOen0ps5UTWpMuMMe/3vlNEUkZurg+eOi8buBxQRbTbp+pT1Q3LaVnbH5nmrn5jj749q0yZPMQBV2EHdzzn2rhfiB4z0Lwr4bV9S1DfK8gMMER3yzkPnCgV5/qvxl8UR6pbSweBL+LT0ja5kM0nzGDu2B0YelJyRs6Upxsl1f6HvDGXypchA3O3n8s14v8AGxLm81eG3McbmLRbuVvmOASuK9L8KeJNI8T6CdT0a/E9tOCx+bmM45BHYiuN1nTLbxB421K1jvjlNKFqGLZGZM9aHqtCsOuSd5Lby8jrNO1Gxa01LeszIZn3fu2zir0uo2O6x3RzYB/d/u24+U0ukG5EF+RFDv8AtD4G44P6VelNx5lr+7izn5vmPHynpxTKqyhzvT8fL0Mm5fSdRlv7a/tPtMUqqJI5oC6suOhBGK8v1f4ZfD19IluodKurV3lXcLeWaNT+8APyg7entXpmqeK9I0TVJrfWdV0uwkcK0a3FyI2fj0NZHinxZpGleHIv7R1PS7WSd0kiSa5C7180HIz1HepdrM0oNc8VZ2vHr/wB3h/SvC3hdrGz0DTPscOHJ2ROS3HVmPLH3OadrNn4b12w1ex1ax+02szfMrwFsHYPmHHBHY10c008l9p7wpA8TqzBw5PG3jHFFu1402oAxWw+cD755+RfamSpx5b67fzf3vQ+dNR8NeMfDXhyGLwl4ik1OxMirb2V5ZEvGCcYD+g616p4NstL8PPpGlGCWV7TSo4Xb7OTvcfebGO5zXWj7b/Z1hiK2JEqfxn1+lITe/8ACVj91bf8enXe398+1TY6faxtJLtL7X/APGdS8I63YP4ivPBuufYbG9nef7Bcab5io3fax+6D7Cp5NB8fXQ05LrxfBbs4IPkaIuY+OcEjk17Ju1D+y7vdFaD/AFmMO3Tn2qxO179qs/kts5bPzt/d+lPlIdZJ7d/teXoeD2fwu1H7bqsd5498RyQyqDJ5dpsZ+vGSTt4HbFdX4K8GeCdB8P2s8Hh/zr1mUyXVzbtNIzbuu5s4/wCA4Femg332u6/d22PLXHzt/te1UdGN8PDlpiO2LDHV2xjd9KFGz0D2sXG77x+15PyF+2ad/aQ/0GTd5QAP2Y8cn2rFm03wzdQ6pLc+H7WWVpJMvJp6sx4HcrXWKbz+0PmSDy/LGSHOep9qrA3f2XUcLAfnfHzH0+lVYwjOP5faOC1fwf4Ee60gnwpZKXmGdtgFDDb3wOasxeCPh+b24B8I2ZIC8fYeB9OK63VWuhPo2Y4M+eM/OePlPtV+I3v2yfMdvtwuDvbJ6+1Kxc5x5F6P7Xmebx+CfAX9hQOvhO0OWTLGy5PPPNWZfBPgD+1bdf8AhELPBikyPsHBOUxxj6/nXZg339kWwEdtkFP42x1+lWJmvP7VtsJb48mTq7eqe1Fgc43f/b32vI8qX4dfDu6i1c3HhVSRKwUxRSIUA6AbSMVa0f4d/D3SLvS7+z8My/aUIZWlE0oBx12uxGfwrvNKe+K6vlLUsLh8fO2On0q8jXhisTst8kAn52/u/ShIqpKKk9P/ACby9ChFd6b/AGnc/wCgyZ8uMf8AHqf9r2ryn4neA9G1/TE1vSBeaLrdscC4trYKso38+YABu+pNe0w/a/7QuCUg27Ex85z39qyNZ+2f8IjcgrBnHUMT/GPalJaDoTi6kV5x+0eZeBPCuraJ8QmufEN/d61pkUBFlJcWoDrI33zgD2/WvQfE+kaP4n0PV9Lv7OZYLhQpeODbIpA4ZTjgiulmN19tt/kg24bPzHPT6UK115t1tWDII25c+nfimo20MJ1VKzt07+Z4Y3w61/T4LR9I8c60FLhRHdaekwRccdepFJL8M7y414W91418TSRtb5naOFUZ8nouB8or3KN737NBlLffkZ+c4/lUC/af+Ejc7Ytv2YfxHP3vpS5EbRxHxej6nk1l8IPBMVvNcX9rrupeU74ivbiRkJDcHAxk/WvQLKz0LSU0yLStBjtIt5O2CzVP+WbdcDmt9jcnT7jKwht0mPmOMbj7UsxufN0/iL/WfN8x/wCebe1Oxk6qbb9evkZ0VxYG/uv+JdJ9xSf9HHPWsTS7fRn8ORvLoaSszMSTaKx/1h74rr4zcfbrj5YsbF2/MffrxWdoy3Q8OxoghEgZ/wCI4/1h9qLO5aqLk+cevkylJaaG9/CraBEd0bdbJOn5Vj/8Ix4PePUv+KM07cC3zf2ZF/d7ccV3DC4N7CQItgQ7uTnPtxURM5t9Q3CPq23k/wB3vTszKNSOmnbr5nB6l4V8HLaaXt8G6cu6ePONNiBPqDxzWhH4T8HDV3UeDdLH7hSB/ZkWB8zdttdFqf2j7NpefK3faIt2CcVfTf8A2rJ93Z5K8Z5zuakVOceTbv180cOfCfg86Vet/wAIZpowZMf8S2LI49ccVrWOk+HdImhfS/DNrZySEAvb2KRnp3IAzW4fO/s6+yY/M/ebeuOnercvm7oNuzG75859O1MiVRX279fI5yxubU61q27TpTjywf3AP8JrybxH8JNI1C5vNR0yfXtKhvWBmsrPEcLvn72O34V7ZY+cNd1X/VlSIivJz0PWi4+3DTUw0HneYuDzj71Jq6N/apTWn8vXyPO/g/4YbwPoFtp2pWdxe6lK0k1xcGMNliQAMnnAUCn/ABC8F6R40sZZZbG/sNTspy8N/aRqkygAZXd3B969LcXP2yH54guxtwweeR0qALcfZdRAePJZ9pweOO9FiFWi2nbt1fc8Ls/h94u01NNl0HxprKW0pTKXtpHceX8vBXdx+gqa98P/ABdlvYJV8RW/2m1K7QlgiJOueTJjv7DivbNPW4/snS90ke7bHu+Xtt7Vo4l88ncvlbeBjnNJRCriUpNcqe/V9zw+w+HF1rOy/wDiTeXviEW6sIbBbZLeCJ2PLYQgsfQmu+sNH0TQdS02DR/DMVpGIpMeTbIp/g5J6k+5NdZKk/2OQeYhlzw23jrVa6Wb+27DbIu3y5dwK9fuUWsKNZSk3b+bq+xi6vomia+LyHWPDcN4hAGZrdGYfL2PUH3FeZv8EtAWyhfTbnxbpw+QtFb3gCkg8Ngg9M17jCsonudzrgkbfl6cUxFuPskX75A2Fydn0qrXM41lF6eXV9jxyT4aaxbagk2jeMPF8F1GAVkunjuExnoUOAfxqhF4B8WalDcSaj421/yo53BjtLaK33/NySV/wr3fZP55bzV8vbjbs5z9c1Qs1uPsd1mVN3nSY+Tp8xqeVGkcQnHZdO55VcfCt3Nuknijx46OSGBv06bT/s8VHa/CRImntoPEnjpIAoAX7enQjoTivZpEm8yD96oAb5vl68GlRZfPmO9QvGPl9qfKiPrOmy28+55H4b+G+heEI31G2stW1C+dkRZdQlWYxDfzs6bc969PkvJDPEG0u4JII3fLgD060mpJcDSyGkTf5i87P9sVfdJ/NQrKoQA7hs6n86drDnVjKKulu+r8jx2++Gt9Ya1qmq+BdS1Hw0b0N9pto7eKeKZuTkK5wvXtWp8JNI8Q6FpE114utpbzXL26zJKoQfu1BCcDAHFemqlwFfdOpJzt+TGP1prpc4hAnTdu+Y7OvHbmlYj26as0vxMzS1X7PqAW8OTO/wA24cVekC77XN3gg/3h83yms7Szbta6j/oh2id8jyutXZRbiS0BtCeeP3XT5TVIqqvff/A7HgP7TFrbzeMvAzSMjl9RWNi204X5ePpUv7SFlaSP8Pg0iSbtZ8kk7T8hccfT9Kh/aVkjfxf4QW3sbqX7JepcXBhtmYLH8vXA9ulM/aD1OymXwM9nZXDx2+pC9mKWjYEO8deP0qO5rZuKt5fke+3AiXULALebVAcBQy9NtR24Qy6l/wATEnL8YdePkFRtNZXF5pssdk+2RGdSbfHBX6UWhtDPqX/EvYfvO9v1+Qe1MlJqPXbsv5iIRJ/Z1h/xM3GJE/jXnmnBEHisH7cx/wBE6F1/vGmBrP8AsuwJsGI8xMD7P05+lKGtj4rUCyYf6J1MGP4j7UGuvvb7S6ImEaf2Tej+0HOTJzvXjrVqdENxZYvX4Lc715+WqmbX+yLwiyIH7zjyev6VamNuLmxxaEZLYHldPlpmMr3+/t2FVUN5d/6a3+rXjevH3qz9JVB4btcXzgZHO9f73Sry/Z/tl5i0IxEuf3XX71UNI+zjw1af6GcEj5RFn+KjqUvg+ce3ZmptT+0+bt8+V93cOeTVdIwbLU8XTn55Odw44FWT5P8AaQBtiT5XDeX05qshiFhqhEBxvkyoTr8opmUb/l27kOqRr52ik3bcTjALD5vlNaESoL2cm8Y/Kvy7hx1rP1QRebon+j9Z1x8n3flNaEYtzezr9l+YKuW8vr1o6lTfuL0fb+YoCNTotsBfMcMnzb19aszKh1e2/wBMYEQy8bl9UqsnkLotsRZnG5Pl8r3qzKIP7Yth9m58mXnyvdKQ38T/AO3u3YoaUibNYU3zDNw/zb144q6yI0em4vGGMfxD5vlqlpX2fZrLfYzxcP8AL5XXirgEIh00m1PO3pH935aFsXVvzv8A4H8pPCE/tO5/0pi2xPl3Dj71ZOrIn/CJXG66cr67h/fFa0JhOqXS/ZiCI0y/l9evFZGsmP8A4Q65ItTn+7s/2xzSlsKhf2kPWPY2p1X7dbf6Q2cNhcjnimRiP7Rf/wClNyV3fMPl+WlnMf8AaFn+4PIfnZ04psXl/atQ/wBGPBXnYPm+WqOdfD8vLuRlY/sVmFvH2+YuG3DnrxTVCf8ACTN+/bf9m+7kf3qkV1FlaEWbHLL8uwcdeajVgfFJXyD/AMe338D+9SZor+96PsTbUGnXX+kMV3yZbI+X5jxUkqr5un5mYnedvI+b921MDD7BdYgPDycYHzfMeafO2JdN/ddXPYfJ+7agz1u/n+Q6JVF9ckSsTsXIz0rM0d4x4aib7QVUO/z56/vGrUjP+nXP7o/cXnA+brWXobAeFom8jf8AM/yYH/PRqOpcfg+cfyZpOV/tODM5BMbYTP3veoQqeTqWJixJbcCfu/LVpm/06EGA8oTv4+X2qEn/AEfUT5OMFv8Agfy0zOL2+X5lDVhGbTSMXDbRcRYIb71XwE/tuXLtv+zp8ue25uapatIVs9KIt2/4+Ivl44q6jt/bUg8o/wDHunzcf3m4qTWV/Z/f27or/uV0m/xM2zMgLE9OKuzFPMtf3hzu+UZ+9xVRmb+ytQJgIP7z5OOeKvSyFfI/clixx2+XimjOe/zfbsjPsJIv7c1YCUl8Rbh6fKabMtrJpkYNzJ5fmL8249d1GmyE67q48hgQIucjn5TUwlZdPiItH++PkyP71CNJaTVv7vVdh8gt/t8JaVw4RsDceeRUHmWxt9Q/et9593zHjirrSSfbY/8AR2I2N82RxyPeqxmkFtf4tm4Z/wCJeeOvWhkRvZfLqu5HYvbnStMzIQMR45PJ21eBg+2Nh283ZyuTjFUrOaQaVpeLdjlYx1HHy9etXzJJ5x/0dsbfvZH5daFsKr8T+fVdyrI1q1lIBMxj3ctubg5qC9e3GuacXkYHy5cfMefuVdkkk+ysRasDn7uV9frVa6kl/tqxxbsR5cueV4+570MdPf8A8C6rsSxPb+fdHzG6jdyeOKjEtn/Z8O6VggCYO5varEMspnuM27DBGDuXnj601JZfsUR+zHOF+Xcvt70yf+B1XYcHtftRYSN5u3pubpWdYNaCzvcTNt8+TcdzcfNWr50vmlfsz4xnduX8utUdPllNtdf6K2fPk+XcvPzfWkVD4X8uqLDyWxa3/eN975OTz8ppEa2+0zfvG3cZG5uOKklll82D/R25Y5O4cfKfeljll8+UG3bbxg7hzx9aZn0+XddzJ1T7GdH4lfb5q4O5v+elaTvaGeEmR9+DtG5ueKq6pLIdKYm2YHzF43L/AHx71feWXzYgLdiDnJ3Djj60dTWT91er6rsiNRakTAO/zZ3fM1Ru1pstx5j7Q2F+ZueKsmWXY+bdsjOBuHP61GZpiISbVwS3I3LxwfegyTf9NGNpi6yYb4IdPDGd8ZD9atyf22Hth/xLs554f0NM0xIPJv8A/TGCmd8t5g4q3KIQ9sDesOeP3i88Gix1VJ++9F93kVYl1k3dz/yDcfL1D+lZWpjWT4eO8aaR5qcAP/z1Fb0Ih+13RF6wY7cjzBxx1rG1Rbf/AIRsg6g2BKnPmr/z2FS1ozShP95HRbx6Fy4Gt/2hZ5Om/wAfZ/T60lv/AG6Zb75tNzv/ALr/ANxcd6muBB/aVkRfsSA/Hmr/AHaS2EHnaj/p7n5xn96OPkFFiOb3dlt2/vFBF106fYfvdOH7xc/I/PP1p7DWP+EnT95YA/Zem1v731qWMWv9macDfMFEi7T5g55p+YB4tT/SSXNpwN4/vGixrzu8vdW0ugwJrI0263zWP/LTGEbpzU08esm4sv39luDNn5G5+X60Frb+yL7bduVzIGO/oasz+R9o08GZjydh3dflosYubv8ACuvTyKix6z9uu/39ljy0x+7b/a96p6RHq58PWpjntByDyh6bq10aEX97++bPlJu+bp96qGkC3/4Re1zMwjyMNk9d1FlcpVHyfCt49PJl3Zqf2/Pm2m3yxkbGz1+tVI01P7HqQ861yXkx8h44Fah8saquXbzPK4XJ5GaqoY1sdWIc48yTcc9DtFBlGb7Lp08ylqcWpFtIbzrUbZ13fKeTtNXoRqn2yYNJabcL0Rs96j1PyidGJkYEXC7Bn73ymtBDEL6bDnzNq7lz064phOo+RaLZ9PMyPL1X+x4FEtp5mU52N0zU0qan/a1qfNtAPJkz8h9U96WM240OEiZvJ3L85JzndVucp/bNoC5DeTIQM8HlKVhub5novtdPIydOh1MHVQk1qCZ2Iyh9Ksxx6qbay23FqGwMnyzyMVDppgZNaBmfHnvuOTxxVuAW5tNMPmuQgXYeeflprYurJqT0/DyCOLU/t8x+0223YnHlnOeax9Yi1X/hFrjNzb9P+eZ6bxXRQyRHUrgAt5hjTI56c1jawYF8I3Q3NsHU/N13ilJaBQm/aR0W8eiLk8Wq/bLbF1bAYbP7s+lJFDqpnvf9Lt8krt/ddPlq5cPEb+0JLbsNgYPPFIhtxNfZZ+SN/wB7j5aLGSqS5fhW3ZdyiIdXFnbAXluH3KCfK7VEItT/AOEiIF5Bt+z5I8r/AGqtn7GLK1BZzGHXafm5NRn7OfEpyX3i26fN/eoaNYzfve70f2UCwamLG4zew53vj910G40s8Gpmaw/02LHmHP7of3GqVWtRYXIBfbvfd97+8aLhrbztP5f752/e6eW1OxHPK707/ZXYakGo/bJx9ujxsXH7oVmaPBqX/CNx7L2IPuf/AJZDH+sNbELWpvrjBfdsXPDdKytGNmvhqMSNIE3Pz8//AD0al1NIylybdY/ZXZmi8Gp/bIAL6PZsbcDEOT7VALfUjFf7r+Pb82AIh/d71aka1+2253PnY2B8/Soh9j8i/wBhkyd277/92nYzjJ22/wDJV3KWo22o/Z9N330Zb7RFnEQ/Sri2+of2vJ/pybfIX/lkM/eaq2p/Y/sul5Mm0Txbfv8ANX1Nv/az/f3eQuPvdNzUFynLk27/AGV3RBFFfLYXpnvFcjzOkYx04qWe21Hdb41BfvfNmFeeO1Ru1r/Zd+QXKfvM/e9Ksym0LW+S+d3yff8ASnYzcne9u/2V2MvT7bUf7c1T/iYJjEWMQj0PWrJtNVNmo/tJPN3jnyFx1ptj9l/tzVMF9xEWR83oasgWAtFwZPL3gZy/XNJI0qVJcy06R+yuwNaah9qjI1L5QpyPIXPaqrWeom2v86mOS+P3C+ner7/ZRdJnzN+04+/7VWk+yC2vQ3mfebP3/SixnCctNO32V3Ktlaah/ZemY1LHyx5HkL029K0Daah53/IUITb93yFzmqdk1mNK0zPmYxHj7/XbWgv2Q3JI3+Zt5+/0oS0HVnLmenf7K7laW11I2zH+1AG9fIXHWq9zZ6h/a9jjVD9yXJ8heny1cc2P2WT/AFnl5Ofv+tVrl7MazYD95kpLj7/+zQ0OnKV9u/2V2JYrTUfPnB1Q4yMfuE9KatpqIsov+Jqc4XP7hPapYfsYubr/AFmSRu+/6Ui/YhYQ58zZ8uPv+1FieeV9u32V2FNnqPn5GqkJt+75CZzVKwtNR+z3ZGqnPnvj9wnrWp/opuOkm/b/ALfSqditn9nu22vt85933+eadgjUlyvTt9lD5bPUPMg/4mh4bn9wn9009LS/82TOpHHGP3KelSubZJLf7+d3y/e/umlT7OLib7+7A3fe6YosRzytt0/lXcy9Ts9R/sw/8TQ5Ei5/cpz84q+9pf8AnREamwABBHkpzVPURbJoxwshXzFwPn/56Vpv9nNxDkOXwdv3umKLFynLlWnV/ZXkQra3wWTOpEnnH7leKa9rfbYR/aZzuGT5K88GpwLULPtDgc7+G9KaVtfKtsK+zcNn3uOKLGanLt/5KirpDo0WoZtmAFw/y7fvVbmZA9r/AKMxyf7n3eDVXSFuDFqA8yPzDcPtO3gdPer0izb7cCSPIPzZXrwenNMdVr2j/wCD2IoWT7bdD7O3G35tnXjpWLqrxjwuxFo/+uX5dn/TYVtwrcfbro74tny4G05zj61j6mLoeF2/exbxKnOz/psPepexrQt7SPrHuX7mRf7SscWj9H52Dj5elLbSDztQP2NuHGPlHzfIKdcrc/2hY/vYsfPn5OT8v1otI7vztQ3zoSXGz5OnyCgi65fl5/zFRXxplhmyYnzE4wPl+agO58Wp/oxA+yfe44+Y1LHDc/2bZA3SqwdcnYOeajMVz/wliEzgp9kx9wf3qGapr3ttpdyUM39l3pFoRzJ8vHNWLh3FzYf6MSSW7j5flqARzjTL4m6DElyp2j5frU88cv2iy/0jnLZO0c/LRcxdr9OvfsCPJ9uvP9Hx+7TByPm+9WfpEkv/AAjFqfs2Tx8uR/e61oJHIb67H2k58tMfKvH3vas/S45v+Eatv9Kw3rtXH3qXUtW5em8e/ZmqWcamAISV8r7+Rxz0qsGYWWp/uejycZHPy1Y8uT+0gfPbaIvu4HPNVQr/AGLVMzn78mOBx8tBlG35d+5FqzN5mifuc5uF5yPl+U1oxyOb+YeRgBV+fI+brWbqqyZ0bE5x9pTPA5+U1fiST+0Zz5527FwuBkdaEVNL2a9H37lISSDRIWa1JbcvyZH96rsjv/aduPJyPKkOcjjlKqiOZdHhU3I37l+faMfeqxKj/wBq2379seTJxgc8p7Uwla72+137FHSmk3awBbnJnb+IfNxVqGWYWmn4tichQfmHy/LVbS4pc6uPtPzGdsHA+XjvU0UU5s9PK3ZHCbvlXn5fpSRdSzk9unfsWY5Zvt8y/Zjt2L824c9aytZeU+FbnNv26bh/fFakUcv9oTD7UxGxPl2r789KytYjdfCtzuumYY64UD749qJbBQt7SO28e5r3Ekv2y2xASMNk7hxxRA8purvMGACuPmHzfLROkn222xOwHzcYHPH0oiRzc3YE7Dlew+X5aZhpy9NvPuIHmFrFi1JO4fLvHHNVTJMPEfFtlfs33tw/vVZMcptYcXjA7hl9q88/Sq4SX/hISv2nj7PnG1c/e+lNmkLe9ts+5Kjz/YZ/9G53yYG8c/MaWaWYS2ObbkyH+McfI1J5cv2G4xdnO58Havy/Mfaknil87T/9KY/vDn5V5/dt7UugtLvbr37EqSTfbpx9n+XYuDuHPWsnSXnbwygS23He/G4f89WrSSOX+0LgfbGHyL8u1eOvtWTo0cv/AAjEZW+KfO/O1cf61vajqawS5Om8e/Zm28k/2uD/AEbja2TuHFRtJL9nvswYxuI+Yc/LRIHF9br9sblG+XC/N79KiKMIb8/bSc7uML8vy/SnoYpLTb8e5Bqks/2bTD9n5+0RZG8VeV5P7Uk/cnHkrzuH95qztUVza6Xi+PNxF82F5/Sr8auuqyBrkn9wvBCg/ebnpSNJpezW3Xv3RG0kx06+zb8/vONw54q1JJPmDFvxu+b5xxxVMhzpl/8A6USR5nzYXjj6VbnV824+0kHd6L83H0pmckr9OvfsUbB5hrmqZtyBiLB3D0NXlkuBAP8ARcMG+7vHrVOwjca5qf8ApRY7YvlwvHDe1W9r/Z/mvTncPnwvr06UDq25lttHv2Q95ZxcIBb5TacneOOlVzJP9mvM256tj5xyMVOyOLmPN0QNp+XC89Paop4pBbXZ+1MMhiOF+Xj6UERtpt+Pcr2kkx0zTP8AR+cR5+ccfLV8yz/aNv2f5Nv3t4rOtFcaTpebsjiPJwvPy9OlX8H7Vxd87PuYXPXr0oVrF1UuZ7de/cb5s5tnJtsNuPG8etVrqSb+2bDFvkbJed44+7UmMWsoN+D8x+f5eOagvP8AkM6eTebfkl4+Xn7tJ2HTS5nt179i/G8vnT/uOMjB3Dnio0eU2MP7n5sJxuHHSkjYCe4zeDqOMr8vFMVlOnw4vVXhPnyvPSndGfL5du/YuF5fNwIspjruHWqFhJOba8LQYYTvtG4c81bDp5+ftg6fcyv51Rs3QW15vvF/1z/Nlfl5ouhwj7r07dzQd5fMh/dcbjn5hxwaVGfz5QY/lGMHPXio5ZYxJBm5QDcerD5vlNJHPF9on/0lM8cbhxxRdEcrtt08+5V1J5jpLHyxv8xcjd28wVoMZDLFhBs53EnkVk6hJENGKm9TiRfm3Lz+8rReeDzoibtBwfl3r81K5pKL5dur7+RPmTbJ8gyM7eetRlptsH7td5YbxngDHao/Pg2zD7ZGc5/jX5eKYJ7cQ26i9jOCPmMi/NxRoZqD7fmY2k2Onm11M5lMYnfcdzcVeuLGw/0EMZQCfkw7c/LTtJeXytQPkDcLh8Lu+90q3K82+0xbqcnn5/u/KaDpq1Z+0er+/wAjOh0/T/t90v7/AHgLkbn6YrG1Ww03/hGHbdNt81Ru3N/z1Ga6mGSf7bdD7ONo24bf1OOlZN+058Mtm3UN5q/Lv6/vhUtaG1CtNVI+8949Rk+maWmp2GBNnD4G5+Rtp9pZ6YZdQAE5AbDDL8DaK0LmWf8AtOxH2Ychznf0OOnSkt5LoXGoH7Kv3xj951+RfanoQ6s3HWT2/mX8xkJp+lrptiTHNgyLgkvzzSSafph8UxoYpc/ZSdv7z+91rRjkuv7Nsv8ARUJ8xcjzOnP0ppkuf+ErXNsuPsnXzP8Aa+lJo0VWpeXvPaX2igNO0n+y74iGUgM+f9ZVmXT9J8+xxby7STjiT+7VsS3X9nXmbVM5kwPM6/pU88t19ps8WyZy2f3nTj6U7Ih1ql/ifX7XkZiabpIvrv8A0eXiNc8Sf7VUdNsdJbw1bsbeRhkc4k67q6JJLn7Zcn7MmdiY/edfve1Z+lS3Q8N2+y2QsRjHmY/i+lFlcqNapy/E94/a8mOax0r+0ADbvu8vj5ZPWqo0/S/sOpn7O+A8mch/7tbRkuftwxbLjy+T5nTn6VV825+xalm2QHdJj95/s/SixnCrU/mfT7XmZeo2Gm50bZA4zcLjh/7prQisdLGoz7YH8zYu7h/ek1KS5xpH+jrzcJu/edPlNXopLk38wa3QKEXB8zr19qaWo51J8i957P7XmYn2DSRo6bYJCm8ZJEmfvValstLXVbYeQ+4xSY+V/VKnE12dJjJtkLbhx5nH3vpVmWSf+1Lb9wuPKkyd/TlPaiwSqzu7yf2vteRhaTYaS8mrBreRlFw2eJOmOlWorDSRY2O+1fBC4+WTjip9GlufO1Um2QYuGx+868D2qzHJcG0sStsh4TOZMY+X6UJKxVWrU537z6fa8ipDp2ktfTBbV94RckrJ05rL1fTtKHhe6aO2cDHPD/3hXTpJcfapc26hdq4PmfX2rM1l5v8AhGLkvCobHTfn+IUmlYVGtU9pH3nvH7QsumaULy3T7M24hscP6UR6XpQnus2zdRnh/StKZpftlv8AuhjDfxe1JFLP59yPJXgjHz9ePpVWRj7apb4nt/N5maNO0c2kRNq+wkYGJOuarHTdKHiLYbZt32fPR/WtoSTm1iYW6bty5Xf05qvvnHiDAhXabfk7+fvUNFwrVPe957P7RTOnaT9jnP2VsBnz8sn940XGn6X5un4tnwZDj5ZOmxq1S8xs5SIl3ZfALcdTTZnn8yy/crnec/P0+RqVkSq07v3n1+15GamnaT9uuAbV9wRSflfpzWZotlpbeF42ktWILPxtf/nocV00TTfb5/3S7di4O/61maI8/wDwja7YVJ3Scb/+mjUrK5tGtPk+J7x+15Me9hpY1C2AtW3bG2na/Apq6fpnkX+y16bs/K3Py1pymf7dbnyk2bWz83INNLTGG9zEgxu24br8veqsYKrOy95/f5mLqdjpq2umEWhAM8QA2tkCtBdPsW1R82/PkryQ395qTVTP9m03Eab/ALRFuG7gVfUv/acg2jHkrznvuapsVOrPkXvPr180ZLWOnDTL8i2IUeZkYb0q1cWGn7rTdbE5b5DhuOKlcynTr75F3/vMDPtVmcy7rfCL9/5uenFUTKrO/wAT69fIxrCxsDrupqIDuCxZOG9Gq0+n6WLXm1Plbh8uG65p9g0h13VAyKFCxYOeTw1Wy1z9mBEUfm7vu7uMZo0HVqz517z2j18kVnsNPa4jVrYlsHBw2B0qA2Vh9nvcW5GCwbhueK1SZPPTCLs2nJzzmoJPNFvd5Rf4tuD1GO9BlGrP+Z/f5mXaWNgdK00/ZsqRHxhuu2ro0+wF3gWuH2Z3YPTNFp5h0vTPlXdiPcM9Plq7mT7Vgqvl7eDnnOaSLqVZ3fvPr18zNNhpptJCbL5NxypQ8nNV76wsF1nTQ1qDlJcYUnH3a2AZzbvlY/NycDPHWoLnf/a9jhV27JNxJ5H3elDCnWnzP3n16+RBFYWHn3P+iDIIydp54pqWGnnToD9kXYdmF2njpWjH5nn3GQuzjb69O9NjEosodoXfhcjt2zTI9rP+Z9OvkQnT7L7SP9ETft+/t4+lUbG1sza3260BQTyAgr157VtfP5v8Pl4/HNUdO84QXZYR7/Pk24zjr3pDhUlyvXt1Feys99tm1XJb5cr935T1ojs7M3U+LVN3y5YqMHirb790P3fvfN+R6UIH86XO3bxj16UGftJW36d/Mw9StbNNFObJSvmqAoQcfvK0ntLUzw5skLAHDbB8o9Kh1ITnSm2+UG8xcgg4/wBYKvN9o86PBj8vndwc5oNpVJcu/V9X5FZba0xORYgdd37sfN9KY1rZtFb/AOgLtLDC+WPl471cH2n95kw9fkwD+vNNIuCsWWiD5+bg46duaDNTff8AFmfpUcixaj/pEhPnvg4HHH0q28cjfY8XEgIPPA+b5fpRRVJFVJPnb/rYIYZPtdyftEm07cDA44+lZGrwTJ4acC6k3CROcD/nqPaiioezLoTftY+sTQuLeX+0bH/S5cYcEYXnj6U63t5vOvh9rl5cYOF4+Qe1FFCM+d8vy7L+YrJbzDTrMfbJs+YuThefm+lRNBL/AMJYg+1S4+yZ6L/e+lFFN9DaM3eXpLoiwbeVdMvAbuYnMhzhf8KsTW0v2i0/0qbIJycLzx9KKKDJ1Hf7+i7Cpby/bbk/apeY0xwvH3vas3SLeVvDNti6lBxnOB/e+lFFLqXGb5H6x6eTNMwy/bxi5lx5fIwvPP0qqYZPsGpA3MnLSc4Xj5fpRRTZEJvT5fmQ6nBJnRv9Jl4uEzwOflPtV9LeT+0Jm+1S4KLxheOvtRRQipzfIvR/mU4reVtFiBupclgd2Bn730q1NDJ/a9qftEuBDLxgc8p7UUUClN8z/wC3vyK2kQP5uqj7RLlp2weOOB7VatreR7Gy/wBJlBVVJIA54+lFFCFWm+Z/L8idY3+1ynz5MbVwMDjr7Vla3C//AAjV0pnkJI68cfMPaiiiWw6En7SPrE05o3+2W3758fN6c8fSkihb7RdnzpPmK46cfL9KKKZlzPl+X6iLA4s4l8+XIK/Nxk8/SoDC/wDwkIfz5MfZ8beMdfpRRQVGbvL5k4hb7JOvnyfMznPHHJ6cUlxG4m0/98/Ehz05/dt7UUUhKTu/n+QsUTf2lct50mCijHGB+lZejwsfCyoJpAQ8nzDGf9a1FFLqbRk+T5x/JmtJE3262bzX+VW44waYIysWoHzHO4see3y9qKKoxUnp/XUr6kha100F2yJ4ue5q4q/8TSRsn/UqMdvvNRRSLk/c+/8ANEMiEadfje2T5hz6cVZnXL253MMP+fFFFMzb1+/8inYpt13U23MdyxcHoOGq75JNv5fmSA5+8Dz1oopDrSfMvSP5IlZcyK2TwDx+VV5UxbXeGb5gx+nHaiigzi9StZxn+ytNXe3AjOe5+WruzF3v3NymMdutFFC2LqN8z+ZG8GbWSPzJPmJO7PI5qvdRk6vpx3thEl4z977vWiihjpyfN8n+RZjj/f3JLP8AMR36cdqasI+wwpvf5QnIbk9KKKaJ5nf7icxjzQ25umMZ4rP0+BRbXi7nw0787uRz2oopLccJPlfyLskQLwnc/wAp/vHng9aSKIC5mO5+dvG4+lFFBHM7f13M/VLZW0hl3yDEinIc5/1grQeBTNE26T5QRjccHiiin1NZSfKter/QcYFw/wA0nzf7Z4qJrVDHAu+XCHP3zk8d6KKDJTl3P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34582=[""].join("\n");
var outline_f33_49_34582=null;
var title_f33_49_34583="Amoxicillin: Pediatric drug information";
var content_f33_49_34583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amoxicillin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"    see \"Amoxicillin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/2/39972?source=see_link\">",
"    see \"Amoxicillin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Moxatag&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Amoxi&reg;;",
"     </li>",
"     <li>",
"      Mylan-Amoxicillin;",
"     </li>",
"     <li>",
"      Novamoxin&reg;;",
"     </li>",
"     <li>",
"      NTP-Amoxicillin;",
"     </li>",
"     <li>",
"      Nu-Amoxi;",
"     </li>",
"     <li>",
"      PHL-Amoxicillin;",
"     </li>",
"     <li>",
"      PMS-Amoxicillin;",
"     </li>",
"     <li>",
"      Pro-Amox-250;",
"     </li>",
"     <li>",
"      Pro-Amox-500",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     All neonatal dosing recommendations based on immediate release product formulations (ie, oral suspension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"     Oral: 20-30 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      UTI, prophylaxis (hydronephrosis, vesicoureteral reflux):",
"     </b>",
"     Oral: 10-15 mg/kg once daily (Belarmino, 2006; Greenbaum, 2006; Matoo, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"      see \"Amoxicillin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Unless otherwise specified, all pediatric dosing recommendations based on immediate release product formulations (oral suspension, chewable tablet, tablet, and capsule).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild to moderate infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &le;3 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     AAP recommendations (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012): 25-50 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Manufacturer labeling: 20-30 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &gt;3 months, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     AAP recommendations (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):  25-50 mg/kg/day in divided doses every 8  hours; maximum dose: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Manufacturer  labeling: 20-40 mg/kg/day in divided doses every 8 hours (maximum dose: 500 mg) or 25-45 mg/kg/day in divided doses every 12 hours (maximum dose: 875 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe infection (as step-down therapy): Oral: 80-100 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg for most indications (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cutaneous, community-acquired or bioterrorism-related  (Stevens, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &lt;20 kg: 40 mg/kg/day in divided doses every 8 hours for 5-9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;20 kg: 500 mg every 8 hours for 5-9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Inhalational, postexposure prophylaxis (ACIP recommendations):",
"     <b>",
"      Note:",
"     </b>",
"     Use only if",
"     <i>",
"      B. anthracis",
"     </i>",
"     isolate is susceptible to amoxicillin (MIC &le;0.125 mcg/mL). Continue therapy for 30 to &ge;60 days depending on vaccination status and for 14 days after the third vaccine dose (CDC, 2010); see Additional Information",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &lt;40 kg: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     CDC recommendations: 45 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     AAP recommendations: 80 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg; higher dose recommended due to the lack of data on lower amoxicillin dosages for treating anthrax and the high mortality rate (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;40 kg: 500 mg every 8 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis prophylaxis:",
"     </b>",
"     Oral: 50 mg/kg 1 hour before procedure; maximum dose: 2000 mg (Wilson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     Oral: 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg  (Halperin, 2007; Wormser, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Otitis media, acute (AOM):",
"     </b>",
"     Oral: 80-90 mg/kg/day in divided doses every 12 hours; most experts recommend initiating with 90 mg/kg/day (AAP, 2004;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia, community-acquired:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients 5-15 years of age, a macrolide antibiotic may be a more reasonable first choice since",
"     <i>",
"      M. pneumoniae",
"     </i>",
"     is the chief cause of pneumonia in this age group (Bradley, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day in divided doses every 12 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Group A",
"     <i>",
"      Streptococcus",
"     </i>",
"     :  50-75 mg/kg/day in divided doses every 12 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Haemophilus influenza:",
"     </i>",
"     75-100 mg/kg/day in divided doses every 8 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Streptococcus pneumonia",
"     </i>",
"     (penicillin MIC  &le;2 mcg/mL); mild infection or step-down therapy: 90 mg/kg/day in divided doses every 12 hours or 45 mg/kg/day in divided doses every 8 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Tonsillopharyngitis; Group A streptococcal infection, treatment and primary prevention of rheumatic fever:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release (oral suspension, chewable tablets, tablets, capsules): Children and Adolescents 3-18 years: 50 mg/kg once daily or 25 mg/kg twice daily for 10 days; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     (Gerber, 2009; Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release tablets: Children &ge;12 years and Adolescents: 775 mg once daily for 10 days;",
"     <b>",
"      Note:",
"     </b>",
"     Patient must be able to swallow tablet whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      UTI, prophylaxis (hydronephrosis, vesicoureteral reflux):",
"     </b>",
"     Oral:  Infants &le;2 months: 10-15 mg/kg once daily; some suggest administration in the evening (drug resides in bladder longer);",
"     <b>",
"      Note:",
"     </b>",
"     Due to resistance, amoxicillin should not be used for prophylaxis after 2 months of age (Belarmino, 2006; Greenbaum, 2006; Mattoo, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection:",
"     </b>",
"     Oral: Immediate release: 250-500 mg every 8 hours",
"     <b>",
"      or",
"     </b>",
"     500-875 mg tablets twice daily",
"     <b>",
"      or",
"     </b>",
"     extended release tablet 775 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chlamydial infection during pregnancy:",
"     </b>",
"     Oral: 500 mg 3 times daily for 7 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis prophylaxis:",
"     </b>",
"     Oral: 2000 mg 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       H. pylori",
"      </i>",
"      eradication:",
"     </b>",
"     Oral: 1000 mg twice daily for 14 days in combination with a proton pump inhibitor and at least one other antibiotic (clarithromycin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Tonsillitis and/or pharyngitis:",
"     </b>",
"     Oral: Extended release tablets: 775 mg once daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release: Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild to moderate infection: Dosing based on 25-50 mg/kg/day divided every 8 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 8-20 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 8-20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Hemodialysis: 8-20 mg/kg/dose every 24 hours; give after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Peritoneal dialysis: 8-20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe infection: Dosing based on 80-90 mg/kg/day divided every 12 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 20 mg/kg/dose every 12 hours; do not use the 875 mg tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Hemodialysis: 20 mg/kg/dose every 24 hours; give after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Peritoneal dialysis: 20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: Children &ge;12 years and Adolescents:  Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30mL/minute:  Do not use the 775 mg tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     The immediate release 875 mg tablet and the extended release 775 mg tablet should not be used in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 250-500 mg every 12 hours depending on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 250-500 mg every 24 hours depending on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Give dose after dialysis (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis: 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg, 875 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 125 mg, 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moxatag&trade;: 775 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended-release formulation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: May be administered on an empty or full stomach; may be mixed with formula, milk, cold drink, or juice; administer dose immediately after mixing; shake suspension well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Take within 1 hour of finishing a meal; do not chew or crush tablet.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release formulations (oral suspension, chewable tablets, tablets, capsules): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in a tight, light-resistant container; reconstituted suspensions are stable for 14 days at room temperature or refrigerated; refrigeration is preferred",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release preparations (oral suspension, chewable tablets,  tablets, and capsules):  Treatment of infections of ear, nose, skin, and soft tissue, genitourinary tract, or upper or lower respiratory tract  due to susceptible  (beta-lactamase negative) organisms including",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     ,",
"     <i>",
"      E. faecalis",
"     </i>",
"     , streptococci, and nonpenicillinase-producing staphylococci (FDA approved in all ages); treatment of gonorrhea (FDA approved in ages &ge;2 years and adults); combination therapy of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (FDA approved in adults); has also been used for the treatment of Lyme disease, prophylaxis of bacterial endocarditis, and postexposure prophylaxis and treatment of anthrax",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet (Moxatag&reg;): Treatment of tonsillitis and/or pharyngitis secondary to",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"     (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amoxicillin may be confused with amoxapine, Augmentin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amoxil may be confused with amoxapine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fisamox [Australia] may be confused with Fosamax brand name for alendronate [U.S., Canada, and multiple international markets] and Vigamox brand name for moxifloxacin [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Limoxin [Mexico] may be confused with Lanoxin brand name for digoxin [U.S., Canada, and multiple international markets]; Lincocin brand name for lincomycin [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zimox: Brand name for amoxicillin [Italy], but also the brand name for carbidopa/levodopa [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zimox [Italy] may be confused with Diamox which is the brand name for acetazolamide [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F134567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, behavioral changes, confusion, dizziness, headache, hyperactivity (reversible), insomnia,  seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acute exanthematous pustulosis, erythematous maculopapular rash, erythema multiforme, exfoliative dermatitis, hypersensitivity vasculitis, mucocutaneous candidiasis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Black hairy tongue, diarrhea, hemorrhagic colitis, nausea, pseudomembranous colitis, tooth discoloration (brown, yellow, or gray; rare), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, leukopenia,thrombocytopenia, thrombocytopenia purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Acute cytolytic hepatitis, ALT increased, AST increased, cholestatic jaundice, hepatic cholestasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Crystalluria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, serum sickness-like reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amoxicillin, penicillin, other beta-lactams, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in renal impairment, dosage adjustment is required;  avoid use of extended release 775 mg tablet and immediate release 875 mg tablet in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or patients requiring hemodialysis. Use with caution in patients with a history of colitis, cephalosporin allergy, or asthma. Chewable tablets contain aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Administration to patients with confirmed penicillin allergies should be avoided; in patients with confirmed cephalosporin allergy, consider skin testing to rule out cross-sensitivity to penicillins.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Epstein-Barr virus infection (infectious mononucleosis), acute lymphocytic leukemia, or cytomegalovirus infection increases risk for amoxicillin-induced maculopapular rash. Appearance of a rash should be carefully evaluated to differentiate a nonallergic amoxicillin rash from a hypersensitivity reaction. Amoxicillin rash occurs in 5% to 10% of children receiving amoxicillin and is a generalized dull, red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. A high percentage (43% to 100%) of patients with infectious mononucleosis have developed rash during therapy; amoxicillin-class antibiotics are not recommended in these patients. Prolonged use may result in fungal or bacterial superinfection including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD); CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immediate release preparations are not interchangeable on a mg:mg basis with the extended release tablet. Some oral suspensions may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of amoxicillin products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Maternal use of amoxicillin has generally not resulted in an increased risk of adverse fetal effects; however, an increased risk of cleft lip with cleft palate has been observed in some studies. It is the drug of choice for the treatment of chlamydial infections in pregnancy and for anthrax prophylaxis when penicillin susceptibility is documented. Amoxicillin may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, oral amoxicillin clearance is increased during pregnancy resulting in lower concentrations and smaller AUCs. Oral ampicillin-class antibiotics are poorly absorbed during labor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; observe for change in bowel frequency; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis during active multiplication by binding to one or more of the penicillin-binding proteins, causing cell wall death and resultant bactericidal activity against susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and nearly complete (74% to 92% of a single dose is absorbed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended-release tablet: Rate of absorption is slower compared to immediate-release formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into liver, lungs, prostate, muscle, middle ear effusions, maxillary sinus secretions, bone, gallbladder, bile, and into ascitic and synovial fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17% to 20%, lower in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates, full-term: 3.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and children: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal function: 0.7-1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 7-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 3.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: Neonates: 3-4.5 hours; children: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal excretion (60% unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%); &sim;30% removed by 3-hour hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/2/39972?source=see_link\">",
"      see \"Amoxicillin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple daily doses should be taken at equal intervals around-the-clock. May be taken with milk, juice, or food. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause nausea, vomiting, or diarrhea. Report respiratory difficulty; rash, itching, or hives; easy bruising or bleeding; persistent diarrhea; signs of opportunistic infection (eg, unusual sore throat, fever, chills, fatigue, thrush, vaginal discharge); CNS changes (confusion, agitation, dizziness, insomnia); or if condition being treated worsens or does not improve by time prescription is completed. May cause tooth discoloration (most reports occurred in pediatric patients); tooth brushing or dental cleaning will reduce or eliminate discoloration.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Only use amoxicillin for postexposure inhalational anthrax prophylaxis if isolates of the specific",
"     <i>",
"      B. anthracis",
"     </i>",
"     are susceptible to amoxicillin (MIC &le;0.125 mcg/mL). Duration of antibiotic postexposure prophylaxis (PEP) is &ge;60 days in a previously unvaccinated exposed person. Antimicrobial therapy should continue for 14 days after the third dose of PEP vaccine. Those who are partially or fully vaccinated should receive at least a 30-day course of antimicrobial PEP and continue with licensed vaccination regimen. Unvaccinated workers, even those wearing personal protective equipment with adequate respiratory protection, should receive antimicrobial PEP. Antimicrobial PEP is not required for fully vaccinated people (5-dose I.M. vaccination series with a yearly booster) who enter an anthrax area clothed in personal protective equipment. If respiratory protection is disrupted, a 30-day course of antimicrobial therapy is recommended (CDC, 2010).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, \"Diagnosis and Management of Acute Otitis Media,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belarmino JM and Kogan BA, \"Management of Neonatal Hydronephrosis,\"",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):9-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/16427220/pubmed\" id=\"16427220\" target=\"_blank\">",
"        16427220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/7761188/pubmed\" id=\"7761188\" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canafax DM, Yuan Z, Chonmaitree T, et al, &ldquo;Amoxicillin Middle Ear Fluid Penetration and Pharmacokinetics in Children with Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(2):149-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/9493813 /pubmed\" id=\"9493813 \" target=\"_blank\">",
"        9493813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      CDC and Johns Hopkins Working Group on Civilian Biodefense, &ldquo;Commentary on Non-Labeled Dosing of Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax,&rdquo; December 10, 2001, file://www.fda.gov/cder/drugprepare/amox-anthrax.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Use of Anthrax Vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-6):1-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/20651644/pubmed\" id=\"20651644\" target=\"_blank\">",
"        20651644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson WW, et al, &ldquo;Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(22):1794-1801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/9178793 /pubmed\" id=\"9178793 \" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, \"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute",
"      <i>",
"       Streptococcal pharyngitis",
"      </i>",
"      : A Scientific Statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenbaum LA and Mesrobian HG, \"Vesicoureteral Reflux,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2006 , 53(3):413-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/16716788/pubmed\" id=\"16716788\" target=\"_blank\">",
"        16716788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halperin JJ, Shapiro ED, Logigian E, et al, \"Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2007, 69(1):91-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/17522387/pubmed\" id=\"17522387\" target=\"_blank\">",
"        17522387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mattoo TK, \"Medical Management of Vesicoureteral Reflux - Quiz Within the Article. Don't Overlook Placebos,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2007, 22(8):1113-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/17483966/pubmed\" id=\"17483966\" target=\"_blank\">",
"        17483966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIntosh K, \"Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(6):429-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/11832532/pubmed\" id=\"11832532\" target=\"_blank\">",
"        11832532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012. Available at file://aapredbook.aappublications.org/cgi/content/full",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al, \"Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(10):1373-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, \"Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(15):1736-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(9):1089-134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?33/49/34583/abstract-text/17029130/pubmed\" id=\"17029130\" target=\"_blank\">",
"        17029130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12631 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34583=[""].join("\n");
var outline_f33_49_34583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134511\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134512\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045040\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431486\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045033\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134488\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134472\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045044\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045036\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045043\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134567\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045047\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045032\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045031\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298741\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134481\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134484\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720643\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045039\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045030\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045046\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045038\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045048\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=related_link\">",
"      Amoxicillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/2/39972?source=related_link\">",
"      Amoxicillin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34584="Clinical presentation, diagnosis, and treatment of nasal obstruction";
var content_f33_49_34584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, diagnosis, and treatment of nasal obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34584/contributors\">",
"     Neil Bhattacharyya, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34584/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34584/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/49/34584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16905660\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal and sinus complaints are among the most common reasons for visits to primary care clinicians, otolaryngologists, and allergists. Although some clinicians consider nasal obstruction to imply a blockage within the nasal cavity, nasal obstruction is most commonly defined as a patient symptom manifested as a sensation of insufficient airflow through the nose [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/1\">",
"     1",
"    </a>",
"    ]. Nasal obstruction may be the cardinal presenting symptom of many common disease processes, such as rhinitis, sinusitis, septal deviation, adenoid hypertrophy, and nasal trauma.",
"   </p>",
"   <p>",
"    This topic will focus on the clinical manifestations, evaluation, and treatment of nasal obstruction in adults. The structural causes of nasal symptoms and other specific diseases associated with nasal obstruction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"     \"Etiologies of nasal symptoms: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=see_link\">",
"     \"Cancer of the nasal vestibule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=see_link\">",
"     \"Tumors of the nasal cavity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link\">",
"     \"Congenital anomalies of the nose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=see_link\">",
"     \"Nasal trauma and fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16905667\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for nasal obstruction relate directly to the underlying etiology. Several common risk factors for nasal obstruction include a history of atopy, recurrent sinusitis, nasal trauma, nasal surgery, having household pets, exposure to poor air quality, and a family history of nasal polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Nasal obstruction commonly accompanies many other comorbid conditions including asthma and obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16905674\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of nasal obstruction may be related to abnormalities occurring with any of the anatomic structures and functions within the nose. Normal nasal anatomy and function are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiologies of nasal symptoms: An overview\", section on 'Nasal anatomy and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasal obstruction may be generally divided into mucosal and structural causes (",
"    <a class=\"graphic graphic_table graphicRef79359 \" href=\"UTD.htm?38/19/39228\">",
"     table 1",
"    </a>",
"    ). The nasal mucosa is a complex tissue that is subject to local and systemic insults, leading to nasal obstruction. Examples of mucosal causes of nasal obstruction include bacterial sinusitis, nasal polyps, and soft tissue turbinate hypertrophy due to allergic rhinitis. There is also a normal, cyclical pattern of turbinate mucosal swelling, which alternates between sides of the nasal septum at intervals of two to five hours, referred to as the nasal cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/6\">",
"     6",
"    </a>",
"    ]. Disruption of the nasal cycle can contribute to nasal obstruction.",
"   </p>",
"   <p>",
"    Airflow through the nose is limited structurally by the width of the nasal cavity. The nasal cavity includes the anterior nasal cartilaginous structures as well as the borders of the bony piriform aperture (",
"    <a class=\"graphic graphic_figure graphicRef56105 \" href=\"UTD.htm?21/25/21905\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67813 \" href=\"UTD.htm?33/24/34180\">",
"     figure 2",
"    </a>",
"    ). The nasal valve is the narrowest portion of the human airway (",
"    <a class=\"graphic graphic_figure graphicRef52471 \" href=\"UTD.htm?11/59/12208\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/7\">",
"     7",
"    </a>",
"    ]. Collapse of any of the structures making up the nasal cavity can lead to nasal obstruction. Examples of other structural causes include nasal septal deviation (cartilaginous or bony), bony inferior turbinate hypertrophy, concha bullosa formation (air in the middle turbinate), benign and malignant tumors, and choanal atresia or stenosis.",
"   </p>",
"   <p>",
"    The underlying pathogenesis of nasal obstruction may be multifactorial. As an example, it is common to have compensatory mucosal hypertrophy of the inferior turbinate on the side opposite a deviated nasal septum [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16905681\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical manifestations of obstruction within the nasal cavity are the patient's complaint of congestion, stuffiness, fullness, or blockage within the nose. Difficulty sleeping is another common complaint as the inferior turbinates may engorge in the supine position. Patients may report being able to sleep on one side only, as contralateral sleeping causes increased nasal obstruction. Nasal obstruction itself is a risk factor for poor sleep quality, independent of obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Difficulty breathing is a less common complaint, which can occur due to nasal disease on one or both sides of the nose.",
"   </p>",
"   <p>",
"    Patients will often report other symptoms that may suggest the underlying etiology of nasal obstruction. In the case of rhinosinusitis, these symptoms include facial congestion, facial pain or pressure, dysosmia, anterior rhinorrhea, postnasal discharge, cough, pruritic conjunctivitis, sneezing, or throat",
"    <span class=\"nowrap\">",
"     irritation/itching.",
"    </span>",
"    It is common for symptoms of nasal etiology to wax and wane with respect to daily time course, body position, seasonality, and exposures to environmental stimuli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H3250712#H3250712\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of nasal obstruction is difficult to predict and may vary based on underlying etiology. Structural abnormalities such as nasal septal deviation or bony inferior turbinate hypertrophy typically worsen slowly over time. Mucosal abnormalities, such as those caused by seasonal allergies or noxious stimuli, typically fluctuate in duration and severity [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"     \"Etiologies of nasal symptoms: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H3250712#H3250712\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of nasal obstruction, as measured objectively by acoustic rhinometry, peak nasal airflow, or rhinomanometry, may not correlate well with the patient's subjective sense of nasal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/13\">",
"     13",
"    </a>",
"    ]. As an example, minimal changes in nasal patency (measured objectively) may still manifest as a significant symptomatic problem in the individual patient. (See",
"    <a class=\"local\" href=\"#H492107719\">",
"     'Other testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16905688\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with nasal symptoms involves a detailed history and physical examination. Some patients may require further evaluation involving nasal endoscopy or diagnostic imaging.",
"   </p>",
"   <p>",
"    This section provides a general approach to the patient with nasal obstruction. The differential diagnosis of nasal obstruction is broad and includes both structural causes (congenital abnormalities, acquired diseases, tumors) and mucosal causes (medication-induced, infectious, and inflammatory conditions) (",
"    <a class=\"graphic graphic_table graphicRef79359 \" href=\"UTD.htm?38/19/39228\">",
"     table 1",
"    </a>",
"    ). Diagnostic criteria for specific etiologies of nasal obstruction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic nonallergic rhinitis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H39#H39\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"     \"Etiologies of nasal symptoms: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link\">",
"     \"Congenital anomalies of the nose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492107512\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should focus on several key features of the clinical history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location &mdash; Whether symptoms are unilateral (suggesting structural causes) or bilateral (suggesting mucosal causes)",
"     </li>",
"     <li>",
"      Time course &mdash; Temporal course of the nasal symptoms, including diurnal and seasonal variation suggesting an allergic process",
"     </li>",
"     <li>",
"      Triggers &mdash; Allergic stimuli and airborne exposures (eg, cigarette smoke, particulate matter, pets, chemicals)",
"     </li>",
"     <li>",
"      Symptoms of rhinosinusitis &mdash; Facial pain or pressure, nasal congestion, dysosmia, headache, purulent nasal discharge",
"     </li>",
"     <li>",
"      Symptoms suggesting malignancy &mdash; Facial deformity, cranial nerve dysfunction (eg, facial numbness), and unexplained epistaxis",
"     </li>",
"     <li>",
"      Intranasal drug use &mdash; Intranasal cocaine or overuse of topical nasal decongestant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      or neosynephrine",
"     </li>",
"     <li>",
"      Oral medications &mdash; Oral contraceptives, antithyroid medication, antihypertensive medication, antidepressants, and benzodiazepines",
"     </li>",
"     <li>",
"      Trauma &mdash; History of nasal trauma or previous nasal surgery, particularly rhinoplasty",
"     </li>",
"     <li>",
"      Medical history &mdash; Wegener&rsquo;s granulomatosis, cystic fibrosis (associated with nasal polyposis), sarcoidosis, and syphilis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492107529\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the nose is of primary importance in identifying or confirming the cause of nasal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/7\">",
"     7",
"    </a>",
"    ]. Most of the underlying causes of nasal obstruction can be determined based on a thorough examination of the nose, nasal cavity, and the nasopharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492108362\">",
"    <span class=\"h3\">",
"     External examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external nasal contour is examined with close attention to any bony and cartilaginous deformities, looking for evidence of prior trauma, the structural integrity of the nasal tip, and indentation or depression of the surrounding nasal bones. In older patients, deterioration or hypertrophy of the cartilage in the nasal tip may contribute to nasal obstruction. The examiner should manually elevate the nasal tip to a neutral (rather than exaggerated) position and assess for improvement of nasal airflow. Airflow improvement suggests disease of the cartilage of the nasal tip. The clinician should also examine airflow both during shallow and deep inspiration. Early collapse of nasal patency suggests nasal valve incompetence.",
"   </p>",
"   <p>",
"    The Cottle maneuver is an additional physical examination maneuver to assess nasal valve competency [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/7\">",
"     7",
"    </a>",
"    ]. The Cottle maneuver is performed by retracting the cheek laterally which pulls the upper lateral cartilage away from the septum and widens the internal nasal valve angle. If the patient&rsquo;s symptoms are relieved with this maneuver, the cause of nasal obstruction is likely related to the nasal valve.",
"   </p>",
"   <p>",
"    Palpation of the neck is also important to detect cervical lymphadenopathy, particularly if nasal malignancy is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492108355\">",
"    <span class=\"h3\">",
"     Anterior rhinoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior rhinoscopy can be performed with a nasal speculum or with an otoscope, along with a bright light source to improve visualization. Examination of the nose is conducted with the patient's head tilted back and the clinician sitting directly opposite. To reduce patient discomfort and steady the head, the examiner should position the outer ulnar aspect of the palm not holding an instrument against the patient's forehead; the thumb of that hand is used to elevate the tip of the nose. This procedure allows for optimal visualization of each vestibule, the nasal turbinates, septum, and mucosal surfaces (",
"    <a class=\"graphic graphic_picture graphicRef73419 \" href=\"UTD.htm?2/3/2097\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The assessment should start at the level of the naris looking for mucosal abnormalities, patency, and collapse of the soft tissues with respiration (",
"    <a class=\"graphic graphic_figure graphicRef52743 \" href=\"UTD.htm?11/43/11967\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/15\">",
"     15",
"    </a>",
"    ]. Normal mucosal surfaces are pink, and the vestibules are patent and easily visible to the level of the middle turbinates (",
"    <a class=\"graphic graphic_picture graphicRef73166 \" href=\"UTD.htm?5/40/5760\">",
"     picture 2",
"    </a>",
"    ). The septum should be midline, although a slight deviation may be normal. Anterior rhinoscopy provides assessment of the size and caliber of the inferior turbinates and the position of the anterior to mid-nasal septum. Although there are no strict definitions for normal size of the nasal cavity, clinicians should assess the overall dimensions of the nasal cavity relative to the septum and the turbinates while identifying septal deviation, significant inferior turbinate hypertrophy, and possible contact between mucosal surfaces (",
"    <a class=\"graphic graphic_picture graphicRef53443 \" href=\"UTD.htm?10/6/10337\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Occluded nasal passageways caused by boggy, red nasal mucosa may develop as a result of allergies, nonallergic rhinitis, or overuse of nasal decongestants. Ulcerated, friable mucosa may indicate granulomatous disease. Polyps at the level of the middle turbinate or mid-nasal cavity may be visible (",
"    <a class=\"graphic graphic_figure graphicRef50105 \" href=\"UTD.htm?26/4/26688\">",
"     figure 5",
"    </a>",
"    ). Identification of purulent nasal discharge is helpful in identifying cases of rhinosinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492108348\">",
"    <span class=\"h3\">",
"     Nasal endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior nasal structures are best visualized with nasal endoscopy. Fiberoptic nasal endoscopy is a diagnostic tool with low risk and high diagnostic yield but is typically available only to otolaryngologists. Patients in whom the etiology of nasal obstructive symptoms is unclear after initial evaluation, or in whom symptoms persist after treatment for a presumptive cause, should be referred for endoscopy.",
"   </p>",
"   <p>",
"    After preparation of the nose with topical decongestant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical anesthetic spray, a rigid or flexible endoscope is used to directly examine the middle meatus, posterior aspects of the nasal cavity, and the nasopharynx to identify polyps, posterior turbinate hypertrophy, middle and posterior nasal septal deviations, adenoid hypertrophy, nasal tumors, choanal atresia, and purulent discharge draining posteriorly in rhinosinusitis (",
"    <a class=\"graphic graphic_picture graphicRef79734 \" href=\"UTD.htm?13/11/13488\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54181 \" href=\"UTD.htm?41/50/42799\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492107576\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic imaging to assess both mucosal disorders and anatomical deformities is indicated when the diagnosis is not clear based upon the history and physical examination alone. CT scan of the nose and paranasal sinuses is the primary diagnostic imaging modality [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/14\">",
"     14",
"    </a>",
"    ]. Plain film radiography lacks the sensitivity and specificity required in the diagnostic evaluation of nasal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI, which allows for more detailed soft tissue assessment compared to CT, is generally a secondary study and is indicated for better characterization of nasal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of abnormal CT findings include air-fluid levels in acute bacterial rhinosinusitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68163 \" href=\"UTD.htm?31/9/31888\">",
"     image 1",
"    </a>",
"    ), bony narrowing in choanal atresia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82266 \" href=\"UTD.htm?2/30/2543\">",
"     image 2",
"    </a>",
"    ), stenosis of the pyriform aperture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68161 \" href=\"UTD.htm?19/14/19695\">",
"     image 3",
"    </a>",
"    ), and nasal septal deformities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52826 \" href=\"UTD.htm?28/22/29038\">",
"     image 4",
"    </a>",
"    ). Although an anatomic abnormality may be seen on CT scan, the etiology of obstruction may not be apparent. As an example, any cause of inferior turbinate hypertrophy can lead to nasal obstruction, including allergic rhinitis (both seasonal and perennial), nonallergic rhinitis, rhinitis medicamentosa, and other medication-induced rhinitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492107719\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other tests can be performed to help characterize nasal obstruction. The data supporting the use of these measurements are somewhat controversial and results can be less than definitive. Thus, these tests are usually ordered under select clinical situations after specialist evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergy testing should be considered in patients with chronic symptoms, given the high prevalence of allergic rhinitis and its contribution to nasal obstruction. It should be particularly considered in patients with concurrent asthma.",
"     </li>",
"     <li>",
"      Acoustic rhinometry is a simple, noninvasive measure of cross-sectional area of the nasal cavity longitudinally along the nasal passageway.",
"     </li>",
"     <li>",
"      Peak nasal airflow is a noninvasive measure indicating peak nasal airflow in liters per minute achieved during maximal forced nasal inspiration.",
"     </li>",
"     <li>",
"      Rhinomanometry is a computerized, functional assessment of airflow.",
"     </li>",
"     <li>",
"      Mucosal biopsy is indicated for cases of suspected malignancy and may be helpful in the diagnosis of infection or inflammatory disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16905695\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of nasal obstruction should target the underlying etiology. This section will focus on treatments of several causes of nasal obstruction, including nasal polyposis, nasal vestibulitis, nasal septal deviation, mucoceles, and nasal valve abnormalities. Treatments for other specific causes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link\">",
"     \"Congenital anomalies of the nose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link&amp;anchor=H11#H11\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Nasal obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=see_link&amp;anchor=H10#H10\">",
"     \"Nasal trauma and fractures in children\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of adults with snoring\", section on 'Nasal patency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer of the nasal vestibule\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=see_link&amp;anchor=H362247871#H362247871\">",
"     \"Tumors of the nasal cavity\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic therapy is generally used as first-line treatment for mucosal causes of nasal obstruction. Nasal glucocorticoid sprays are first-line therapy for several mucosal etiologies of nasal obstruction (eg, rhinitis, nasal polyposis) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/14\">",
"     14",
"    </a>",
"    ]. Some structural causes (eg, adenoidal hypertrophy) can be treated with pharmacologic therapy initially and referred for surgical treatment if medication response is inadequate. Other structural causes of nasal obstruction are less likely to respond to pharmacologic treatment and surgery is the initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As an example, choanal atresia usually requires transnasal puncture or palatal repair with subsequent stenting (",
"    <a class=\"graphic graphic_picture graphicRef51419 \" href=\"UTD.htm?13/35/13872\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66077 \" href=\"UTD.htm?9/58/10158\">",
"     picture 7",
"    </a>",
"    ). Malignancy of the nasal cavity usually requires radiation therapy in combination with surgical resection.",
"   </p>",
"   <p>",
"    The etiology of nasal obstruction may be multifactorial, and treating more than one condition may be required for effective management of nasal obstruction. A combination of both nasal septal deviation and turbinate hypertrophy leading to nasal obstruction is common. Medical treatment of the turbinate hypertrophy component, possibly due to allergic rhinitis may provide only partial relief depending on the degree of contribution of the individual elements. Similarly, surgical treatment may only provide partial relief, with pharmacologic treatment of comorbid allergic rhinitis needed to fully relieve symptoms.",
"   </p>",
"   <p>",
"    The majority of cases of nasal obstruction are effectively treated with a combination of pharmacologic and surgical therapy. However, nasal symptoms may wax and wane and it is not uncommon for nasal obstruction to recur if allergic stimuli are encountered again or if structural abnormalities recur after treatment. Such failure may occur months or even years after initial therapy, but generally responds well to another course of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809634100\">",
"    <span class=\"h2\">",
"     Mucosal disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809627388\">",
"    <span class=\"h3\">",
"     Nasal polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the mainstay of treatment and prevention of nasal polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/20\">",
"     20",
"    </a>",
"    ]. Intranasal rather than oral corticosteroids should be used as first-line treatment. Multiple randomized trials have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    (200 mcg bid),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (200 mcg twice daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    (280 mcg daily) are superior to placebo in reducing symptoms of nasal obstruction in patients with nasal polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. There are little data directly comparing different intranasal preparations.",
"   </p>",
"   <p>",
"    Oral glucocorticoids are reserved for patients with severe nasal polyposis or in cases refractory to intranasal glucocorticoids. Other medical treatments for nasal polyposis include treatment of underlying allergies, antileukotriene agents, and daily lavage of the sinuses with saline [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of chronic rhinosinusitis\", section on 'CRS with nasal polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"      aspirin",
"     </a>",
"     /NSAID",
"    </span>",
"    exacerbated respiratory disease (AERD), aspirin desensitization followed by long-term daily therapy may be an additional therapeutic option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with polyps that remain symptomatic despite medical therapy should be considered for surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/25\">",
"     25",
"    </a>",
"    ]. Surgery can offer temporary relief, although polyps tend to recur within a few months to years following surgical intervention alone. Continued medical management of the underlying etiology is therefore required after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809627946\">",
"    <span class=\"h3\">",
"     Nasal vestibulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nasal vestibulitis consists of the application of warm compresses and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    nasal ointment twice daily for five days, or oral antibiotics if the infection appears to be widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiologies of nasal symptoms: An overview\", section on 'Nasal vestibulitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1069269842\">",
"    <span class=\"h3\">",
"     Rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple therapies are utilized in the management of acute and chronic rhinosinusitis, including intranasal saline, topical and systemic glucocorticoids, antibiotics, antileukotriene agents, antifungals, and surgery. These treatments are combined in various ways to manage the different subtypes of rhinosinusitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1069269787\">",
"    <span class=\"h3\">",
"     Rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of allergic rhinitis combines allergen avoidance and pharmacologic therapy. Intranasal glucocorticoids are the most effective single therapy for allergic rhinitis in patients with significant or persistent symptoms. Oral antihistamines can also be helpful for nasal obstruction in patients with persistent allergic rhinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic nonallergic rhinitis are less responsive to pharmacologic therapy than those with allergic rhinitis. However, intranasal glucocorticoids and the topical antihistamine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    are useful in treating the total symptom-complex of chronic nonallergic rhinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic nonallergic rhinitis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809628059\">",
"    <span class=\"h3\">",
"     Medication-induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal obstruction caused by medication use generally resolves with termination of the offending medication (",
"    <a class=\"graphic graphic_table graphicRef79359 \" href=\"UTD.htm?38/19/39228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, an intranasal glucocorticoid can help reduce nasal symptoms that persist soon after discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H7#H7\">",
"     \"An overview of rhinitis\", section on 'Topical nasal medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H8#H8\">",
"     \"An overview of rhinitis\", section on 'Systemic medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809634136\">",
"    <span class=\"h2\">",
"     Structural disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, structural disorders are most effectively treated with surgical intervention. In addition, nasal strips may be helpful in cases in which the soft tissues around the lateral external nose collapse, either unilaterally or bilaterally, during regular or moderate inspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809630633\">",
"    <span class=\"h3\">",
"     Nasal septal deviation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septoplasty is the definitive treatment in patients with nasal obstruction due to septal deviation. Reported rates of long-term efficacy vary, but one study reported that septoplasty was successful in reducing nasal symptoms in up to 89 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809630640\">",
"    <span class=\"h3\">",
"     Mucoceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal and sinus mucoceles are effectively treated with endoscopic sinus surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809630647\">",
"    <span class=\"h3\">",
"     Nasal valve abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal valve collapse generally requires surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34584/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. Correction of nasal valve weakness usually involves cartilage grafts to buttress and support the existing cartilage. Alternatively, adhesive nasal strips applied externally can stent the nasal valve. Because of cosmetic issues, these are most often applicable at night during sleep. They should be applied to the lower one-third (fleshy) part of the nose, not over the bony dorsum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H809634165\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with symptoms or signs of potentially serious nasal or sinus disease should be referred to an otolaryngologist (ie, facial deformity, cranial nerve dysfunction, and unexplained epistaxis). Patients with structural causes of nasal obstruction should be also referred, as these conditions generally require specialized diagnostic equipment (eg, nasal endoscopy) and surgical treatment.",
"   </p>",
"   <p>",
"    Further evaluation and management of mucosal causes of nasal obstruction depend on individual clinician experience with a particular disorder. It is reasonable to start medical therapy (eg, intranasal glucocorticoids) for most mucosal disorders and refer to an allergist or otolaryngologist if nasal obstruction persists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/12/11457?source=see_link\">",
"       \"Patient information: Deviated septum (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/18/29985?source=see_link\">",
"       \"Patient information: Nasal polyps (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492107460\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Underlying causes of nasal obstruction include both mucosal disorders (medication-induced, infectious, and inflammatory conditions) and structural abnormalities (congenital deformities, acquired diseases, tumors) (",
"      <a class=\"graphic graphic_table graphicRef79359 \" href=\"UTD.htm?38/19/39228\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"       \"Etiologies of nasal symptoms: An overview\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16905674\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a patient with nasal symptoms involves a detailed history and physical examination. Some patients may require further evaluation involving nasal endoscopy or diagnostic imaging. (See",
"      <a class=\"local\" href=\"#H16905688\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The history should include a description of nasal symptoms, potential triggers, intranasal drug use, oral medication use, previous trauma or surgery, and pertinent medical history. (See",
"      <a class=\"local\" href=\"#H492107512\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the underlying causes of nasal obstruction can be identified with a thorough examination of the external nose, nasal cavity, and the nasopharynx. Anterior rhinoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nasal endoscopy should be used for better visualization of internal nasal structures. (See",
"      <a class=\"local\" href=\"#H492107529\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases where the diagnosis is not clear based upon the history and physical examination, CT scan may be helpful in assessing for mucosal disorders and anatomic deformities. Plain film radiography lacks the sensitivity and specificity required in the diagnostic evaluation of nasal obstruction. (See",
"      <a class=\"local\" href=\"#H492107576\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of nasal obstruction should specifically target the underlying etiology. Pharmacologic therapy, particularly intranasal glucocorticoids, is generally used as first-line therapy for mucosal causes of nasal obstruction (eg, rhinitis, nasal polyposis). Many structural causes of nasal obstruction do not respond to medical treatment and require surgical intervention (eg, nasal septal deviation, nasal valve abnormalities). (See",
"      <a class=\"local\" href=\"#H16905695\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presenting with symptoms or signs of potentially serious nasal or sinus disease should be referred to an otolaryngologist (ie, facial deformity, cranial nerve dysfunction, and unexplained epistaxis). Patients with structural causes of nasal obstruction should be also referred, as these conditions generally require surgical intervention. (See",
"      <a class=\"local\" href=\"#H809634165\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/1\">",
"      Jessen M, Malm L. Definition, prevalence and development of nasal obstruction. Allergy 1997; 52:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/2\">",
"      Becker SS, Dobratz EJ, Stowell N, et al. Revision septoplasty: review of sources of persistent nasal obstruction. Am J Rhinol 2008; 22:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/3\">",
"      Bhattacharyya N. Air quality influences the prevalence of hay fever and sinusitis. Laryngoscope 2009; 119:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/4\">",
"      Delagrand A, Gilbert-Dussardier B, Burg S, et al. Nasal polyposis: is there an inheritance pattern? A single family study. Rhinology 2008; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/5\">",
"      Bhattacharyya N, Kepnes LJ. Additional disease burden from hay fever and sinusitis accompanying asthma. Ann Otol Rhinol Laryngol 2009; 118:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/6\">",
"      Baraniuk JN, Kim D. Nasonasal reflexes, the nasal cycle, and sneeze. Curr Allergy Asthma Rep 2007; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/7\">",
"      Chandra RK, Patadia MO, Raviv J. Diagnosis of nasal airway obstruction. Otolaryngol Clin North Am 2009; 42:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/8\">",
"      Akolu E, Karazincir S, Balci A, et al. Evaluation of the turbinate hypertrophy by computed tomography in patients with deviated nasal septum. Otolaryngol Head Neck Surg 2007; 136:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/9\">",
"      Jun BC, Kim SW, Kim SW, et al. Is turbinate surgery necessary when performing a septoplasty? Eur Arch Otorhinolaryngol 2009; 266:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/10\">",
"      Storms W. Allergic rhinitis-induced nasal congestion: its impact on sleep quality. Prim Care Respir J 2008; 17:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/11\">",
"      Udaka T, Suzuki H, Fujimura T, et al. Chronic nasal obstruction causes daytime sleepiness and decreased quality of life even in the absence of snoring. Am J Rhinol 2007; 21:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/12\">",
"      Bellanti JA, Wallerstedt DB. Allergic rhinitis update: Epidemiology and natural history. Allergy Asthma Proc 2000; 21:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/13\">",
"      Lam DJ, James KT, Weaver EM. Comparison of anatomic, physiological, and subjective measures of the nasal airway. Am J Rhinol 2006; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/14\">",
"      Fraser L, Kelly G. An evidence-based approach to the management of the adult with nasal obstruction. Clin Otolaryngol 2009; 34:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/15\">",
"      Wittkopf M, Wittkopf J, Ries WR. The diagnosis and treatment of nasal valve collapse. Curr Opin Otolaryngol Head Neck Surg 2008; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/16\">",
"      Bhattacharyya N, Lee LN. Evaluating the diagnosis of chronic rhinosinusitis based on clinical guidelines and endoscopy. Otolaryngol Head Neck Surg 2010; 143:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/17\">",
"      Hamdan AL, Sabra O, Hadi U. Prevalence of adenoid hypertrophy in adults with nasal obstruction. J Otolaryngol Head Neck Surg 2008; 37:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/18\">",
"      Corey CL, Most SP. Treatment of nasal obstruction in the posttraumatic nose. Otolaryngol Clin North Am 2009; 42:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/19\">",
"      Tan BK, Lane AP. Endoscopic sinus surgery in the management of nasal obstruction. Otolaryngol Clin North Am 2009; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/20\">",
"      Newton JR, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag 2008; 4:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/21\">",
"      Jankowski R, Klossek JM, Attali V, et al. Long-term study of fluticasone propionate aqueous nasal spray in acute and maintenance therapy of nasal polyposis. Allergy 2009; 64:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/22\">",
"      Stj&auml;rne P, Blomgren K, Cay&eacute;-Thomasen P, et al. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2006; 126:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/23\">",
"      Filiaci F, Passali D, Puxeddu R, Schrewelius C. A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis. Rhinology 2000; 38:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/24\">",
"      Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998; 124:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/25\">",
"      Becker SS. Surgical management of polyps in the treatment of nasal airway obstruction. Otolaryngol Clin North Am 2009; 42:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/26\">",
"      Rambur B, Winbourn MW. Recognizing nasal vestibulitis in the primary care setting. Nurse Pract 1994; 19:22, 25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/27\">",
"      Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. Clin Exp Allergy 2010; 40:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/28\">",
"      Gandomi B, Bayat A, Kazemei T. Outcomes of septoplasty in young adults: the Nasal Obstruction Septoplasty Effectiveness study. Am J Otolaryngol 2010; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/29\">",
"      Caylakli F, Yavuz H, Cagici AC, Ozluoglu LN. Endoscopic sinus surgery for maxillary sinus mucoceles. Head Face Med 2006; 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/30\">",
"      Brachlow A, Schwartz RH, Bahadori RS. Intranasal mucocele of the nasolacrimal duct: an important cause of neonatal nasal obstruction. Clin Pediatr (Phila) 2004; 43:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/31\">",
"      Devars du Mayne M, Moya-Plana A, Malinvaud D, et al. Sinus mucocele: natural history and long-term recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis 2012; 129:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/32\">",
"      Soon SR, Lim CM, Singh H, Sethi DS. Sphenoid sinus mucocele: 10 cases and literature review. J Laryngol Otol 2010; 124:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34584/abstract/33\">",
"      O'Halloran LR. The lateral crural J-flap repair of nasal valve collapse. Otolaryngol Head Neck Surg 2003; 128:640.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14609 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34584=[""].join("\n");
var outline_f33_49_34584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H492107460\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16905660\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16905667\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16905674\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16905681\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16905688\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H492107512\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H492107529\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H492108362\">",
"      - External examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H492108355\">",
"      - Anterior rhinoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H492108348\">",
"      - Nasal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H492107576\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H492107719\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16905695\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H809634100\">",
"      Mucosal disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H809627388\">",
"      - Nasal polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H809627946\">",
"      - Nasal vestibulitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1069269842\">",
"      - Rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1069269787\">",
"      - Rhinitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H809628059\">",
"      - Medication-induced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H809634136\">",
"      Structural disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H809630633\">",
"      - Nasal septal deviation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H809630640\">",
"      - Mucoceles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H809630647\">",
"      - Nasal valve abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H809634165\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H492107460\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14609|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/9/31888\" title=\"diagnostic image 1\">",
"      Coronal CT in pt with ABRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/30/2543\" title=\"diagnostic image 2\">",
"      CT choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/14/19695\" title=\"diagnostic image 3\">",
"      Pyriform aperture stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/22/29038\" title=\"diagnostic image 4\">",
"      Nasal septal deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14609|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/25/21905\" title=\"figure 1\">",
"      Nose external anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/24/34180\" title=\"figure 2\">",
"      Nose lat wall nasopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/59/12208\" title=\"figure 3\">",
"      Nasal valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/43/11967\" title=\"figure 4\">",
"      Internal nasal exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/4/26688\" title=\"figure 5\">",
"      Nasal polyps in nostril",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14609|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/3/2097\" title=\"picture 1\">",
"      Nasal polyposis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/40/5760\" title=\"picture 2\">",
"      Anterior rhinoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/6/10337\" title=\"picture 3\">",
"      Anterior rhinoscopy with septal deviation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/11/13488\" title=\"picture 4\">",
"      Endoscopy choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/50/42799\" title=\"picture 5\">",
"      Purulent drainage ABRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/35/13872\" title=\"picture 6\">",
"      Choanal atresia repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/58/10158\" title=\"picture 7\">",
"      Nasal stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/19/39228\" title=\"table 1\">",
"      Etiology of nasal obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=related_link\">",
"      Aspirin exacerbated respiratory disease: NSAID challenge and desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=related_link\">",
"      Cancer of the nasal vestibule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=related_link\">",
"      Nasal trauma and fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/12/11457?source=related_link\">",
"      Patient information: Deviated septum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/18/29985?source=related_link\">",
"      Patient information: Nasal polyps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2008?source=related_link\">",
"      Treatment of adults with snoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34585="Clinical manifestations and diagnosis of enterovirus and parechovirus infections";
var content_f33_49_34585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34585/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34585/contributors\">",
"     John F Modlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34585/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34585/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34585/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34585/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34585/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/49/34585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human enteroviruses and parechoviruses are ubiquitous viruses found throughout the world, and are transmitted from person to person through fecal-oral contact [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/1\">",
"     1",
"    </a>",
"    ]. Polioviruses, the prototypic enteroviruses, are the cause of paralytic poliomyelitis, a disease that has been eradicated in the United States and other developed countries (except for very rare cases that are attributable to live, attenuated polio vaccine viruses), and that is targeted for worldwide eradication.",
"   </p>",
"   <p>",
"    The non-polio enteroviruses (group A and B coxsackieviruses, echoviruses, and enteroviruses) and parechoviruses continue to be responsible for a wide spectrum of disease in persons of all ages, although infection and illness occur most commonly in infants and young children.",
"   </p>",
"   <p>",
"    The clinical manifestations and laboratory diagnosis of enterovirus and parechovirus infections will be reviewed here. The microbiology, epidemiology, pathogenesis, treatment, and prevention of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of infections caused by the non-polio enteroviruses are asymptomatic or result only in an undifferentiated febrile illness [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/2\">",
"     2",
"    </a>",
"    ]. When disease occurs, the spectrum and severity of clinical manifestations vary with the age, gender, and immune status of the host. Some clinical syndromes (viral meningitis and some exanthems) are caused by many enterovirus serotypes; others are predominantly caused by certain enterovirus subgroups (eg, pleurodynia and myocarditis due to the group B coxsackieviruses).",
"   </p>",
"   <p>",
"    The spectrum of diseases attributed to parechoviruses is similar to that of the echoviruses, including fever, respiratory tract infections, exanthems, viral meningitis, encephalitis, myocarditis, and serious neonatal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/3-9\">",
"     3-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Exanthems and enanthems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coxsackieviruses, echoviruses, and parechoviruses cause a variety of exanthems, which sometimes are associated with enanthems. With the exception of hand-foot-and-mouth disease, these eruptions are not sufficiently distinctive in appearance to permit reliable etiologic diagnosis on clinical grounds alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Maculopapular eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized maculopapular eruptions commonly occur with enterovirus infections, particularly those due to echoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Most cases are nonspecific and cause the patient little or no distress. The prototypic \"Boston exanthem\" is characteristic of these rash illnesses whereby multiple cases of mild illness occur sequentially in families, with as many as one-quarter of the children in a household developing a rash [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/11\">",
"     11",
"    </a>",
"    ]. Fever lasts 24 to 36 hours, and then declines simultaneously with the appearance of discrete, nonpruritic, salmon-pink macules and papules of approximately 1 cm diameter on the face and upper chest [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hand, foot, and mouth syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hand, foot, mouth syndrome (HFM) is a common acute illness, affecting mostly children, which is characterized by fever, oral vesicles on the buccal mucosa and tongue, and peripherally distributed small, tender cutaneous lesions on the hands, feet, buttocks and (less commonly) genitalia (",
"    <a class=\"graphic graphic_picture graphicRef81027 \" href=\"UTD.htm?15/61/16339\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52800 \" href=\"UTD.htm?4/12/4293\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58566 \" href=\"UTD.htm?13/2/13344\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53423 \" href=\"UTD.htm?14/22/14689\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71314 \" href=\"UTD.htm?20/27/20912\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/15\">",
"     15",
"    </a>",
"    ]. Onychomadesis (proximal separation of the nail plate from the nail bed) has also been associated with HFM [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/16\">",
"     16",
"    </a>",
"    ]. The group A coxsackieviruses are recovered most often from hand-foot-mouth syndrome patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Laboratory diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The incubation period for hand, foot and mouth disease is three to five days; the illness usually resolves in two to three days without complication [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/17\">",
"     17",
"    </a>",
"    ]. HFM caused by enterovirus 71 has been associated with severe illness, with concomitant central nervous system (CNS) disease, pulmonary edema and hemorrhage, and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HFM is moderately contagious; infection is spread by direct contact with nasal discharge, saliva, blister fluid, or stool of infected individuals. Infected individuals are most contagious during the first week of the illness. However, the viruses that cause HFM can persist for weeks after symptoms have resolved, most commonly in stool, allowing transmission following resolution of symptoms. Exclusion of children from group settings is appropriate during the first few days of the illness in the setting of open lesions in the mouth or on the skin. This may reduce the spread of infection but will not interrupt transmission completely [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Herpangina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coxsackie A virus is the etiologic agent of herpangina, a vesicular enanthem of the tonsillar fauces and soft palate that principally affects children 3 to 10 years of age. Oropharyngeal symptoms of sore throat are accompanied by fever and odynophagia. Most cases of disease occur during summer outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of herpangina is primarily supportive and consists of administration of appropriate oral pain medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours as needed) and encouragement of adequate fluid intake. Topical therapy (eg, equal parts of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    [eg, Maalox&reg;]) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    may be effective in some patients. Topical viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    should be avoided in young children because of the risk for toxicity from mucosal absorption or ingestion. In severe cases, oral opiates may be required for pain control. On occasion, children will refuse to drink and require intravenous treatment for dehydration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Petechiae and purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Petechial and purpuric rashes have been described with echovirus 9 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/12,24\">",
"     12,24",
"    </a>",
"    ] and coxsackievirus A9 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/25\">",
"     25",
"    </a>",
"    ] infections. When these rashes with a hemorrhagic component occur, the illness is easily confused with meningococcal disease, especially if aseptic meningitis occurs simultaneously. Occasionally, cutaneous eruptions of coxsackievirus A9 disease have an urticarial nature [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=see_link\">",
"     \"Fever and rash in the immunocompetent patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Central nervous system infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infection of the CNS occurs at all ages. Meningitis is by far the most common CNS manifestation. Both generalized and focal encephalitis occur less frequently. Certain enteroviruses (ie, polioviruses, enterovirus 71) preferentially target the motor nuclei and anterior horn cells of the brain and spinal cord, causing acute paresis of cranial and spinal nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Viral (aseptic) meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic meningitis affects persons of all ages but is most commonly observed in infants less than one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The enteroviruses cause more than 90 percent of cases in infants; the great majority is due to the group B coxsackieviruses and echoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/29\">",
"     29",
"    </a>",
"    ]. When older children and adults are included, enteroviruses remain the most common cause of viral meningitis, accounting for well over 50 percent of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants, the characteristic symptoms and signs of meningitis are difficult to elicit by history and examination. The most common clinical manifestations are fever and irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/31\">",
"     31",
"    </a>",
"    ]. In practice, aseptic meningitis is often diagnosed during the clinical evaluation of febrile infants without an apparent source of fever.",
"   </p>",
"   <p>",
"    In the older child and adult, aseptic meningitis presents with fever to 40&ordm;C, headache, meningismus, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/28\">",
"     28",
"    </a>",
"    ]. Symptoms of encephalitis complicate the course of aseptic meningitis in as many as 5 to 10 percent of patients who develop diminished consciousness or seizures.",
"   </p>",
"   <p>",
"    The differential diagnosis for viral meningitis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Partially treated bacterial meningitis",
"     </li>",
"     <li>",
"      Parameningeal bacterial infection",
"     </li>",
"     <li>",
"      Brain abscess",
"     </li>",
"     <li>",
"      Tuberculous or fungal meningitis",
"     </li>",
"     <li>",
"      Meningitis caused by a spirochete such as Borrelia burgdorferi, Treponema pallidum, and Leptospira spp",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete recovery from viral meningitis is the rule. Most infants and children recover completely within three to seven days of onset, but symptoms often persist in adults for longer [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroviruses account for about 5 percent of all cases of acute encephalitis which undergo comprehensive diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/33\">",
"     33",
"    </a>",
"    ]. Numerous serotypes have been implicated as causes of encephalitis; coxsackievirus types A9, B2, and B5, and echovirus types 6 and 9 are the serotypes reported most often. Typically, enteroviruses isolated from encephalitis patients are representative of the serotype(s) concurrently circulating in the community. Enterovirus encephalitis occurs in all ages with a slight predilection for children and young adults. While clinical manifestations range from mild illness to fatal encephalitis, comparative studies suggest that enterovirus encephalitis is associated with less severe disease, shorter hospitalization, and better outcomes than encephalitis commonly caused by other viruses (eg, HSV, arboviruses) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acute paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poliomyelitis is an acute, febrile illness characterized by aseptic meningitis and weakness or paralysis of one or more extremities. Disease due to wild type poliovirus infection no longer occurs in the Western hemisphere, and a World Health Organization led international eradication program is making progress in the rest of the world. Very rare cases continue to occur in developed countries as a complication of live, attenuated oral polio vaccine use.",
"   </p>",
"   <p>",
"    Sporadic cases of acute paralysis similar to paralytic poliomyelitis also occur with other enterovirus serotypes, the most important of which is enterovirus 71, the only non-polio serotype associated with outbreaks of paralytic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]. Large outbreaks involving hundreds of cases, mostly in children less than six years old have been reported from eastern Europe and Russia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], and more recently in Taiwan and Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/19,20,37\">",
"     19,20,37",
"    </a>",
"    ]. Some of these children have presented with brainstem encephalitis, non-cardiogenic pulmonary edema, and a rapidly fatal course [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The muscle paralysis caused by the non-polio enteroviruses is characteristically less severe than poliovirus-associated paralysis, and is usually not permanent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ocular infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hemorrhagic conjunctivitis (AHC) is a highly contagious ocular infection characterized by pain, lid edema, and subconjunctival hemorrhage that is self-limited and rarely leads to permanent visual impairment. Worldwide pandemics caused by enterovirus 70 and coxsackie A24 have occurred mostly in tropical coastal areas [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/41\">",
"     41",
"    </a>",
"    ]. Transmission occurs via indirect routes involving eye discharge, fingers, and fomites, with rapid spread enhanced by crowding and unsanitary conditions. Symptoms peak in two to three days, and the infection resolves within 10 days without complication. In severe cases, keratitis may persist for several weeks, but does not lead to permanent scarring. Concomitant CNS disease can occur when AHC is caused by enterovirus 70.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pleurodynia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleurodynia is an acute illness characterized by fever and paroxysmal spasms of the chest and abdominal muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/42\">",
"     42",
"    </a>",
"    ]. Most cases occur during localized summer outbreaks among adolescents and adults. Regional and nationwide outbreaks involving a large number of older children and young adults have been reported at infrequent intervals, often separated by decades. The role of the group B coxsackieviruses, the most important cause of epidemic pleurodynia, was established in 1949 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Other agents rarely implicated in pleurodynia include echoviruses 1, 6, 9, 16, and 19 and group A coxsackieviruses 4, 6, 9, and 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/45\">",
"     45",
"    </a>",
"    ]. Pleurodynia sometimes mimics more serious diseases including bacterial pneumonia, pulmonary embolus, myocardial infarction, acute surgical abdomen, and herpes zoster infection. Most patients are ill for four to six days. Children have milder disease than adults, who are often confined to bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Myopericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement during enterovirus infection typically occurs in the form of myopericarditis, as enteroviruses typically affect both the subepicardial myocardium in addition to the pericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/46\">",
"     46",
"    </a>",
"    ]. Clinically, however, the signs of either myocarditis or pericarditis predominate [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/47\">",
"     47",
"    </a>",
"    ]. The severity of myopericarditis varies from asymptomatic cardiac involvement to fulminant disease with intractable heart failure and death [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/48\">",
"     48",
"    </a>",
"    ]. The group B coxsackieviruses are the most frequently implicated viral cause of myocarditis in the United States and Western Europe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5882578\">",
"    <span class=\"h2\">",
"     Infections in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women are frequently exposed to enteroviruses. The risk of infection is higher among those who do not have antibodies from earlier exposure to these viruses and for those who are exposed to young children (the primary spreaders of enteroviruses). Most enterovirus infections during pregnancy cause mild or no maternal illness. Enterovirus infections in pregnant women do not readily cross the placenta and cause fetal disease, nor is there an association with miscarriage or preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/49\">",
"     49",
"    </a>",
"    ]. However, rare cases of intrauterine fetal death from enterovirus infection and severe maternal abdominal pain suggestive of abruption have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Vertical transmission is much more likely to occur in the perinatal period. Strict adherence to good hygiene practices may help to decrease the risk of infection during pregnancy and around the time of delivery.",
"   </p>",
"   <p>",
"    There is no strong evidence that maternal enterovirus infections cause congenital malformation even though a few reports have suggested a possible relationship with certain anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infections in neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates are uniquely susceptible to enterovirus disease. Although many enterovirus serotypes cause self-limited clinical syndromes in neonates as they do in older persons (eg, aseptic meningitis, exanthems), some serotypes are capable of producing fulminant, frequently fatal disease in the newborn infant. The group B coxsackievirus serotypes 2 to 5 and echovirus 11 are most frequently associated with overwhelming, systemic neonatal infections. Although most neonatal enterovirus infections are acquired directly from the mother, some infections are acquired via nosocomial transmission. Infant-to-infant spread within nurseries probably occurs via the hands of personnel engaged in mouth care, gavage feeding, and other activities requiring close direct contact [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most newborns with life-threatening enterovirus disease acquire the infection from a symptomatic mother in the perinatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]; approximately 60 to 70 percent of mothers of infected infants develop a febrile illness during the last week of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/56,58\">",
"     56,58",
"    </a>",
"    ]. Ample experimental evidence indicates that the fetus is relatively protected during maternal infection by the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/57\">",
"     57",
"    </a>",
"    ], but the newborn has a high risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] resulting from exposure to either virus-positive cervical secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/61,62\">",
"     61,62",
"    </a>",
"    ] or viremic maternal blood [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of neonatal infection is strongly influenced by the presence or absence of passively acquired maternal antibody specific for the infecting enterovirus serotype [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/60,64,65\">",
"     60,64,65",
"    </a>",
"    ]. Thus, the timing of maternal infection in relation to development of maternal IgG antibody and delivery of the infant may be the most critical factor in determining the outcome of neonatal enterovirus infection.",
"   </p>",
"   <p>",
"    Most neonates with generalized coxsackievirus and echovirus disease develop symptoms between three and seven days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/56,66\">",
"     56,66",
"    </a>",
"    ]. Early symptoms may be mild and nonspecific, including listlessness, anorexia, and transient respiratory distress. Approximately one-third of cases have a biphasic illness with a period of one to seven days of apparent well-being interspersed between the initial symptoms and the appearance of more serious manifestations.",
"   </p>",
"   <p>",
"    Generalized enterovirus disease in the newborn most often occurs in one of two characteristic clinical syndromes: myocarditis or fulminant hepatitis. Neonatal myocarditis, which is often accompanied by encephalitis and sometimes by hepatitis, is characteristically a manifestation of group B coxsackievirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Fulminant hepatitis presents with hypotension, profuse bleeding, jaundice, and multiple organ failure. Echovirus 11 is responsible for a large proportion of cases, but there are well-documented cases of severe hepatitis in neonates resulting from echovirus serotypes 4, 6, 7, 9, 12, 14, 19, 20, 21, and 31 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/56,69-73\">",
"     56,69-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of neonatal enterovirus disease is supportive. Infants in congestive heart failure require judicious fluid management and administration of inotropic agents and diuretics. The profuse bleeding and coagulopathy that result from hepatic failure necessitate frequent replacement therapy with packed red blood cells, platelets, and fresh-frozen plasma. Vitamin K should be administered intravenously in pharmacologic doses.",
"   </p>",
"   <p>",
"    Large doses of IVIG, which have been reported to improve outcome in at least one case [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/74\">",
"     74",
"    </a>",
"    ], may be justified given the extremely poor prognosis. No antiviral agent is available in the United States or Canada to treat enterovirus infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Infections in immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enteroviruses cause persistent, sometimes fatal, infections in patients with hereditary or acquired defects in B lymphocyte function; most reported patients are children with X-linked agammaglobulinemia or adults with common variable immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These persons have an increased risk of vaccine associated paralytic poliomyelitis when exposed to OPV viruses by direct administration of oral vaccine, or via contact with a vaccinee [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/76\">",
"     76",
"    </a>",
"    ]. In one recent, well-documented case, OPV infection was estimated to have persisted for approximately 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The non-polio enteroviruses also cause persistent CNS infections in these patients, in addition to a dermatomyositis-like syndrome, and chronic hepatitis. Most cases have been caused by echoviruses; single cases caused by group A coxsackievirus serotypes 4, 11, and 15 and by group B coxsackievirus serotypes 2 and 3 are recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/75,78\">",
"     75,78",
"    </a>",
"    ]. Nervous system manifestations may be absent, or there may be mild nuchal rigidity, headache, lethargy, papilledema, seizure disorders, motor weakness, tremors, and ataxia. These neurologic abnormalities may fluctuate in severity, disappear, or steadily progress.",
"   </p>",
"   <p>",
"    An enterovirus can be repeatedly recovered from the CSF over a period of months to years. Enteroviruses have been recovered from many other sites in these patients, including brain, lung, liver, spleen, kidney, myocardium, pericardial fluid, skeletal muscle, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/75\">",
"     75",
"    </a>",
"    ]. In many persons, possibly a majority, the disease ends fatally. Autopsy findings have included chronic meningitis and encephalitis, with lymphocytic perivascular cuffing, focal loss of neurons, and gliosis of both gray and white matter.",
"   </p>",
"   <p>",
"    Intravenous immunoglobulin (IVIG) replacement therapy appears to prevent most cases of chronic enterovirus infection in these patients. Use of IVIG for treatment has met only limited success, even when using IVIG lots with relatively high concentrations of specific antibody. Some patients have experienced clinical improvement when IVIG has been injected directly into the ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/75\">",
"     75",
"    </a>",
"    ], but relapse of infection may occur even after long term intraventricular IVIG therapy. Anecdotal reports suggest that pleconaril may be more successful [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/77,79\">",
"     77,79",
"    </a>",
"    ], but this experimental drug is no longer available.",
"   </p>",
"   <p>",
"    Hematopoietic cell allograft recipients have profoundly suppressed immunologic responses during the immediate post-transplant period, including the ability to mount a humoral immune response. Some have developed enterovirus infections in the post-transplant period that were disseminated, prolonged, and contributed to fatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory diagnosis of enterovirus infection is accomplished by the isolation and identification of virus in cell culture, by detection of enterovirus RNA by polymerase chain reaction (PCR), or retrospectively by serologic methods. Each method has advantages and disadvantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Virus isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroviruses are detected by producing a characteristic cytopathic effect (CPE) in cultured cells [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In some laboratories, enterovirus CPE is confirmed by indirect immunofluorescence using a broadly specific monoclonal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/85\">",
"     85",
"    </a>",
"    ]. Cell culture is labor intensive and expensive. However, recovery of an isolate in cell culture permits typing of the isolate for clinical, epidemiologic, and research purposes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Submitting specimens from several sites enhances enterovirus isolation. Stool and rectal swabs are most likely to produce an isolate. Other sites often sampled include CSF (in cases of CNS disease), throat swabs, urine, and serum.",
"     </li>",
"     <li>",
"      Culture in multiple cell lines is required for optimal sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Identification of CPE requires two to six days in primary cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OPV viruses in the oropharynx or stool can produce \"false\" positive results.",
"     </li>",
"     <li>",
"      Because children excrete enteroviruses for up to eight weeks in stool, some isolates may represent only prolonged \"carriage\" from a previous infection. However, most non-polio viruses isolated in stool can be considered as the etiology of the current illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR using a reverse transcriptase step and primers derived from the highly conserved 5'-non-coding region of the genome has superior sensitivity compared with cell culture for the identification of enteroviruses in the CSF (up to 86 percent versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/87-91\">",
"     87-91",
"    </a>",
"    ]. Sensitivity of PCR compares favorably with that of culture for respiratory and serum specimens, although urine culture may still be superior to urine PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although PCR does not allow identification of the enterovirus serotype, modification of the technique may make it feasible to detect the enterovirus genotype directly from clinical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enterovirus PCR is generally available in hospital laboratories and also offered by many reference and commercial laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microneutralization test is the most widely employed method for the determination of antibodies to enteroviruses. Because microneutralization is serotype specific, it has limited utility in the routine diagnosis of non-polio enterovirus infections because of the low feasibility of testing with multiple live viral antigens and because methods based upon neutralization are relatively insensitive, poorly standardized, and labor intensive. Type-specific immunoassays are more versatile methods that are now offered in commercial laboratories for assay of antibodies against the more common enterovirus serotypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both acute and convalescent sera are required.",
"     </li>",
"     <li>",
"      Serology should not be used for the diagnosis of acute disease except when a specific serotype or a small number of serotypes can be tested.",
"     </li>",
"     <li>",
"      Commercial laboratories often offer a \"battery\" of tests against coxsackie B serotypes 1-6, a few echoviruses, and one or two coxsackie A serotypes. These are rarely useful.",
"     </li>",
"     <li>",
"      Other serologic methods (eg, EIA, IFA) generally show some degree of cross-reactivity among different serotypes, and are not useful for diagnosis.",
"     </li>",
"     <li>",
"      Serum IgM antibody to the group B coxsackieviruses can often be detected early in the course of illness, but positive test results are not serotype specific and may occur during infections with enteroviruses of other classes [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/94,95\">",
"       94,95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32984786\">",
"    <span class=\"h2\">",
"     RNA sequencing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterovirus serotypes are defined and distinguished from one another by serum neutralization. However, many reference laboratories employ RNA sequencing to identify the viral serotype, generally through the VP1 coding region of the genome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34585/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24513?source=see_link\">",
"       \"Patient information: Hand, foot, and mouth disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24150583\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The human enteroviruses include polioviruses, group A and B coxsackieviruses, echoviruses, and enteroviruses. They are transmitted via fecal-oral contact. Most infections caused by the non-polio enteroviruses are asymptomatic or result in an undifferentiated febrile illness. Other clinical manifestations of disease include exanthems and enanthems, central nervous system infection, ocular infection, pleurodynia and myopericarditis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonspecific maculopapular eruptions due to enteroviruses are common. Hand, foot, mouth syndrome (HFM), due to group A coxsackievirus, is characterized by oral vesicles on the buccal mucosa and tongue, and small tender lesions on the hands, feet and other areas (",
"      <a class=\"graphic graphic_picture graphicRef81027 \" href=\"UTD.htm?15/61/16339\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef52800 \" href=\"UTD.htm?4/12/4293\">",
"       picture 2",
"      </a>",
"      ). Herpangina, due to group A coxsackievirus, is a vesicular enanthem of the tonsillar fauces and soft palate. Petechial and purpuric rashes have been described with coxsackievirus A9 and echovirus 9. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exanthems and enanthems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aseptic meningitis is the most common manifestation of central nervous system (CNS) disease. In general, enteroviruses are the most common cause of aseptic meningitis. Among infants, aseptic meningitis is most frequently due to group B coxsackieviruses and echoviruses. Other CNS manifestations include encephalitis, an unusual manifestation of coxsackievirus and echovirus infection, and paralytic poliomyelitis, a complication of poliovirus and enterovirus 71. Ocular infections have been attributed to enterovirus 70 and coxsackie A24. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Central nervous system infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleurodynia is an acute illness characterized by fever and paroxysmal spasms of the chest and abdominal muscles. Cardiac involvement of enterovirus infection typically occurs in the form of myopericarditis, as enteroviruses typically affect both the subepicardial myocardium in addition to the pericardium. The group B coxsackieviruses are the most important cause of pleurodynia and myopericarditis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pleurodynia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Myopericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enterovirus infections in pregnant women do not readily cross the placenta and cause fetal disease; transmission is much more likely to occur in the perinatal period. Rare cases of intrauterine fetal death from echoviruses or coxsackieviruses have been reported. (See",
"      <a class=\"local\" href=\"#H5882578\">",
"       'Infections in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonates are uniquely susceptible to enterovirus infection. Some serotypes are capable of producing fulminant, frequently fatal disease in the newborn infant. Most neonates with generalized coxsackievirus and echovirus disease develop symptoms between three and seven days of life. Generalized enterovirus disease in the newborn most often occurs in one of two characteristic clinical syndromes: myocarditis or fulminant hepatitis. The management of neonatal enteroviral disease is supportive. Intravenous immune globulin (IVIG) may be justified given the extremely poor prognosis though supporting data are lacking. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Infections in neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of enterovirus infection is accomplished by the isolation and identification of virus in cell culture, by detection of enterovirus RNA by polymerase chain reaction (PCR), or retrospectively by serologic methods. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Laboratory diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/1\">",
"      Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/2\">",
"      Kogon A, Spigland I, Frothingham TE, et al. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VII. Observations on viral excretion, seroimmunity, intrafamilial spread and illness association in coxsackie and echovirus infections. Am J Epidemiol 1969; 89:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/3\">",
"      Joki-Korpela P, Hyypi&auml; T. Parechoviruses, a novel group of human picornaviruses. Ann Med 2001; 33:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/4\">",
"      Harvala H, Robertson I, McWilliam Leitch EC, et al. Epidemiology and clinical associations of human parechovirus respiratory infections. J Clin Microbiol 2008; 46:3446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/5\">",
"      Verboon-Maciolek MA, Krediet TG, Gerards LJ, et al. Severe neonatal parechovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J 2008; 27:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/6\">",
"      Wolthers KC, Benschop KS, Schinkel J, et al. Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis 2008; 47:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/7\">",
"      Abed Y, Boivin G. Human parechovirus types 1, 2 and 3 infections in Canada. Emerg Infect Dis 2006; 12:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/8\">",
"      Harvala H, Wolthers KC, Simmonds P. Parechoviruses in children: understanding a new infection. Curr Opin Infect Dis 2010; 23:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/9\">",
"      Levorson RE, Jantausch BA. Human parechoviruses. Pediatr Infect Dis J 2009; 28:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/10\">",
"      Bell EJ, Ross CA, Grist NR. ECHO 9 infection in pregnant women with suspected rubella. J Clin Pathol 1975; 28:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/11\">",
"      LERNER AM, KLEIN JO, LEVIN HS, FINLAND M. Infections due to Coxsackie virus group A, type 9, in Boston, 1959, with special reference to exanthems and pneumonia. N Engl J Med 1960; 263:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/12\">",
"      SABIN AB, KRUMBIEGEL ER, WIGAND R. ECHO type 9 virus disease. AMA J Dis Child 1958; 96:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/13\">",
"      NEVA FA. A second outbreak of Boston exanthem disease in Pittsburgh during 1954. N Engl J Med 1956; 254:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/14\">",
"      NEVA FA, FEEMSTER RF, GORBACH IJ. Clinical and epidemiological features of an usual epidemic exanthem. J Am Med Assoc 1954; 155:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/15\">",
"      Adler JL, Mostow SR, Mellin H, et al. Epidemiologic investigation of hand, foot, and mouth disease. Infection caused by coxsackievirus A 16 in Baltimore, June through September 1968. Am J Dis Child 1970; 120:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/16\">",
"      Davia JL, Bel PH, Ninet VZ, et al. Onychomadesis outbreak in Valencia, Spain associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol 2011; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/17\">",
"      ROBINSON CR, DOANE FW, RHODES AJ. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can Med Assoc J 1958; 79:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/18\">",
"      Alexander JP Jr, Baden L, Pallansch MA, Anderson LJ. Enterovirus 71 infections and neurologic disease--United States, 1977-1991. J Infect Dis 1994; 169:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/19\">",
"      Lum LC, Wong KT, Lam SK, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998; 133:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/20\">",
"      Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/21\">",
"      Chan KP, Goh KT, Chong CY, et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003; 9:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/22\">",
"      Jiang M, Wei D, Ou WL, et al. Autopsy findings in children with hand, foot, and mouth disease. N Engl J Med 2012; 367:91.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dvrd/revb/Enterovirus/hfmd-qa.htm (Accessed on June 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/24\">",
"      Cherry JD, Jahn CL. Herpangina: the etiologic spectrum. Pediatrics 1965; 36:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/25\">",
"      FROTHINGHAM TE. ECHO virus type 9 associated with three cases simulating meningococcemia. N Engl J Med 1958; 259:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/26\">",
"      CHERRY JD, LERNER AM, KLEIN JO, FINLAND M. Coxsackie A9 infections with exanthems, with particular reference to urticaria. Pediatrics 1963; 31:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/27\">",
"      Marier R, Rodriguez W, Chloupek RJ, et al. Coxsackievirus B5 infection and aseptic meningitis in neonates and children. Am J Dis Child 1975; 129:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/28\">",
"      Wilfert CM, Lauer BA, Cohen M, et al. An epidemic of echovirus 18 meningitis. J Infect Dis 1975; 131:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/29\">",
"      Berlin LE, Rorabaugh ML, Heldrich F, et al. Aseptic meningitis in infants &lt; 2 years of age: diagnosis and etiology. J Infect Dis 1993; 168:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/30\">",
"      Huang C, Morse D, Slater B, et al. Multiple-year experience in the diagnosis of viral central nervous system infections with a panel of polymerase chain reaction assays for detection of 11 viruses. Clin Infect Dis 2004; 39:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/31\">",
"      Rorabaugh ML, Berlin LE, Heldrich F, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics 1993; 92:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/32\">",
"      Rotbart HA, Brennan PJ, Fife KH, et al. Enterovirus meningitis in adults. Clin Infect Dis 1998; 27:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/33\">",
"      Fowlkes AL, Honarmand S, Glaser C, et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis 2008; 198:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/34\">",
"      Hayward JC, Gillespie SM, Kaplan KM, et al. Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J 1989; 8:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/35\">",
"      Nagy G, Tak&aacute;tsy S, Kuk&aacute;n E, et al. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 1982; 71:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/36\">",
"      Shindarov LM, Chumakov MP, Voroshilova MK, et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol 1979; 23:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/37\">",
"      Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/38\">",
"      McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001; 32:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/39\">",
"      Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004; 291:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/40\">",
"      Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007; 356:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/41\">",
"      Sklar VE, Patriarca PA, Onorato IM, et al. Clinical findings and results of treatment in an outbreak of acute hemorrhagic conjunctivitis in southern Florida. Am J Ophthalmol 1983; 95:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/42\">",
"      WARIN JF, DAVIES JB, SANDERS FK, VIZOSO AD. Oxford epidemic of Bornholm disease, 1951. Br Med J 1953; 1:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/43\">",
"      CURNEN EC, SHAW EW, MELNICK JL. Disease resembling nonparalytic poliomyelitis associated with a virus pathogenic for infant mice. J Am Med Assoc 1949; 141:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/44\">",
"      WELLER TH, ENDERS JF, BUCKINGHAM M, FINN JJ Jr. The etiology of epidemic pleurodynia: a study of two viruses isolated from a typical outbreak. J Immunol 1950; 65:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/45\">",
"      Bell EJ, Grist NR. ECHO viruses, carditis, and acute pleurodynia. Am Heart J 1971; 82:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/46\">",
"      Smith WG. Adult heart disease due to the Coxsackie virus group B. Br Heart J 1966; 28:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/47\">",
"      Verma NA, Zheng XT, Harris MU, et al. Outbreak of life-threatening coxsackievirus B1 myocarditis in neonates. Clin Infect Dis 2009; 49:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/48\">",
"      Freund MW, Kleinveld G, Krediet TG, et al. Prognosis for neonates with enterovirus myocarditis. Arch Dis Child Fetal Neonatal Ed 2010; 95:F206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/49\">",
"      Amstey MS, Miller RK, Menegus MA, di Sant 'Agnese PA. Enterovirus in pregnant women and the perfused placenta. Am J Obstet Gynecol 1988; 158:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/50\">",
"      Johansson ME, Holmstr&ouml;m S, Abebe A, et al. Intrauterine fetal death due to echovirus 11. Scand J Infect Dis 1992; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/51\">",
"      Modlin JF. Fatal echovirus 11 disease in premature neonates. Pediatrics 1980; 66:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/52\">",
"      Brown GC, Karunas RS. Relationship of congenital anomalies and maternal infection with selected enteroviruses. Am J Epidemiol 1972; 95:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/53\">",
"      Elizan TS, Ajero-Froehlich L, Fabiyi A, et al. Viral infection in pregnancy and congenital CNS malformations in man. Arch Neurol 1969; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/54\">",
"      Gauntt CJ, Gudvangen RJ, Brans YW, Marlin AE. Coxsackievirus group B antibodies in the ventricular fluid of infants with severe anatomic defects in the central nervous system. Pediatrics 1985; 76:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/55\">",
"      Kinney JS, McCray E, Kaplan JE, et al. Risk factors associated with echovirus 11' infection in a hospital nursery. Pediatr Infect Dis 1986; 5:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/56\">",
"      Modlin JF. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev Infect Dis 1986; 8:918.",
"     </a>",
"    </li>",
"    <li>",
"     Modlin JF, Kinney JS. Perinatal enterovirus infections. In: Advances in Pediatric Infectious Diseases, Aronoff SC, Hughes WT, Kohl S, et al (Eds), Year Book Medical Publishers, Chicago 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/58\">",
"      Lake AM, Lauer BA, Clark JC, et al. Enterovirus infections in neonates. J Pediatr 1976; 89:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/59\">",
"      Cherry JD, Soriano F, Jahn CL. Search for perinatal viral infection. A prospective, clinical, virologic, and serologic study. Am J Dis Child 1968; 116:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/60\">",
"      Modlin JF, Polk BF, Horton P, et al. Perinatal echovirus infection: risk of transmission during a community outbreak. N Engl J Med 1981; 305:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/61\">",
"      Jones MJ, Kolb M, Votava HJ, et al. Case reports. Intrauterine echovirus type II infection. Mayo Clin Proc 1980; 55:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/62\">",
"      Reyes MP, Ostrea EM Jr, Roskamp J, Lerner AM. Disseminated neonatal echovirus 11 disease following antenatal maternal infection with a virus-positive cervix and virus-negative gastrointestinal tract. J Med Virol 1983; 12:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/63\">",
"      YOSHIOKA I, HORSTMANN DM. Viremia infection due to ECHO virus type 9. N Engl J Med 1960; 262:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/64\">",
"      Berry PJ, Nagington J. Fatal infection with echovirus 11. Arch Dis Child 1982; 57:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/65\">",
"      Modlin JF, Bowman M. Perinatal transmission of coxsackievirus B3 in mice. J Infect Dis 1987; 156:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/66\">",
"      Kaplan MH, Klein SW, McPhee J, Harper RG. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev Infect Dis 1983; 5:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/67\">",
"      KIBRICK S. CURRENT STATUS OF COXSACKIE AND ECHO VIRUSES IN HUMAN DISEASE. Prog Med Virol 1964; 6:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/68\">",
"      Gear JH, Measroch V. Coxsackievirus infections of the newborn. Prog Med Virol 1973; 15:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/69\">",
"      Chambon M, Delage C, Bailly JL, et al. Fatal hepatic necrosis in a neonate with echovirus 20 infection: use of the polymerase chain reaction to detect enterovirus in liver tissue. Clin Infect Dis 1997; 24:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/70\">",
"      Georgieff MK, Johnson DE, Thompson TR, et al. Fulminant hepatic necrosis in an infant with perinatally acquired echovirus 21 infection. Pediatr Infect Dis J 1987; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/71\">",
"      Spector SA, Straube RC. Protean manifestations of perinatal enterovirus infections. West J Med 1983; 138:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/72\">",
"      Speer ME, Yawn DH. Fatal hepatoadrenal necrosis in the neonate associated with echovirus types 11 and 12 presenting as a surgical emergency. J Pediatr Surg 1984; 19:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/73\">",
"      Wreghitt TG, Gandy GM, King A, Sutehall G. Fatal neonatal echo 7 virus infection. Lancet 1984; 2:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/74\">",
"      Johnston JM, Overall JC Jr. Intravenous immunoglobulin in disseminated neonatal echovirus 11 infection. Pediatr Infect Dis J 1989; 8:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/75\">",
"      McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1987; 9:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/76\">",
"      Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994; 11:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/77\">",
"      Centers for Disease Control and Prevention (CDC). Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 1997; 46:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/78\">",
"      O'Neil KM, Pallansch MA, Winkelstein JA, et al. Chronic group A coxsackievirus infection in agammaglobulinemia: demonstration of genomic variation of serotypically identical isolates persistently excreted by the same patient. J Infect Dis 1988; 157:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/79\">",
"      Rotbart HA, Webster AD, Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001; 32:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/80\">",
"      Aquino VM, Farah RA, Lee MC, Sandler ES. Disseminated coxsackie A9 infection complicating bone marrow transplantation. Pediatr Infect Dis J 1996; 15:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/81\">",
"      Biggs DD, Toorkey BC, Carrigan DR, et al. Disseminated echovirus infection complicating bone marrow transplantation. Am J Med 1990; 88:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/82\">",
"      Galama JM, de Leeuw N, Wittebol S, et al. Prolonged enteroviral infection in a patient who developed pericarditis and heart failure after bone marrow transplantation. Clin Infect Dis 1996; 22:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/83\">",
"      MELNICK JL, SHAW EW, CURNEN EC. A virus isolated from patients diagnosed as non-paralytic poliomyelitis or aseptic meningitis. Proc Soc Exp Biol Med 1949; 71:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/84\">",
"      GORDON RB, LENNETTE EH, SANDROCK RS. The varied clinical manifestations of Coxsackie virus infections: observations and comments on an outbreak in California. AMA Arch Intern Med 1959; 103:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/85\">",
"      Trabelsi A, Grattard F, Nejmeddine M, et al. Evaluation of an enterovirus group-specific anti-VP1 monoclonal antibody, 5-D8/1, in comparison with neutralization and PCR for rapid identification of enteroviruses in cell culture. J Clin Microbiol 1995; 33:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/86\">",
"      Dagan R, Menegus MA. A combination of four cell types for rapid detection of enteroviruses in clinical specimens. J Med Virol 1986; 19:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/87\">",
"      Rotbart HA, Sawyer MH, Fast S, et al. Diagnosis of enteroviral meningitis by using PCR with a colorimetric microwell detection assay. J Clin Microbiol 1994; 32:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/88\">",
"      Sawyer MH, Holland D, Aintablian N, et al. Diagnosis of enteroviral central nervous system infection by polymerase chain reaction during a large community outbreak. Pediatr Infect Dis J 1994; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/89\">",
"      Nolte FS. Case studies in cost effectiveness of molecular diagnostics for infectious diseases: pulmonary tuberculosis, enteroviral meningitis, and BK virus nephropathy. Clin Infect Dis 2006; 43:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/90\">",
"      Pozo F, Casas I, Tenorio A, et al. Evaluation of a commercially available reverse transcription-PCR assay for diagnosis of enteroviral infection in archival and prospectively collected cerebrospinal fluid specimens. J Clin Microbiol 1998; 36:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/91\">",
"      Yerly S, Gervaix A, Simonet V, et al. Rapid and sensitive detection of enteroviruses in specimens from patients with aseptic meningitis. J Clin Microbiol 1996; 34:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/92\">",
"      Rotbart HA, Ahmed A, Hickey S, et al. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr Infect Dis J 1997; 16:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/93\">",
"      Mirand A, Henquell C, Archimbaud C, et al. Prospective identification of enteroviruses involved in meningitis in 2006 through direct genotyping in cerebrospinal fluid. J Clin Microbiol 2008; 46:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/94\">",
"      Bell EJ, McCartney RA, Basquill D, Chaudhuri AK. Mu-antibody capture ELISA for the rapid diagnosis of enterovirus infections in patients with aseptic meningitis. J Med Virol 1986; 19:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/95\">",
"      Pozzetto B, Gaudin OG, Aouni M, Ros A. Comparative evaluation of immunoglobulin M neutralizing antibody response in acute-phase sera and virus isolation for the routine diagnosis of enterovirus infection. J Clin Microbiol 1989; 27:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34585/abstract/96\">",
"      Oberste MS, Maher K, Kilpatrick DR, et al. Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 1999; 37:1288.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2693 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34585=[""].join("\n");
var outline_f33_49_34585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24150583\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Exanthems and enanthems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Maculopapular eruptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hand, foot, and mouth syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Herpangina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Petechiae and purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Central nervous system infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Viral (aseptic) meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acute paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ocular infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pleurodynia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5882578\">",
"      Infections in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infections in neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Virus isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32984786\">",
"      RNA sequencing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24150583\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2693|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/61/16339\" title=\"picture 1\">",
"      Enanthem in Coxsackie infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/12/4293\" title=\"picture 2\">",
"      Hand-foot-and-mouth disease - lip and hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/2/13344\" title=\"picture 3\">",
"      Hand-foot-and-mouth disease - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/22/14689\" title=\"picture 4\">",
"      Hand-foot-and-mouth disease - foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/27/20912\" title=\"picture 5\">",
"      Hand-foot-and-mouth disease - tongue",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=related_link\">",
"      Fever and rash in the immunocompetent patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24513?source=related_link\">",
"      Patient information: Hand, foot, and mouth disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34586="Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment";
var content_f33_49_34586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     M Fatih Okcu, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     John Hicks, MD, DDS, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Marc Horowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?33/49/34586/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?33/49/34586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyosarcomas (RMS) are malignant soft tissue tumors that are thought to originate from immature cells that are destined to form striated skeletal muscle; however, these tumors can arise in locations where skeletal muscle is not typically found (eg, the urinary bladder). Undifferentiated sarcomas (UDS), which have been classified and treated similar to RMS, derive from mesenchyme that cannot be ascribed to a specific tissue lineage.",
"   </p>",
"   <p>",
"    The treatment of RMS has evolved considerably over the past several decades. Cure rates have risen, largely due to the use of combined modality therapy large international cooperative groups, such as the Intergroup Rhabdomyosarcoma Study Group (IRSG), which is now known as the Soft Tissue Sarcoma Committee of the Children's Oncology Group [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of treatment for RMS and UDS. The epidemiology, pathology, molecular pathogenesis, clinical presentation, diagnostic evaluation, and staging of RMS are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF RISK-ADAPTED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, fewer than 20 percent of patients with RMS were cured with surgery alone, implying that micrometastatic disease was present at diagnosis in the majority of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, with the use of modern combined modality therapy, over 70 percent of children with localized RMS can be cured of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These improved outcomes are the direct result of multimodality therapeutic protocols that have been developed by large international cooperative groups, such as the IRSG (now known as the Soft Tissue Sarcoma Committee of the Children's Oncology Group). Modern treatment for RMS and UDS includes chemotherapy for primary cytoreduction and eradication of both macroscopic and microscopic metastatic disease, surgery if feasible, and radiation therapy (RT) to control microscopic local residual disease.",
"   </p>",
"   <p>",
"    The specific regimen depends on the estimated risk of a disease recurrence, which is based upon a variety of prognostic factors that have been identified through a series of treatment protocols carried out by the IRSG. This is termed risk-adapted therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview of IRSG I-V study results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IRSG, a National Cancer Institute-sponsored cooperative group, was formed in 1972 to investigate the biology and treatment of RMS and UDS; it was merged into the Children's Oncology Group (COG) in the year 2000.",
"   </p>",
"   <p>",
"    Since its inception, six protocols involving over 5000 patients have been completed: IRS-I (which accrued between 1972 and 1978); IRS-II (1978 to 1984); IRS-III (1984 to 1991); IRS-IV Pilot (1987 to 1991); IRSG-IV (1991 to 1997), and the D series protocols of IRS-V (1996 to 2005) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. These studies have been instrumental in identifying prognostic factors, developing risk-based therapies, and improving outcomes for RMS and UDS. The group's success is reflected in overall five-year survival rates for patients with RMS, which increased from 55 percent in IRS-I, to 63 percent in IRS-II, and to approximately 71 percent in the IRS-III and IRS-IV protocols. Long term clinical outcome data has been reported from only one of the D-series generation of protocols (D9602, for low-risk embryonal RMS [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]); the others have not yet been reported.",
"   </p>",
"   <p>",
"    All five studies enrolled all stages of disease, but separate protocols were carried out for completely resected localized disease, incompletely resected localized disease, and regionally",
"    <span class=\"nowrap\">",
"     advanced/distant",
"    </span>",
"    disease. The most important findings of these studies can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extent of surgical resection (ie, the Clinical Group [CG] classification, (",
"      <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"       table 1",
"      </a>",
"      )) correlated with outcome in IRS-I, II, and III [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5,7,8\">",
"       5,7,8",
"      </a>",
"      ]. In IRS-III, for example, patients with completely resected RMS (CG I) had a five-year survival rate of over 90 percent, as compared to 80, 70, and 30 percent for those with CG II, III, and IV disease, respectively. For CG III patients (gross residual disease after surgery), neither a higher total dose of RT nor the use of an accelerated fractionation RT improved local control or survival [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prognostic value of the complementary tumor-node-metastasis (TNM) staging system (",
"      <a class=\"graphic graphic_table graphicRef62717 \" href=\"UTD.htm?7/13/7389\">",
"       table 2",
"      </a>",
"      ) was shown in IRS-II and IRS-III [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/8,13\">",
"       8,13",
"      </a>",
"      ]. For IRS-IV, TNM stage was used to assign chemotherapy treatment, while CG stage was used to select patients for radiation therapy (RT). In subsequent studies (eg, IRS V), a combined prognostic stratification scheme was used to assign all therapeutic modalities based upon estimated prognosis (ie, risk-adapted therapy, (",
"      <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"       table 3",
"      </a>",
"      )) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=see_link&amp;anchor=H20#H20\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Prognostic stratification scheme for risk-adapted therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with low-risk tumors at sites such as the orbit, paratesticular, head and neck (non-parameningeal) can be treated effectively with two drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      , VA) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5,7,8\">",
"       5,7,8",
"      </a>",
"      ]. For others, a three drug regimen (vincristine, dactinomycin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [VAC], (",
"      <a class=\"graphic graphic_table graphicRef53178 \" href=\"UTD.htm?0/13/222\">",
"       table 4",
"      </a>",
"      )) is needed. The addition of other individually active agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ) does not improve outcome in any patient subgroup [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5-8\">",
"       5-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections provide an overview of standard treatment recommendations for RMS and UDS, which are based mainly upon the results of IRS-IV and the D series studies of IRS-V. Treatment is constantly evolving and if the reader's goal is to obtain information on how to treat a specific patient,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    should contact a pediatric oncologist who is a member of the Children's Oncology Group and who has expertise in soft tissue sarcoma for the latest recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete excision should be considered for localized disease as long as functional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cosmetic results are acceptable. If complete resection is not feasible, or if disease involves the orbit, vagina, bladder, or biliary tract, patients are better approached with an initial diagnostic biopsy followed by induction (neoadjuvant) chemotherapy then definitive local therapy. In some cases, debulking surgery may be considered, although its utility is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This issue has been studied in IRS-V, and the results are pending.",
"   </p>",
"   <p>",
"    For disease at any primary site, palpable or radiologically enlarged lymph nodes should be excised and submitted for histologic evaluation. The necessity of routine surgical sampling of nonsuspicious lymph nodes depends on the primary site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary head and neck tumors are rarely amenable to wide local excision because of proximity to vital structures and cosmetic concerns. This generally limits the role of surgery to initial diagnostic biopsy. However, the availability of highly skilled otolaryngologic and craniofacial reconstructive teams at selected institutions may permit resection of some tumors that would otherwise be considered unresectable [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/16\">",
"     16",
"    </a>",
"    ]. Because of the low incidence of locoregional node involvement (about 20 percent, no different from other sites except for orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/17\">",
"     17",
"    </a>",
"    ]), routine cervical lymph node sampling is unnecessary. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H19#H19\">",
"     \"Head and neck sarcomas\", section on 'Rhabdomyosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Paratesticular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paratesticular tumors should be removed via radical inguinal orchiectomy and resection of the entire spermatic cord. As with testicular germ cell tumors, a trans-scrotal approach is specifically contraindicated in order to avoid scrotal contamination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All boys 10 years of age or older who have a paratesticular RMS should undergo routine ipsilateral nerve-sparing retroperitoneal lymph node dissection (RPLND). The rationale for this recommendation is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, approximately 14 percent of boys with paratesticular RMS without radiographic lymph node enlargement will be found to harbor metastases; the risk appears higher among adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In IRS-IV, nodal relapses were observed in 50 percent of boys over the age of 10 who had apparently localized paratesticular RMS but did not undergo routine RPLND; their three-year FFS rate was significantly worse than that of younger boys (68 versus 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The histologic documentation of nodal metastases is clinically important since patients with positive nodes are referred for postoperative RT as well as three-drug (VAC) chemotherapy, while both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and RT can be withheld in those with negative nodes, and outcome is 100 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For younger boys (under the age of 10), surgical excision of radiographically enlarged lymph nodes is warranted, but RPLND is not indicated in the absence of suspicious radiographic findings.",
"   </p>",
"   <p>",
"    An alternative approach for older boys with clinically enlarged retroperitoneal nodes is the administration of a more intensive adjuvant chemotherapy regimen (VAC or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [VAI]) rather than RPLND. This alternative approach is based upon results from IRS-III, which indicated a poor outcome from RPLND followed by VA in these patients (five-year survival 69 percent compared to 96 percent for those with clinically negative nodes undergoing RPLND followed by VA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other GU tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The functional morbidity of initial surgery for other genitourinary (GU) tract tumors has prompted the avoidance of upfront surgery in favor of multimodality approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/20\">",
"     20",
"    </a>",
"    ]. Vulvar, vaginal, uterine, bladder, and prostatic RMS usually respond well enough to induction chemotherapy to render them locally resectable, often with clear resection margins [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One possible exception is a tumor arising in the dome of the bladder, for which partial cystectomy may be performed before chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The benefit and timing of RT in this setting are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extremity and trunk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in therapy, outcome for children with extremity RMS is inferior to that of more favorable sites (eg, orbit) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5,28\">",
"     5,28",
"    </a>",
"    ] Initial resection of a localized extremity RMS should be attempted as long as limb function is not compromised; outcomes are significantly worse if gross residual disease remains [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] In all cases, extremity RMS should undergo sentinel node biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. If the sentinel node(s)",
"    <span class=\"nowrap\">",
"     is/are",
"    </span>",
"    positive by pathological evaluation, assessment of higher lymph node levels in the chain of lymphatic drainage should be considered. Routine ilioinguinal lymphadenectomy is also recommended for perineal or anal RMS [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempted resection is also appropriate for truncal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/34\">",
"     34",
"    </a>",
"    ]. Like extremity tumors, those involving chest wall seem to do worse if excision margins are not widely negative [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/18,35\">",
"     18,35",
"    </a>",
"    ]. In all of these cases, reexcision should be considered for questionable margins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Second-look surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with residual gross tumor remaining after primary surgery (CG III, (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    )), the value of second-look surgery following induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT is unclear. It has been evaluated in two different clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Documenting a complete response to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a clinical (radiographically) complete response (CR) to induction chemotherapy, second-look surgery has been studied as a means of documenting pathologic remission status in the hope of diminishing the dose or avoiding the administration of RT.",
"   </p>",
"   <p>",
"    This issue was addressed in the International Society of Pediatric Oncology Malignant Mesenchymal Tumors Study, in which 237 patients with nonparameningeal RMS underwent initial biopsy or limited surgery, followed by three to six cycles of chemotherapy and a second-look surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/36\">",
"     36",
"    </a>",
"    ]. Additional local therapy was withheld in patients with a pathologic complete response (pCR). Unfortunately, 50 percent of patients ultimately had a local recurrence, regardless of whether they underwent second-look surgery or were followed clinically.",
"   </p>",
"   <p>",
"    Therefore, the practice of basing therapy on the results of a second-look procedure represents an unacceptable therapeutic strategy.",
"   </p>",
"   <p>",
"    A lack of correlation between tumor response to induction therapy and overall prognosis was shown in IRS-IV trial 419, in which CG III participants who completed all protocol therapy without developing progressive disease were assessed for response (complete resolution [CR], partial response [PR; &ge;50 percent decrease], or no response [NR; &lt;50 percent decrease and &lt;25 percent increase]) by radiographic measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/37\">",
"     37",
"    </a>",
"    ]. When categorized as to the best response to therapy, five-year failure-free survival was similar for participants achieving CR and for those whose best response was a PR or NR (80 versus 78 percent). After adjustment for age, nodal status, primary site, and histology, the risk of treatment failure and death was not significantly lower among patients whose best response was a CR as compared to",
"    <span class=\"nowrap\">",
"     PR/NR.",
"    </span>",
"    Seventeen participants with a best response of",
"    <span class=\"nowrap\">",
"     PR/NR",
"    </span>",
"    had surgical procedures; eight (50 percent) of 16 with available pathology reports had residual viable tumors, and resection of these tumors did not improve outcomes (see below).",
"   </p>",
"   <p>",
"    Finally, the impact on clinical outcome following a second-look surgical procedure during treatment has been addressed in an analysis of a subset of patients who participated in IRS-IV and who underwent a second look procedure before the completion of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/38\">",
"     38",
"    </a>",
"    ]. The initial protocol had stipulated that a second-look procedure be considered for patients who still had a persistent tumor mass at week 46 or 47, approximately four weeks after completing treatment. Despite this, 79 children had a second-look procedure prior to completing chemotherapy. Overall, 13 of the 14 patients with a clinical CR had no viable tumor, while 41 percent of those without a CR had no viable tumor. Five-year failure-free survival (FFS) rates were significantly higher in patients without viable tumor when compared to those who had viable tumor (81 versus 53 percent, HR 0.38, 95% CI 0.15 to 0.99); overall survival did not reach the level of statistical significance (81 versus 67, HR for death 0.42, 95% CI 0.12 to 1.41). Based on this report, it is unclear whether there is an advantage to second-look surgical procedures in children with rhabdomyosarcoma. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Resection of posttherapy residual disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-look surgery has also been undertaken for the purpose of resecting viable tumor that remains after chemotherapy and RT, in the hope of improving outcomes. This approach was evaluated in the IRS-III study, in which patients with CG III disease (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    ) underwent induction chemotherapy and local RT; some patients underwent second-look surgery, which was delayed until 20 weeks after therapy initiation, when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5\">",
"     5",
"    </a>",
"    ]. The following results were noted in a subset of 111 patients with pelvic tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-seven patients had a clinical complete response, 27 had a partial response, and there were 29 minor responses (objective tumor regression of less than 50 percent of baseline tumor size).",
"     </li>",
"     <li>",
"      Among those undergoing second-look surgery, 14 (25 percent) of the partial responders were in fact pCRs, and an additional 12 (22 percent) were rendered tumor-free by surgery.",
"     </li>",
"     <li>",
"      Five of 29 patients with a minor response were found to be pCRs, while seven others were converted to a pCR as a result of surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, second-look surgery was beneficial for confirming the pathologic tumor response, for identifying patients who required second-line chemotherapy, and the procedure was able to convert some PRs to CRs, a prerequisite for cure. However, the impact of a second-look procedure on survival in CG III patients was unclear.",
"   </p>",
"   <p>",
"    As noted above, in the IRS-IV trial, resection of residual masses did not result in an improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, aggressive alternative therapy may not be warranted for RMS patients with a residual mass at the end of planned therapy, and the benefit of identifying such patients through the use of second-look surgery remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other pediatric bone and soft tissue sarcomas, where metastasectomy is often considered, particularly for limited pulmonary metastases, the role of such surgery for patients with metastatic RMS is unclear. In a series of 152 children with a variety of sarcomas undergoing metastasectomy, those with RMS had a uniformly poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is a major tool for the treatment of RMS and UDS, particularly for achieving local control in patients with residual microscopic or gross disease following surgery and chemotherapy (ie, CG II or III disease, (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    The optimal timing and sequence of RT is not established. In general, when it is administered, RT is generally given after three or four cycles of chemotherapy, with the exception of parameningeal tumors with intracranial extension, for which RT is begun immediately. Delaying RT beyond 18 weeks decreases the likelihood of achieving local control in certain sites [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/40\">",
"     40",
"    </a>",
"    ] and should be avoided. Computerized three-dimensional treatment planning and conformal delivery systems should be applied whenever available to minimize exposure to surrounding normal tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment volume is determined by tumor extent at diagnosis, including involved nodes, with a 2 cm margin of normal tissue. RT is typically given over four to six weeks in once-daily fractions of 1.8 to 2 Gy. Although early guidelines recommended doses as high as 55 to 60 Gy for control of the primary, clinical practice has evolved over time, with the underlying strategy of reduced RT doses to minimize post-treatment complications. However, even with reduced doses, the decision to pursue RT in very young children (under the age of three) is difficult, as there are minimal data regarding the potential long-term effects of RT to various locations in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/42\">",
"     42",
"    </a>",
"    ], and limited data regarding cancer outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/43\">",
"     43",
"    </a>",
"    ]. Treatment must be individualized in this situation.",
"   </p>",
"   <p>",
"    Because it can potentially eliminate the exit dose to normal tissue, proton beam RT can provide a significant reduction in late effects with orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/44\">",
"     44",
"    </a>",
"    ] and parameningeal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/45\">",
"     45",
"    </a>",
"    ], and is permitted in ongoing RMS trials.",
"   </p>",
"   <p>",
"    The following sections discuss specific RT recommendations for patients with RMS and UDS, which are largely based upon results from the IRS I-IV studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical Group I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant RT is unnecessary for patients with CG I embryonal (any site) RMS (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    ), but is recommended (RT dose 36 Gy) for all patients with CG I alveolar RMS or UDS [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/7,8,46\">",
"     7,8,46",
"    </a>",
"    ]. This recommendation is based upon a report of 439 patients with CG I disease treated in IRS I, II, and III [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/46\">",
"     46",
"    </a>",
"    ]. Pretreatment factors associated with an inferior outcome included size &gt;5 cm, sites other than the GU tract, and alveolar or undifferentiated histology. Patients with alveolar histology who received adjuvant RT had significantly better failure-free and overall survival than those who did not.",
"   </p>",
"   <p>",
"    However, the recommendation that all CG I alveolar RMS receive RT has been called into question by a later analysis of 71 patients with CG I alveolar RMS who were treated on the IRS III and IV studies [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/47\">",
"     47",
"    </a>",
"    ]. RT was assigned and not randomized, and 30 patients received chemotherapy plus RT while 41 were treated with chemotherapy alone. Among the 54 patients with stage 1 (favorable site, any size) or stage 2 (unfavorable site, size &le;5 cm) CG I disease, eight-year EFS was similar with and without RT (90 versus 88 percent), as was local control (100 versus 92 percent). However, the small number of patients with stage 3 (unfavorable site, &gt;5 cm, node-negative) disease did not have a favorable outcome in the absence of RT (eight-year EFS was 84 percent with 100 percent local control in the 13 patients given RT; eight-year EFS was only 25 percent and local control was 50 percent in the four patients treated without RT). The need for RT in CG I alveolar tumors remains uncertain but current treatment protocols recommend the addition of RT in these patients. &nbsp;",
"   </p>",
"   <p>",
"    These numbers are very small, and larger studies are needed before it can be concluded that RT is not needed in patients with alveolar histology and Group I disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical Group II",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with residual microscopic disease after surgery (CG II, (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    )), RT doses from 41.4 to 45 Gy are sufficient to achieve local control [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/48\">",
"     48",
"    </a>",
"    ]. In the IRS-III and IV studies, this approach resulted in five-year FFS rates of 75 and 87 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data suggest that lower RT doses (36 Gy) are adequate in conjunction with systemic chemotherapy for patients with microscopic residual disease and no nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/10,11,50,51\">",
"     10,11,50,51",
"    </a>",
"    ]. For all histologies, the total dose is increased to 41.4 Gy if there is evidence of nodal involvement, and the field includes the involved lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical Group III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gross residual disease (CG III, (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    )) require higher RT doses, generally 45 to 50.4 Gy. In IRS-III, the five-year FFS in this group was 70 percent and was higher for those with node-negative as compared to node-positive disease (75 versus 45 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In current RMS studies, 50.4 Gy is recommended for all sites except the orbit, where the recommended total dose is 45 Gy. Later studies support the use of even lower doses (40 Gy) in children with CG III disease who have only microscopic disease remaining after induction chemotherapy (as determined by second-look surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/51\">",
"     51",
"    </a>",
"    ]. The five-year cumulative incidence of local failure for D9602 patients with embryonal histologic features Group III orbital tumors treated with 45 Gy without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (VA only) was 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/11\">",
"     11",
"    </a>",
"    ]. This is greater than the five-year cumulative incidence rate of 2 percent for similar patients treated in IRS IV with 50.4 to 59.4 Gy and alkylating agent containing chemotherapy. However, it is similar to the 16 percent cumulative incidence rate seen in Group III orbital tumors treated in IRS III with the use of 41.4 to 50.4 Gy (depending on patient age and tumor size) without an alkylating agent. This suggests that reducing the RT dose to 45 Gy does not result in inferior local control for these children when cyclophosphamide is part of the regimen. The number of failures in these comparisons are very small and there is no legitimate statistical comparison. Therefore it is difficult to make sound conclusions if one treatment is superior to the other. We recommend either of these three treatment approaches as appropriate for Group III orbital tumors.",
"   </p>",
"   <p>",
"    RT is recommended for all patients with CG III disease. While a subset of patients, notably those with botryoid variant of embryonal RMS, were reported to do well with induction chemotherapy followed by resection, if negative margins can be achieved, this is not a preferred approach. In patients with localized vaginal disease, the last two US trials, D9602 and ARS0331, attempted to delay local control and omit RT based on response to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/53\">",
"     53",
"    </a>",
"    ]. In a recent report, this approach led to an unacceptably increased rate of local failure. Local control in these patients should be given like all other low risk RMS patients at week 12 based on chemotherapy response. It is possible that this increased risk for local failure may be much higher with less cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dose. Therefore, for any Group III vaginal RMS patients we recommend VAC chemotherapy with RT at week 12.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Parameningeal sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with parameningeal tumors with or without intracranial extension, improvements in RT field definition and the routine use of higher RT doses up to 55 Gy have led to dramatic improvements in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/40,54-57\">",
"     40,54-57",
"    </a>",
"    ]. RT (minimum dose 50.4 Gy) should be administered to the primary site, the adjacent meninges, and the region of intracranial extension, all with a 2 cm margin of normal tissue. Because it can potentially eliminate the exit dose to normal tissue, proton beam RT can provide superior sparing of normal tissue and a significant reduction in late effects [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted previously, patients with intracranial extension should begin RT within two weeks of diagnosis. If there are tumor cells in the cerebrospinal fluid (CSF), suggesting diffuse meningeal disease, craniospinal RT is indicated. If there are multiple parenchymal brain metastases, and there are no tumor cells in the CSF, whole brain RT should be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with small, critically located tumors (such as head and neck, bladder, prostate,",
"    <span class=\"nowrap\">",
"     vulva/vagina),",
"    </span>",
"    intracavitary or interstitial implants (brachytherapy) may be considered in an attempt to deliver RT to a restricted tissue volume with preservation of anatomy and organ function, and less scatter to adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with overt metastatic disease, RT can be used to control both the primary and metastatic sites. The total dose is 50.4 Gy for all sites (except the orbit, where the total dose is 45 Gy). The role of whole-lung RT (generally to 14.4 Gy) for patients with overt pulmonary metastases is unclear; some protocols recommend it, particularly for those undergoing surgical resection, given the radiosensitivity of RMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of combined modality therapy, local therapy alone for rhabdomyosarcoma (RMS) resulted in survival rates of &lt;20 percent, presumably due to the presence of subclinical micrometastatic disease in most patients. The incorporation of systemic chemotherapy into treatment protocols has increased survival rates in patients with apparently localized disease to approximately 60 to 90 percent. However, outcomes are worse in certain subsets, including children under the age of one year or over age 10, and in those with alveolar histology, unfavorable tumor sites, tumor size larger than 5 cm, and higher Clinical Group (CG) risk strata (",
"    <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=see_link&amp;anchor=H20#H20\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\", section on 'Prognostic stratification scheme for risk-adapted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;VAC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) has been considered the gold standard regimen for RMS in North America, against which other more or less aggressive combinations have been compared (",
"    <a class=\"graphic graphic_table graphicRef53178 \" href=\"UTD.htm?0/13/222\">",
"     table 4",
"    </a>",
"    ). A rapid response to chemotherapy during the initial nine weeks of treatment does not necessarily correlate with a better outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In sequential IRS trials, the addition of many individually active agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ) did not improve outcomes, compared to VAC, in any subgroup [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/27,62-68\">",
"     27,62-68",
"    </a>",
"    ]. More recently",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is under study in combination with VAC in current RMS studies for patients with intermediate- and poor-risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    from adjuvant chemotherapy (ie, VA as compared to VAC, (",
"    <a class=\"graphic graphic_table graphicRef53178 \" href=\"UTD.htm?0/13/222\">",
"     table 4",
"    </a>",
"    )) did not compromise outcome in the subgroup of patients who are classified as having an excellent outcome in the prognostic stratification system (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/62,64,65\">",
"     62,64,65",
"    </a>",
"    ]. For these patients, adjuvant VA is the standard of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment strategies in current cooperative group protocols (ARST)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients currently diagnosed with RMS, there are two active clinical research protocols designed by the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) and administered by Children's Oncology Group centers according to risk groups (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"     table 3",
"    </a>",
"    ): ARST0331 for low-risk, and ARST0531 for intermediate-risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. There are no national collaborative clinical trials open at present for patients with high-risk disease. All eligible patients with RMS should be enrolled in these studies through the Children's Oncology Group. Although in the US, pediatric oncologists treat patients up to the age of 20, any patient younger than 50 years old is eligible for these protocols.",
"   </p>",
"   <p>",
"    A new development for this generation of treatment protocols is the exclusion of undifferentiated sarcoma (UDS) as an allowable histology. It is recommended that these patients be treated according to non-rhabdomyosarcoma soft tissue sarcoma protocols, particularly if they have high-risk disease. However, for patients who have intermediate-risk localized UDS, VAC chemotherapy and RT represents the standard approach. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment of undifferentiated sarcoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Low-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon data from IRS-III and IRS-IV, patients with low-risk disease have an estimated three-year FFS rate of 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/27\">",
"     27",
"    </a>",
"    ]. In the ARST0331 protocol, low-risk patients were divided into two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subgroup A included patients with embryonal tumors and:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage 1 or 2 CG I or II",
"     </li>",
"     <li>",
"      Stage 1 CG III orbit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subgroup B included other patients with embryonal tumors and:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage 1 CG III, non-orbit disease",
"     </li>",
"     <li>",
"      Stage 3 CG I, II disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Standard treatment recommendations for patients with low-risk (excellent to very good prognosis) RMS (as determined by the most recent cooperative group protocol for these patients [D9602] that was open in IRS-V [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]) as well as a preliminary report of a COG trial of VAC using lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/72\">",
"     72",
"    </a>",
"    ] are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most recent completed protocol ARST0331 studied the use of low",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    doses in this group. Compared to previous protocols, the total cumulative dose of cyclophosphamide was limited to 4.8",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    and RT to areas of residual tumor to patients in each of the two subsets. The goal was to improve outcome without significant acute or long-term toxicity for the majority of subgroup A patients, and to maintain the excellent outcome and reduce acute and long-term toxicity for patients in subgroup B. Treatment duration was 22 weeks for patients in subgroup A and 46 weeks for those in subgroup B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Intermediate-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocol ARST0531 for intermediate-risk patients includes those patients with alveolar tumors and CG I-III disease, and those with stage 2,3, CG III embryonal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/71\">",
"     71",
"    </a>",
"    ]. Based upon data from IRS III and IV, patients with intermediate-risk disease have an estimated three-year failure-free survival rate of 55 to 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To improve long-term survival, ARST0531 is randomly assigning patients with intermediate-risk disease to standard VAC chemotherapy or VAC alternating with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (VI) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/73\">",
"     73",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dose in this trial is 1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    RT starts at week 4 of therapy for all patients (with some rare exceptions that are discussed in the protocol). The local control and survival for patients receiving early (week 4) RT and VAC chemotherapy are to be compared to results in a cohort of similar patients treated with delayed (week 10) RT and VAC (currently the accepted standard therapy (",
"    <a class=\"graphic graphic_table graphicRef53178 \" href=\"UTD.htm?0/13/222\">",
"     table 4",
"    </a>",
"    )) on IRS-IV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     High-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk disease includes all patients with metastatic disease at diagnosis, either alveolar or embryonal histology. Overall five-year event-free survival (EFS) for a patient with high-risk disease is approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To improve on these results, the recently completed protocol ARST0431 evaluated intensive multiagent therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and included dose-compressed cycles of VDC (vincristine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) alternating with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"      ifosfamide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"    </span>",
"    (IE) (ie, treatment cycles were given every two rather than three weeks through use of hematopoietic growth factor support). The protocol reached its target accrual in 2008 and is awaiting data maturation. In a preliminary report presented at the 2010 meeting of the American Society of Clinical Oncology, toxicity and early outcomes data (at 18 months, FFS and overall survival rates are 66 and 80 percent, respectively) appear promising [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes will be compared to a cohort of patients treated on the prior cooperative protocol for high-risk disease in IRS-V (D9802), in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    was followed by standard VAC, and RT to primary and metastatic sites; responders to vincristine plus irinotecan were given four additional cycles of irinotecan plus vincristine. Patients with parameningeal disease did not receive irinotecan, and only received VDC and RT. The results of this protocol are not yet reported.",
"   </p>",
"   <p>",
"    Not all patients presenting with metastatic disease do poorly with standard therapy. Age between one and 10 years old, embryonal histology, absence of bone or bone marrow involvement, and two or fewer sites of metastases predict a better outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5,9,75\">",
"     5,9,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because these outcomes approach those of selected patients with localized, nonmetastatic disease, patients who fall into these groups should not be considered appropriate candidates for regimens that include experimental agents with substantial toxicities or unproven antitumor activity. One acceptable strategy to identifying new treatment options in this group is the \"window\" approach, in which an investigational drug or combination is administered for 4 to 12 weeks before standard chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/76\">",
"     76",
"    </a>",
"    ]. This approach was tested in the IRS-V protocol D9802, using the drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    There is clearly a need for novel treatment strategies, and patients with metastatic disease are appropriate for clinical trials. Inhibition of the insulin-like growth factor 1 receptor (IGF1R) using an anti-IGF1R monoclonal antibody in combination with chemotherapy is an approach being taken in the ARST 08P1 clinical trial to overcome the dismal outcomes for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180141657\">",
"    <span class=\"h4\">",
"     High-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the poor prognosis associated with high-risk disease, high-dose chemotherapy (HDT) with or without total body irradiation and autologous hematopoietic stem cell transplantation has been studied as an initial treatment strategy. In uncontrolled series that generally involve small numbers of patients, the survival rates using this approach for previously untreated children with metastatic",
"    <span class=\"nowrap\">",
"     RMS/UDS",
"    </span>",
"    range between 19 to 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. However, it is unclear if these results are better than can be achieved with standard dose chemotherapy in RMS, since there are no randomized trials directly comparing both approaches.",
"   </p>",
"   <p>",
"    Two meta-analyses concluded that there was no significant survival advantage to",
"    <span class=\"nowrap\">",
"     HDT/stem",
"    </span>",
"    cell rescue for patients with advanced RMS [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], and a greater risk of grade 3 or 4 toxicity compared with conventional chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the benefits of HDT are unproven, and this modality should not be pursued unless within the context of a clinical trial. If protocol enrollment is either not feasible or declined, we consider VAC treatment according to the standard arm of ARST0531 an acceptable standard palliative approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT OF UNDIFFERENTIATED SARCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with UDS are currently excluded from RMS protocols. Patients with intermediate-risk localized UDS could still be treated with VAC chemotherapy and RT as a standard approach (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, patients with metastatic disease, as well as those with localized disease, are eligible for a separate protocol for non-rhabdomyosarcoma soft tissue sarcoma (ARST0332) testing six cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (9",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/84\">",
"     84",
"    </a>",
"    ]. Preoperative RT is started after two cycles of chemotherapy. The efficacy of this latter combination is not yet established in UDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety percent of deaths from RMS occur within two years following diagnosis. For this reason, patients who survive free of disease beyond this point have a high probability of cure. Late relapses (beyond five years) occur in approximately 9 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prognosis of recurrent or persistent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse after initial therapy or whose tumors progress while on treatment have a poor outcome. Recurrences are often, but not uniformly, fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. Five-year post relapse survival rates in two large cooperative group series were 17 and 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/86,88\">",
"     86,88",
"    </a>",
"    ]. Prognostic factors after relapse have been addressed in two publications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, based on 605 relapses observed in 2364 patients treated with IRS_IV pilot and IRSIV protocols, prognosis was dependent upon initial histology, clinical disease grouping, and stage at diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/86\">",
"       86",
"      </a>",
"      ]. Patients with relapsed botryoid embryonal RMS had a 64 percent survival rate at five years, compared with 26 percent for patients with relapsed embryonal RMS, and only 5 percent for those relapsed alveolar RMS or UDS.",
"     </li>",
"     <li>",
"      In the second series, there were 1398 patients with localized disease at diagnosis who were treated within three consecutive European cooperative group protocols and who achieved a clinical remission [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/89\">",
"       89",
"      </a>",
"      ]. In all, 474 had a relapse and 176 were alive &ge;3 years from the last event. In multivariable analysis, the factors that were most strongly associated with poor outcomes were metastatic disease at relapse, prior RT treatment, initial tumor size &gt;5 cm, and relapse within 18 months of diagnosis. Other significant factors included unfavorable site, nodal status, three and six-drug treatment, and alveolar histology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard therapy for relapsed patients is suboptimal and the best regimen has yet to be identified. Local therapy (eg, surgery) should be considered if feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active chemotherapy regimens include VAC (",
"    <a class=\"graphic graphic_table graphicRef53178 \" href=\"UTD.htm?0/13/222\">",
"     table 4",
"    </a>",
"    ) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/91\">",
"     91",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/92\">",
"     92",
"    </a>",
"    ], doxorubicin, ifosfamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (MAID) [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/93\">",
"     93",
"    </a>",
"    ], and others [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT OF ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyosarcoma (RMS) is rare in adults, accounting for 2 to 5 percent of adult soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/63,97\">",
"     63,97",
"    </a>",
"    ]. When it occurs, it most often presents in the head and neck; RMS may also develop in the setting of a teratoma with malignant transformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=see_link&amp;anchor=H19#H19\">",
"     \"Head and neck sarcomas\", section on 'Rhabdomyosarcoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H11#H11\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Teratoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with treatment of adults with RMS is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/62,63,98\">",
"     62,63,98",
"    </a>",
"    ]. Some data suggest that compared to children, adults have an inferior outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/62,63,99-101\">",
"     62,63,99-101",
"    </a>",
"    ]. As an example, in a compilation of data on outcomes of RMS among 1071 adults (age &gt;19 years) and 1529 children derived from the Surveillance, Epidemiology and End Results (SEER) database of the NCI, adults had significantly worse five-year survival (27 versus 61 percent). Tumors in adults were more likely to be at an unfavorable site (65 versus 55 percent, p&lt;.0001) and to have histologies that are unusual during childhood, particularly the pleomorphic subtype and not otherwise specified. However, adults had overall worse survival than children for similar tumors. This was especially evident for localized disease (five-year survival 47 versus 82 percent).",
"   </p>",
"   <p>",
"    The poorer outcomes in adults may, in part, reflect the inadequacy of primary treatment, as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 82 adults with locoregional RMS treated over a 38-year period at M D Anderson Cancer Center, the 10-year disease-free and overall survival rates were 41 and 40 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/62\">",
"       62",
"      </a>",
"      ]. However, only 71 percent received chemotherapy, and 11 percent were treated with RT alone.",
"     </li>",
"     <li>",
"      In a second series of 171 patients over age 19 who were diagnosed with RMS at a single institution over a 25-year period, five-year event-free and overall survival rates were 28 and 40 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/63\">",
"       63",
"      </a>",
"      ]. However, among the 110 patients with embryonal, alveolar, or \"not otherwise specified\" RMS, five-year survival rates were 61 percent for those who had high scores for appropriate treatment, based upon modern treatment guidelines for pediatric RMS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, adults with RMS should be treated using the same principles as established for children, although data are lacking with regards to some specifics such as the total radiation dose (there is a trend towards use of higher radiation doses in adults because late growth-related radiation sequelae are not consequential) and the best way to integrate surgery, radiation, and chemotherapy in these patients. Results are most favorable when adults are treated in pediatric clinical trials, which are generally open to individuals up to age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     LONG-TERM COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant portion of children who are successfully treated for RMS develop long-term treatment-related sequelae. In a report of late complications from the International Rhabdomyosarcoma study (IRS) II and III, short stature or facial asymmetry affected almost one-third, poor dentition one-fourth, and impaired vision, hearing, and learning one-sixth each [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group and are available online [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Bowel and bladder problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;With modern therapy, bladder preservation rates as high as 60 percent are reported for patients with tumors of the bladder or prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/5,27,102\">",
"     5,27,102",
"    </a>",
"    ]. However, 25 percent of patients who retain their bladders suffer from significant bladder functional problems including incontinence, frequency, and nocturia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/103\">",
"     103",
"    </a>",
"    ]. Moreover, patients treated for a bladder or prostate primary are at risk for bowel complications related to surgery or radiation therapy (RT), hemorrhagic cystitis, and primary hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link\">",
"     \"Cystitis in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Dentofacial development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequelae of treatment for RMS involving the head or neck include several dentofacial abnormalities including bony",
"    <span class=\"nowrap\">",
"     hypoplasia/facial",
"    </span>",
"    asymmetry, trismus,",
"    <span class=\"nowrap\">",
"     tooth/root",
"    </span>",
"    agenesis, microdontia, enamel defects, and osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Meticulous long-term dental and radiographic follow-up are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cardiac dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may increase the risk for cardiac dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H20#H20\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Secondary tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary tumors are a potentially devastating late complication of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/108-112\">",
"     108-112",
"    </a>",
"    ]. Among 1770 patients treated in the IRS-I and II protocols, 22 secondary malignancies (11 postradiation bone sarcomas and five acute myeloid leukemias [AML]) developed at a median of seven years post-treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/108\">",
"     108",
"    </a>",
"    ]. Second cancers are more common in children treated with both chemotherapy and radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Endocrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with head and neck RMS, RT to the hypothalamic-pituitary area can induce short stature secondary to growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Eye problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one report, 82 percent of the 79 patients with orbital tumors who had received RT developed cataracts, while 59 percent had orbital hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of rhabdomyosarcoma (RMS) and undifferentiated sarcoma (UDS) has evolved considerably over the past several decades. Using modern combined modality therapy, over 70 percent of children with localized RMS can now be cured. These improved outcomes are the direct result of the use of risk-based multimodality therapeutic protocols that have been developed by large international cooperative groups, such as the IRSG (now known as the Soft Tissue Sarcoma Committee of the Children's Oncology Group [COG]).",
"   </p>",
"   <p>",
"    Modern treatment includes chemotherapy for primary cytoreduction and eradication of both macroscopic and microscopic metastatic disease, surgery if feasible, and radiation therapy (RT) to control microscopic local residual disease. The specific treatment regimen depends on the estimated risk of a disease recurrence, which is based upon a variety of clinicopathologic prognostic factors, an approach termed risk-adapted therapy (",
"    <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview of risk-adapted therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some general principles underlying treatment of RMS are outlined below. Treatment is constantly evolving and if the reader's goal is to obtain information on how to treat a specific patient,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    should contact a pediatric oncologist who is a member of the Children's Oncology Group and who has expertise in soft tissue sarcoma for the latest recommendation. In general, adults with RMS are treated using the same principles as established for children. Results are most favorable when adults are treated in pediatric clinical trials, which are generally open to individuals up to age 50. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Treatment of adults'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend complete excision for localized disease as long as functional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cosmetic results are acceptable (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If complete resection is not feasible, or if disease involves the orbit, vagina, bladder, or biliary tract, patients are better approached with an initial diagnostic biopsy followed by induction (neoadjuvant) chemotherapy then definitive local therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend radiation therapy (RT) to enhance local control in patients with residual microscopic or gross disease following surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The value of this modality for clinical Group I alveolar tumors (",
"      <a class=\"graphic graphic_table graphicRef59875 \" href=\"UTD.htm?31/41/32411\">",
"       table 1",
"      </a>",
"      ) remains to be determined but the most recent COG trial ARST 0531 recommends radiation for these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We recommend chemotherapy in addition to local therapy for all patients with RMS (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The choice of regimen depends on the estimated risk of a disease recurrence. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All eligible patients with RMS should be enrolled in one of the active clinical research protocols designed by the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) and administered by COG centers according to risk groups (",
"      <a class=\"graphic graphic_table graphicRef71404 \" href=\"UTD.htm?10/52/11086\">",
"       table 3",
"      </a>",
"      ). Currently, ARST0531 for intermediate-risk disease is the only open upfront protocol for newly diagnosed patients [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. Although in the US, pediatric oncologists treat patients up to the age of 20, any patient younger than 50 years old is eligible for these protocols. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment strategies in current cooperative group protocols (ARST)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      There is no standard approach for patients with high-risk disease at present. We suggest that these patients be enrolled on available national collaborative clinical trials (eg, ARST 08P1 [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/77\">",
"       77",
"      </a>",
"      ]) or local clinical trials testing novel approaches. If protocol enrollment is either not feasible or declined, we consider VAC treatment according to the standard arm of ARST0531 (21-day cycles) an acceptable standard palliative approach.",
"      <br/>",
"      <br/>",
"      Patients with undifferentiated sarcoma (UDS) are currently excluded from RMS protocols. Patients with intermediate-risk localized UDS could still be treated with VAC chemotherapy and RT as a standard approach (",
"      <a class=\"graphic graphic_table graphicRef53178 \" href=\"UTD.htm?0/13/222\">",
"       table 4",
"      </a>",
"      ). However, we prefer that all of these patients be enrolled in a protocol for non-rhabdomyosarcoma soft tissue sarcoma (ARST0332) testing six cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/84\">",
"       84",
"      </a>",
"      ]. Preoperative RT is started after two cycles of chemotherapy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment of undifferentiated sarcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant portion of children who are successfully treated for RMS or UDS develop long-term treatment-related sequelae. Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group and are available online [",
"      <a class=\"abstract\" href=\"UTD.htm?33/49/34586/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Long-term complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrences are often, but not uniformly, fatal. Standard therapy for relapsed patients is suboptimal and the best regimen has yet to be identified. There are several active chemotherapy regimens, but local therapy (eg, surgery) should be considered if feasible. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD. file://seer.cancer.gov/csr/1975_2003 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/2\">",
"      Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/3\">",
"      Punyko JA, Mertens AC, Baker KS, et al. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 2005; 103:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/4\">",
"      Sutow WW, Sullivan MP, Ried HL, et al. Prognosis in childhood rhabdomyosarcoma. Cancer 1970; 25:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/5\">",
"      Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/6\">",
"      Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/7\">",
"      Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/8\">",
"      Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/9\">",
"      Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/10\">",
"      Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011; 29:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/11\">",
"      Breneman J, Meza J, Donaldson SS, et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys 2012; 83:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/12\">",
"      Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys 2001; 51:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/13\">",
"      Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/14\">",
"      Blakely ML, Lobe TE, Anderson JR, et al. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg 1999; 34:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/15\">",
"      Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. Cancer 2007; 110:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/16\">",
"      Daya H, Chan HS, Sirkin W, Forte V. Pediatric rhabdomyosarcoma of the head and neck: is there a place for surgical management? Arch Otolaryngol Head Neck Surg 2000; 126:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/17\">",
"      Pappo AS, Meza JL, Donaldson SS, et al. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV. J Clin Oncol 2003; 21:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/18\">",
"      Andrassy RJ, Wiener ES, Raney RB, et al. Thoracic sarcomas in children. Ann Surg 1998; 227:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/19\">",
"      Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 2001; 10:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/20\">",
"      Michalkiewicz EL, Rao BN, Gross E, et al. Complications of pelvic exenteration in children who have genitourinary rhabdomyosarcoma. J Pediatr Surg 1997; 32:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/21\">",
"      Martelli H, Oberlin O, Rey A, et al. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology. J Clin Oncol 1999; 17:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/22\">",
"      Andrassy RJ, Wiener ES, Raney RB, et al. Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-year review from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Surg 1999; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/23\">",
"      Filipas D, Fisch M, Stein R, et al. Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery. BJU Int 2004; 93:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/24\">",
"      Heyn R, Newton WA, Raney RB, et al. Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol 1997; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/25\">",
"      Hays DM, Lawrence W Jr, Crist WM, et al. Partial cystectomy in the management of rhabdomyosarcoma of the bladder: a report from the Intergroup Rhabdomyosarcoma Study. J Pediatr Surg 1990; 25:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/26\">",
"      Hays DM, Raney RB, Wharam MD, et al. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant or adjuvant chemotherapy, with or without radiotherapy. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee. J Pediatr Hematol Oncol 1995; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/27\">",
"      Ferrer FA, Isakoff M, Koyle MA. Bladder/prostate rhabdomyosarcoma: past, present and future. J Urol 2006; 176:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/28\">",
"      Andrassy RJ, Corpron CA, Hays D, et al. Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J Pediatr Surg 1996; 31:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/29\">",
"      Neville HL, Andrassy RJ, Lobe TE, et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg 2000; 35:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/30\">",
"      La TH, Wolden SL, Su Z, et al. Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2011; 80:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/31\">",
"      McMulkin HM, Yanchar NL, Fernandez CV, Giacomantonio C. Sentinel lymph node mapping and biopsy: a potentially valuable tool in the management of childhood extremity rhabdomyosarcoma. Pediatr Surg Int 2003; 19:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/32\">",
"      Neville HL, Andrassy RJ, Lally KP, et al. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg 2000; 35:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/33\">",
"      Blakely ML, Andrassy RJ, Raney RB, et al. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997. J Pediatr Surg 2003; 38:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/34\">",
"      Beech TR, Moss RL, Anderson JA, et al. What comprises appropriate therapy for children/adolescents with rhabdomyosarcoma arising in the abdominal wall? A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Surg 1999; 34:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/35\">",
"      Saenz NC, Ghavimi F, Gerald W, et al. Chest wall rhabdomyosarcoma. Cancer 1997; 80:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/36\">",
"      Godzinski J, Flamant F, Rey A, et al. Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study. Med Pediatr Oncol 1994; 22:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/37\">",
"      Rodeberg DA, Stoner JA, Hayes-Jordan A, et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2009; 27:3705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/38\">",
"      Raney B, Stoner J, Anderson J, et al. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group. J Pediatr Surg 2010; 45:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/39\">",
"      Temeck BK, Wexler LH, Steinberg SM, et al. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 1995; 59:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/40\">",
"      Michalski JM, Meza J, Breneman JC, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004; 59:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/41\">",
"      Wolden SL, La TH, LaQuaglia MP, et al. Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma. Cancer 2003; 97:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/42\">",
"      Puri DR, Wexler LH, Meyers PA, et al. The challenging role of radiation therapy for very young children with rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2006; 65:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/43\">",
"      Defachelles AS, Rey A, Oberlin O, et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from international society of pediatric oncology studies MMT 89 and 95. J Clin Oncol 2009; 27:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/44\">",
"      Hug EB, Adams J, Fitzek M, et al. Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: a novel technique. Int J Radiat Oncol Biol Phys 2000; 47:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/45\">",
"      Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012; 82:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/46\">",
"      Wolden SL, Anderson JR, Crist WM, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol 1999; 17:3468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/47\">",
"      Raney RB, Anderson JR, Brown KL, et al. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. Pediatr Blood Cancer 2010; 55:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/48\">",
"      Schuck A, Mattke AC, Schmidt B, et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J Clin Oncol 2004; 22:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/49\">",
"      Smith LM, Anderson JR, Qualman SJ, et al. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol 2001; 19:4058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/50\">",
"      Mandell L, Ghavimi F, Peretz T, et al. Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy. J Clin Oncol 1990; 8:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/51\">",
"      Regine WF, Fontanesi J, Kumar P, et al. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients. Int J Radiat Oncol Biol Phys 1995; 31:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/52\">",
"      Wharam MD, Meza J, Anderson J, et al. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2004; 22:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/53\">",
"      Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Pediatr Blood Cancer 2011; 57:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/54\">",
"      Kozak KR, Adams J, Krejcarek SJ, et al. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 2009; 74:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/55\">",
"      Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002; 38:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/56\">",
"      Benk V, Rodary C, Donaldson SS, et al. Parameningeal rhabdomyosarcoma: results of an international workshop. Int J Radiat Oncol Biol Phys 1996; 36:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/57\">",
"      Meazza C, Ferrari A, Casanova M, et al. Evolving treatment strategies for parameningeal rhabdomyosarcoma: the experience of the Istituto Nazionale Tumori of Milan. Head Neck 2005; 27:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/58\">",
"      Magn&eacute; N, Oberlin O, Martelli H, et al. Vulval and vaginal rhabdomyosarcoma in children: update and reappraisal of Institut Gustave Roussy brachytherapy experience. Int J Radiat Oncol Biol Phys 2008; 72:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/59\">",
"      Nag S, Cano ER, Demanes DJ, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2001; 50:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/60\">",
"      Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006; 24:3844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/61\">",
"      Burke M, Anderson JR, Kao SC, et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2007; 25:4909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/62\">",
"      Little DJ, Ballo MT, Zagars GK, et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 2002; 95:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/63\">",
"      Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 2003; 98:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/64\">",
"      Raney RB, Asmar L, Vassilopoulou-Sellin R, et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol 1999; 33:362.",
"     </a>",
"    </li>",
"    <li>",
"     Children's Oncology Group long-term follow-up guidelines available online at www.survivorshipguidelines.org (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/66\">",
"      Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a phase II \"window\" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001; 37:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/67\">",
"      Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001; 23:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/68\">",
"      Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol 2009; 27:5182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/69\">",
"      Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007; 25:362.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available online at www.cancer.gov/clinicaltrials/COG-ARST0331 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     Protocol information available online at www.cancer.gov/clinicaltrials/COG-arst0531 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     Walterhouse D, Pappo AS, Meza JL, et al. Shorter duration therapy that includes vincristine (V), dactinomycon (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Childreen's Oncology Group (COG). (Abstract 9516). J Clin oncol 2011; 29:589s. (Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=77259 (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     Clinical trial information for ARST0531 (NCT00354835) available online at file://cancer.gov/clinicaltrials/search/view?cdrid=487560&amp;version=healthprofessional (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     Weigel B, Lyden E, Anderson JR, et al. Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). (Abstract 9503). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=48068 (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/75\">",
"      Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008; 26:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/76\">",
"      Soft Tissue Sarcoma Committee of the Children's Oncology Group, Lager JJ, Lyden ER, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006; 24:3415.",
"     </a>",
"    </li>",
"    <li>",
"     Information of Clinical trial ARST 08P1 available online at file://clinicaltrials.gov/ct2/show/NCT01055314?term=ARST+08P1&amp;rank=1 (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/78\">",
"      Carli M, Colombatti R, Oberlin O, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004; 22:4787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/79\">",
"      Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/80\">",
"      Walterhouse DO, Hoover ML, Marymont MA, Kletzel M. High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital. Med Pediatr Oncol 1999; 32:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/81\">",
"      Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999; 17:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/82\">",
"      Admiraal R, van der Paardt M, Kobes J, et al. High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma. Cochrane Database Syst Rev 2010; :CD006669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/83\">",
"      Peinemann F, Kr&ouml;ger N, Bartel C, et al. High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review. PLoS One 2011; 6:e17127.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available at www.cancer.gov/clinicaltrials/COG-arst0332 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/85\">",
"      Sung L, Anderson JR, Donaldson SS, et al. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Eur J Cancer 2004; 40:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/86\">",
"      Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999; 17:3487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/87\">",
"      Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer 2005; 104:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/88\">",
"      Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 2008; 26:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/89\">",
"      Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 2011; 29:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/90\">",
"      Hayes-Jordan A, Doherty DK, West SD, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg 2006; 41:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/91\">",
"      Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/92\">",
"      Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 2007; 25:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/93\">",
"      Antman K, Crowley J, Balcerzak SP, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998; 82:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/94\">",
"      Pappo AS, Bowman LC, Furman WL, et al. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J Pediatr Hematol Oncol 1997; 19:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/95\">",
"      Carpenter PA, White L, McCowage GB, et al. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Cancer 1997; 80:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/96\">",
"      Carli M, Perilongo G, di Montezemolo LC, et al. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 1987; 71:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/97\">",
"      Hawkins WG, Hoos A, Antonescu CR, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 2001; 91:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/98\">",
"      Ogilvie CM, Crawford EA, Slotcavage RL, et al. Treatment of adult rhabdomyosarcoma. Am J Clin Oncol 2010; 33:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/99\">",
"      Esnaola NF, Rubin BP, Baldini EH, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg 2001; 234:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/100\">",
"      Hulse N, Raja S, Kumar A, Paul AS. Rhabdomyosarcoma of the extremities in adults. Acta Orthop Belg 2006; 72:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/101\">",
"      Sultan I, Qaddoumi I, Yaser S, et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol 2009; 27:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/102\">",
"      Atra A, Ward HC, Aitken K, et al. Conservative surgery in multimodal therapy for pelvic rhabdomyosarcoma in children. Br J Cancer 1994; 70:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/103\">",
"      Raney B Jr, Heyn R, Hays DM, et al. Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the Intergroup Rhabdomyosarcoma Study Committee. Cancer 1993; 71:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/104\">",
"      Yeung CK, Ward HC, Ransley PG, et al. Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer 1994; 70:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/105\">",
"      Kaste SC, Hopkins KP, Bowman LC. Dental abnormalities in long-term survivors of head and neck rhabdomyosarcoma. Med Pediatr Oncol 1995; 25:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/106\">",
"      Estilo CL, Huryn JM, Kraus DH, et al. Effects of therapy on dentofacial development in long-term survivors of head and neck rhabdomyosarcoma: the memorial sloan-kettering cancer center experience. J Pediatr Hematol Oncol 2003; 25:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/107\">",
"      Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/108\">",
"      Heyn R, Haeberlen V, Newton WA, et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol 1993; 11:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/109\">",
"      Heyn R, Khan F, Ensign LG, et al. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol 1994; 23:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/110\">",
"      Scaradavou A, Heller G, Sklar CA, et al. Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma. Cancer 1995; 76:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/111\">",
"      Bisogno G, Sotti G, Nowicki Y, et al. Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer 2004; 100:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/112\">",
"      Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005; 103:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/113\">",
"      Paulino AC, Simon JH, Zhen W, Wen BC. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2000; 48:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/114\">",
"      Katz JR, Bareille P, Levitt G, Stanhope R. Growth hormone and segmental growth in survivors of head and neck embryonal rhabdomyosarcoma. Arch Dis Child 2001; 84:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?33/49/34586/abstract/115\">",
"      Raney RB, Anderson JR, Kollath J, et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991. Med Pediatr Oncol 2000; 34:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7721 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34586=[""].join("\n");
var outline_f33_49_34586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF RISK-ADAPTED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview of IRSG I-V study results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Paratesticular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other GU tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extremity and trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Second-look surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Documenting a complete response to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Resection of posttherapy residual disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical Group I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical Group II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical Group III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Parameningeal sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment strategies in current cooperative group protocols (ARST)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Low-risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - High-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H180141657\">",
"      High-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT OF UNDIFFERENTIATED SARCOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prognosis of recurrent or persistent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT OF ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      LONG-TERM COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Bowel and bladder problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Dentofacial development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cardiac dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Secondary tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Eye problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/41/32411\" title=\"table 1\">",
"      Clinical group rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/13/7389\" title=\"table 2\">",
"      Rhabdomyosarcoma TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/52/11086\" title=\"table 3\">",
"      Rhabdomyosarc prognos stratify",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/13/222\" title=\"table 4\">",
"      Comb chemo rhabdomyosarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18327?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_49_34587="RA versus osteoarthritis";
var content_f33_49_34587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical distinction between rheumatoid arthritis and osteoarthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rheumatoid arthritis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Primary joints affected",
"       </td>",
"       <td>",
"        Metacarpophalangeal",
"       </td>",
"       <td>",
"        Distal interphalangeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal interphalangeal",
"       </td>",
"       <td>",
"        Carpometacarpal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heberden's nodes",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Frequently present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint characteristics",
"       </td>",
"       <td>",
"        Soft, warm, and tender",
"       </td>",
"       <td>",
"        Hard and bony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiffness",
"       </td>",
"       <td>",
"        Worse after resting (eg, morning stiffness)",
"       </td>",
"       <td>",
"        If present, worse after effort, may be described as evening stiffness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Laboratory findings",
"       </td>",
"       <td>",
"        Positive rheumatoid factor",
"       </td>",
"       <td>",
"        Rheumatoid factor negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive anti-CCP antibody",
"       </td>",
"       <td>",
"        Anti-CCP antibody negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated ESR and C reactive protein",
"       </td>",
"       <td>",
"        Normal ESR and C reactive protein",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CCP: cyclic citrullinated peptide",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34587=[""].join("\n");
var outline_f33_49_34587=null;
var title_f33_49_34588="Resistance to insulin therapy";
var content_f33_49_34588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Addressing patient resistance to insulin therapy for patients with type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient concerned with pain from injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal with thinner, smaller needles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of insulin pens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient worried that starting insulin signifies worsening diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes is a progressive disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taking insulin will control blood glucose and help prevent complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taking insulin may slow down the rate of beta cell failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient believes that need for insulin signifies patient failure to follow treatment regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes is a progressive disease; beta cell activity declines over time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not related to patient compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient fears low blood sugar reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explain that severe hypoglycemia is rare in type 2 diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-monitoring glucose levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explain how to avoid and how to treat hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient concerned that taking insulin will upset daily routine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Address specific concerns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taking insulin may be less intrusive than complicated drug regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient believes that insulin will decrease his/her quality of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benefits from glucose control: more energy, better sleep, overall well-being",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient thinks insulin will lead to diabetic complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss role of insulin in reducing risk of diabetic complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient concerned that he/she will be treated differently by friends and family",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Educate friends and family: offer reading materials on diabetes, support groups for family",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient has heard insulin causes weight gain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Role of diet and exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient wants a more natural alternative therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin is the most natural therapy for diabetes. It is replacing the hormone that the patient does not make enough of.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brunton S, Carmichael B, Funnell M, et al. Type 2 diabetes: the role of insulin. J Fam Pract 2005; 54:445.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34588=[""].join("\n");
var outline_f33_49_34588=null;
var title_f33_49_34589="Treatment Cushings disease";
var content_f33_49_34589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34589=[""].join("\n");
var outline_f33_49_34589=null;
var title_f33_49_34590="Cervical agenesis B";
var content_f33_49_34590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical agenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fundus of the uterus is present without the body of the cervix. Dotted lines represent missing cervix and upper vagina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34590=[""].join("\n");
var outline_f33_49_34590=null;
var title_f33_49_34591="White blood cell cast II";
var content_f33_49_34591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with white blood cell cast (II)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white blood cell cast, three-quarters of which is filled with leukocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_49_34591=[""].join("\n");
var outline_f33_49_34591=null;
               